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ABSTRACT 
The four serotypes of dengue virus (DENV-1, DENV-2, DENV-3 and DENV-4) cause a wide 
spectrum of clinical disease, ranging from febrile illnesses to life-threatening hemorrhagic 
fever. Worldwide incidence has increased alarmingly to where DENV is now the most 
common mosquito-borne viral disease in the world. However, understanding the mechanisms 
by which DENV causes disease remains elusive, due both to the complexity of vector-host 
transmission and the lack of effective in vitro and animal models with which to test 
mechanisms of pathogenesis. Our previous work, in which we carried out phylogenetic 
analysis of an epidemic sweep of DENV-2 among South Pacific islands that occurred in the 
early 1970s, suggests that strain variation might have a significant impact on epidemic 
severity. Specifically, DENV-2 isolates from an outbreak on the island of Tonga – whose 
epidemiology was notable for being distinctly attenuated compared with outbreaks on all other 
affected islands – were found to have three unique amino acid substitutions in the prM, NS2A 
and NS4A gene regions that distinguished them from all other DENV-2 isolates. Therefore, 
based on the hypothesis that changes in the DENV genome can lead to variations in disease 
severity and epidemic potential between different DENV strains, this study explores the 
relationship between genetic changes in DENV-2 epidemic strains and their phenotypic effects 
using in vitro models. Phenotypic differences between DENV-2 isolates from the entire South 
Pacific sweep were measured on the basis of viral productivity (i.e., viral titer and replication 
rate or rate of virus production per cell) in both human and mosquito cells. In addition, the 
specific mutations characterizing the Tonga synapomorphies suggested additional 
measurements to examine the proportion of infectious virions and possibly the viral effects on 
host-immune responses. .  
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CHAPTER 1: INTRODUCTION 
Dengue virus (DENV) is the single-most significant disease-causing, mosquito-borne virus in the 
tropical and subtropical regions of the world today,22 producing outcomes as varied as mild fever 
to hemorrhage and shock leading to death98. In spite of considerable research, no antiviral drugs 
are currently available145 and vaccine development has been problematic with the only currently 
licensed tetravalent vaccine (Sanofi-Pasteur’s Dengvaxia) showing less than 60% efficacy.29 
This is against a background in which rates of DENV transmission continue to increase164 such 
that DENV infections now range from 50–100 million183 to 390 million22 a year. Transmitted by 
several species of the Aedes genus of mosquitoes but primarily by Aedes aegypti186, DENV is a 
member of the Flavivirus genus, which includes viruses responsible for diseases such as yellow 
fever, Japanese encephalitis, Congenital Zika syndrome, and West Nile neuroinvasive 
disease.129,148 DENV itself is an approximately 11-kb positive-strand RNA virus and has four 
closely related but antigenically distinct serotypes (DENV-1, DENV-2, DENV-3, DENV-4), 
which do not provide complete cross-protective immunity. Infection with any of the four 
serotypes can result in asymptomatic infection or a spectrum of clinical symptoms and signs, 
including non-specific febrile illness, dengue fever (DF), and severe dengue (until recently 
classified as dengue hemorrhagic fever [DHF] and dengue shock syndrome [DSS]248). In spite of 
considerable research, the mechanism by which DENV causes disease and the question of why 
clinical disease shows such considerable variation remains incompletely understood. 
A variety of known risk factors for serious dengue disease have been identified, such as 
viral strain variation,44,135 vector competency31 and secondary infection by a heterologous DENV 
serotype99. Research into the mechanisms of DENV pathogenesis has been hampered by the lack 
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of an animal model and by the multi-factorial nature of its risk factors153. 
Nonetheless, important insights into the question of dengue pathogenesis and DENV 
epidemic potential may be gained from careful study of past outbreaks. The series of outbreaks 
upon which this study is based – an epidemic sweep of DENV-2 in the South Pacific that 
occurred in the early 1970s – represent a unique opportunity to examine the possible contribution 
of evolution and transmission ecology in the epidemiology of DENV outbreaks. These South 
Pacific outbreaks represent a kind of natural experiment in which many, if not most, of the 
confounding factors in dengue disease dynamics were controlled for, thus allowing for clear 
examination of such factors as evolution, strain variation, and the effects of genomic change on 
DENV function. In previous research, we carried out phylogenetic analysis of DENV isolated 
from this series of outbreaks and demonstrated a possible link between strain variation and 
epidemic severity on these South Pacific islands. That work revealed that DENV-2 isolated from 
an outbreak on a specific island revealed unique amino acid substitutions that distinguished them 
from all other isolates, and only occurring on the one island with an outbreak that was distinctly 
attenuated compared with DENV-2 outbreaks on all other affected islands.213 
Thus, we believe that strain variation resulting from viral evolution may play a significant 
role in dengue pathogenesis and DENV epidemic potential. The challenge is to delineate the 
phenotypic differences arising from strain variation and to identify the role these phenotypes 
might play in terms of pathogenesis and transmission. 
Therefore, this introduction begins with a review of DENV structure and our current 
understanding of DENV evolution, and then proceeds to offer a brief overview of our historical 
understanding of dengue as a disease as well as its recent expansion. The introduction continues 
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with a discussion on diagnosis and clinical effects, dengue transmission and epidemiology and a 
review of past and current research on dengue pathogenesis; all in the service of providing the 
context necessary for understanding the research carried out and described herein. 
Dengue Virus Structure  
Dengue virus (DENV) is a small enveloped virus with a virion approximately 50 nm in size, 
containing an electron dense core of genomic RNA complexed with capsid (C) protein and 
surrounded by a membrane composed of lipid bilayers and the envelope (E) and membrane (M) 
proteins. The nucleocapsid (NC) is the single genome RNA packaged within multiple copies of 
the small C protein. Formation of the NC is one of the earliest events in the flavivirus assembly.54 
The E glycoproteins are the major antigenic determinant on flavivirus particles and contain both 
cellular receptor-binding sites and a fusion peptide that mediate membrane fusion during virus 
entry.258 Individual M proteins are small proteolytic fragments resulting from the cleavage of the 
precursor pre-membrane (prM) protein during maturation of nascent virus particles within the 
secretory pathway. Thus, prM probably acts as a chaperone for the folding of the E protein, 
serving as a lock to prevent the E glycoproteins from being prematurely activated by low pH 
during their transport through the trans-Golgi network prior to virion secretion at the plasma 
membrane.144 However, prM cleavage does not appear to be an “all-or-nothing” phenomenon but 
instead progressive and relatively inefficient with one study showing approximately 30 to 40% 
of prM remaining in the extracellular particles of a DENV-2 isolate.118 Given its function as a 
“lock” prM cleavage is a prerequisite for DENV maturation and thus it was assumed infectivity. 
However, recent research suggests that immature DENV may itself play a pathogenic role, in as 
much as anti-prM antibodies may enhance its uptake by Fc-receptor bearing cells.184 From the 
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standpoint of the research described in this dissertation, understanding the role of prM has 
potential importance because a non-synonymous substitution in the prM gene region defines the 
attenuated Tonga clade among those isolates collected from the South Pacific DENV-2 outbreaks 
from 1971 – 1974 (see the section Phylogenetics of the South Pacific Sweep for further detail).  
The DENV genome is an approximately 11-kilobase (kb) single-stranded RNA of 
positive polarity containing a single open reading frame (ORF) that encodes a polyprotein. 
Genomic RNA is infective and acts as the viral mRNA for replication, as well as the template for 
transcription of the complementary negative-sense RNA. The negative-sense RNA serves in turn 
as the template for genomic RNA synthesis. In common with other flavivirus, the DENV 
genome has a gene order of 5’–C-prM-E-NS1-NS2A-NS2B-NS3-NS4A-NS4B-NS5–3’ with the 
three structural genes — C, prM and E — followed by the seven non-structural genes.161 DENV 
ORFs range in size from 3387–3396 amino acids, making them the shortest among the mosquito-
borne flaviviruses.83 The ORF is flanked by 5’ and 3’ untranslated regions (UTR) of ~100 and 
~400 nucleotides, respectively. These noncoding regions assume a secondary structure that is 
believed to regulate viral protein synthesis, RNA replication, and packaging through spatial 
arrangements for interactions with viral or host cell proteins.28,152 There is evidence that the 5’ 
and 3’ ends stack together (in what is sometimes referred to as a 'panhandle structure') to cause 
cyclization of the genome. This in theory would permit the viral replicase to bind to both ends of 
the template RNA at the same time, thus producing cyclized positive strands, perhaps during the 
initial stages of RNA replication.124,152 
The function of many of the DENV non-structural proteins is currently either unknown or 
lacking significant details. Because of their relevance to the research discussed in this dissertation, 
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NS2A and NS4A will be reviewed briefly. NS2A is a relatively small hydrophobic protein of 
around 22 kDa in size, which is cleaved from NS1 by an unknown ER resident host enzyme. 
Mutations in yellow fever virus NS2A that block virus production can be blocked in turn by a 
second mutation on the surface of the NS3 helicase domain suggesting that virion assembly 
involves an interaction between NS2A and NS3. 131 This and other interactions, such as those 
with NS5 and the 3’ UTR, make it seem likely that NS2A is involved in coordinating the shift 
between RNA packaging and RNA replication. 123 In addition, NS2A also has been shown to act 
as an interferon (IFN) antagonist by inhibiting IFN antiviral immune response both alone and in 
coordination with NS4A and NS4B.142,162 Finally, NS2A genes may also play a role, along with 
NS4B, in anchoring the viral replicase complex to cellular lipid membranes.156 
Very little is known about the functions of NS4A. The protein is small (16 kDa), 
hydrophobic, localized to the ER lumen, and membrane associated. NS4A appears to play a key 
role in the replication function of NS1 based upon mutation studies139 and its abundant co-
localization within replication complexes.147 The carboxyl-terminal region of NS4A, designated 
the 2K fragment, serves as signal sequence for the translocation of the adjacent NS4B into the 
ER.156 As mentioned above for the NS2A protein, DENV NS4A, along with NS4B can also 
block type 1 IFN signaling, albeit with NS4B having the strongest neutralizing effect.162 
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Figure 1. Predicted topology of the dengue virus polyprotein across the endoplasmic reticulum (ER) 
membrane. Arrows indicate sites of processing by host cell and viral proteases. Enzymatic cleavage sites 
are indicated by colors as described in the legend. From Perera and Kuhn 2008 
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Dengue Virus Phylogenetics and Evolution  
DENV is a member of the genus Flavivirus, family Flaviviridae. Among the family Flaviviridae, 
which also includes the genera Hepaciviruses and Pestiviruses, only the flaviviruses include 
vector-borne viruses (Figure 2).140 
 
Figure 2. Phylogenetic tree of Flaviviridae family based on analysis of NS3 helicase regions. Some 
members of each genus are shown as examples – Flavivirus genus: yellow fever virus (YFV), dengue 
virus 1-4 (DENV-1 to DENV-4), West Nile virus (WNV), Japanese encephalitis (JEV); the Pestivirus 
genus: bovine viral diarrhea virus (BVDV), classical swine fever (CSFV); Hepacivirus genus: hepatitis C 
virus (HCV); and the unclassified viruses GBV-A and GBV-C.  © 2007 Field Virology, 5th Edition. 
 Those vector-borne viruses that share the genus Flavivirus with DENV include a large 
number of significant human pathogens including Japanese encephalitis virus (JEV), West Nile 
virus (WNV) and yellow fever virus (YFV)108 Beyond humans, the flaviviruses have a variety of 
both invertebrate and vertebrate hosts, the latter including humans, birds, rodents, bats, and 
nonhuman primates.235 Geographically diverse, the complete number of Flavivirus species is 
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uncertain; most estimates range from 56105 to 7070 although a statistical method developed by 
Pybus et al. (2002) using phylogenetic node heights to estimate the true number of taxa in a clade 
came up with an estimate of roughly 2,000 flaviviruses still awaiting identification.176 The origin 
of the Flavivirus genus is a matter of conjecture. Some reviews on flavivirus evolution suggest 
two possibilities: 1) that the mosquito and tick transmission clusters each diverged independently 
from an ancestral non-vector virus group49 or 2) that the evolution progressed from non-vector to 
tick and then to mosquito.83,129  
All flaviviruses have common group epitopes on the E protein. The consequences of such 
serological similarity are two-fold: first, there is abundant evidence of immunological cross-
reactivity. Examples include DENV and Zika virus (ZIKV) where the evidence strongly supports 
an infection enhancing effect 32,174; DENV, JEV and YFV, where cross-immunity may be 
preventing YFV dissemination in Asia80; and JEV and DENV, where there is evidence for both 
neutralization and enhancement at present.6,224 Such immunological interactions have broad 
implications for public health and vaccine development.  
A second implication of flavivirus immunological similarity is that it often results in 
extensive cross- reactions in serologic tests. In an earlier era, when flaviviruses were categorized 
into antigenic complexes and subcomplexes, based upon classic serological criteria, clear-cut 
serologic diagnosis of flaviviruses were always problematic.78 Fortunately, advances in 
phylogenetics have lent clarity to organization of the genus into clusters, clades and species.  
Based on molecular phylogeny therefore, the flaviviruses are now divided into two 
unique groups: the vector-borne viruses transmitted by arthropods and those viruses that have no 
known vector.108 The latter is made up of viruses that are transmitted either directly between 
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vertebrates or between invertebrates, and replicate solely within these hosts. The arthropod-
transmission cluster on the other hand, further divides into another two monophyletic groups 
based around their respective transmission vectors: viruses that are mosquito-transmitted, and 
those that are transmitted by ticks. (Figure 3.)108,115,129 
 
 
Figure. 3. Maximum likelihood (ML) 
phylogeny of Flavivirus genus 
based NS-5 gene sequences (990 
bp) from 70 viruses. Because of 
major differences in base 
composition between the three 
major groups of viruses (tick-borne, 
no-known vector, vector-borne—
Jenkins et al. 2001), the trees for 
these groups were estimated 
separately and then joined in a ﬁnal 
phylogeny in which all branch 
lengths were re-optimised. The tree 
is mid-point rooted for purposes of 
clarity only and all horizontal branch 
lengths are drawn to scale. The four 
dengue viruses are shaded. From 
Holmes and Twiddy 2003. 
 
DENV is notable in 
existing as four antigenically 
defined serotypes (DENV-1–
DENV-4). With only 62-67% 
amino acid identity amongst the polyproteins of the four serotypes, they have no more genetic 
similarity than some flavivirus “species.”19,107 Infection by any one of the four serotype produces 
long-lasting immunity to that serotype, but only temporary cross immunity to the other three. 
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Thus, a person living in an endemic area could theoretically have as many as four DENV 
infections during her or his lifetime, one with each serotype.78 Such heterotypic infections are 
significant, as there is abundant evidence that subsequent infections with a heterologous DENV 
serotype may in fact increase the risk for more serious disease through a process called antibody 
dependent enhancement (ADE).100 At present, there is no clear explanation as to why the virus 
exists as four distinct serotypes or evidence to determine the origins of such an arrangement. It 
has been suggested that the separate serotypes represent four initially geographically separate 
viral populations that have only recently come together or that they could be the outcomes of 
independent cross-species transfer events from the various non-human primate species that 
harbor DENV.107 The most likely explanation however is that their diversification was driven by 
ADE as a means of reducing protective cross-reactions in the primate immunological response.64 
Separate mathematical models developed by Esteva et al. (2003) and Adams et al. (2006) support 
this last hypothesis as both suggest that under any conditions of complete cross-immunity, a 
primary infection reduces the force of infection of subsequent heterologous serotypes.3,62 
Whereas, if heterologous infection resulted in subsequent partial cross-immunity or immune 
enhancement that this would in fact increase the force of infection and thus increase the 
probability that a second serotype would establish itself in the population. On the other hand, a 
recent paper in the journal Science by Katzelnick et al. reports on research demonstrating that 
geographically and temporally diverse DENV isolates clustered only loosely by type, that in fact 
many were as similar antigenically to a virus of a different type as to some viruses of the same 
type.120 Further, they found that primary infection antisera did not neutralize all viruses of the 
same DENV type any better than other types did up to two years after infection and did not show 
improved neutralization to homologous type isolates. Apart from the obvious implications for 
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vaccine research and surveillance, these results also appear to strengthen the case for a more 
balanced view of dengue pathogenicity. It confirms the role of prior immunity to a heterologous 
serotype as being of primary importance but acknowledges that “neutralizing responses to the 
particular DENV lineages circulating in a population modifies the magnitude and severity of 
epidemics caused by subsequent infecting lineages.”120 It has been long suspected for example 
that the severity of dengue symptoms may vary markedly in response to the order of serotype 
infection, for example DENV-1 followed by DENV-2. More recent research however suggests a 
more complicated scenario in which disease severity in response to secondary infection is more 
related to DENV lineage than simply heterologous serotype.3,170 
Even to the extent that the degree of serotypic “clustering” is up for debate, the stable 
configuration of DENV into four serotypes is nonetheless notable given its tremendous genetic 
diversity. As with all organisms, such diversity is a result of evolutionary forces: those which 
introduce genetic variation, such as mutation, gene flow and recombination, and those that 
change the relative proportion of variants in populations over time, i.e., natural selection and 
genetic drift.19 In regards to those factors that introduce variation; DENV is highly mutagenic, 
given a RNA-dependent RNA polymerase that typically generates one error per round of genome 
replication.56,107 Additional genetic variation is also contributed through gene flow as DENV is 
transported, often over large distances, by both human hosts and vectors107. And recombination 
may also contribute to DENV genetic diversity; although its extent and overall significance in 
increasing genetic diversity in natural populations of DENV is uncertain, it is well documented 
that it can occur. 219,226,230,252  
However, it has to be emphasized that while mutation, gene flow and recombination 
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introduce genetic variation; genetic diversity ultimately results from the survival of specific 
phenotypic traits. Moreover, survival of specific phenotypes – whether through the random 
chance of genetic drift or non-randomly through adaptive selection – results in changes in the 
frequency of the underlying genotypes, which ultimately happens with the fixation of 
substitutions. 16,19 With this in mind then, an important question regarding DENV evolution is 
whether genetic clustering, whether as serotypes or “genotypes” (defined below) reflects some 
level of natural selection or is simply a result of drift. If selection does play a role then could 
such selection possibly lead to variants with greater epidemic potential87,108 or strains resistant to 
future vaccination programs?107,250 Numerous papers have debated the role of selection in driving 
DENV evolution and whether positive, negative or neutral selection is of greater importance. A 
tentative consensus appears to have formed around the idea that much of the phylogenetic 
structure within DENV populations consists of lineages in which silent or synonymous 
nucleotide changes (mutations) predominate after vigorous purifying selection.106,228 While the 
broad diversity of DENV lineages may arise partly due to positive selection on certain sites of 
the DENV genome under specific conditions20,21 the more significant factors may include local 
evolution by genetic drift and sporadic gene flow of DENV strains into different geographic 
areas. In some studies, local microevolution has been interrupted by lineage replacement through 
importation, such as been shown with the competitive displacement of the American genotype of 
DENV-2 by the Asian/American.182,244 In some cases where localized evolution of dengue has 
been examined, for example, in schools in rural Thailand, rates of evolution were quite low and 
dominated by genetic drift.114 In other cases, DENV microevolution occurred in situ with little 
influence from importation, due to both selection and genetic drift.20,21 The examples given 
above generally involve geographic partitioning. However, in DENV, as with other arboviruses, 
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host-alternation can also impose significant bottlenecks that contribute to genetic drift and act as 
drivers of evolution. Demographic fluctuations can be severe in vector populations, particularly 
in those areas with seasonal rainfall or cold spells. In addition, each blood feed results in 
stochastic sampling of a small number of viral genomes. This is followed by limited infection 
and traversal of mosquito midgut cells, followed by virus dissemination and invasion of the 
salivary glands; all these steps are expected to result in strong population drops.58,136 Indeed one 
study, using whole-genome deep-sequencing of human- and matched mosquito-derived DENV 
samples to track single nucleotide variants (SNVs) within each sample, found that >90% of 
SNVs were lost upon transition from human to mosquito.206 In addition to the stochastic 
sampling associated with host alternation, negative selection could also be expected given that a 
fit genotype in one host may not be fit in the other and indeed a reduction in the rate of adaptive 
evolution was recently demonstrated experimentally in a related arbovirus, Venezuelan equine 
encephalitis.43 On the other hand, a set of experiments in host alternation, using DENV grown 
either in human cells or insect cells or in both, saw results that were more equivocal. Not 
surprisingly, DENV passaged in either single host cell line exhibited fitness gains in that line and 
fitness loss in the bypassed cell line. However, most DENV passaged in alternating cycles 
exhibited fitness gains in both cell lines.233 Thus, both in the case of geographic isolation and in 
host-alternation there is still no clear sense as to the evolutionary drivers that predominate and 
their ultimate contribution to DENV pathogenicity and/or epidemic potential. Certainly, as 
populations of humans and Aedes aegypti continue to expand, opportunities for viral circulation 
will increase in turn. This creates ever more opportunities for co-infection of mosquito and 
human by multiple serotypes of virus and potentially sets the stage for genetic events that could 
lead to the emergence of more virulent or transmissible strains as well as strains of greater 
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vaccine resistance.250 
Before leaving the topic of DENV serotypes, it must be noted that an additional fifth 
serotype has recently been discovered. Announced in 2013, the fifth serotype was discovered in 
the routine screening of viral samples obtained from a 37-year-old farmer admitted in hospital in 
Sarawak state of Malaysia in 2007. The virus was originally assumed to be spillover from the 
circulation of sylvatic DENV-4 among local primates and local Aedes nivalis forest mosquitoes. 
Subsequent isolation and genetic sequencing demonstrated however that the virus was 
phylogenetically distinct from the three previous forms of sylvatic DENV-4 and bore some 
similarity with DENV-2. Further testing through inoculation of DENV-5 into macaque monkeys 
previously infected with the other four DENV serotypes and allowed to recover resulted in the 
production a significantly different set of antibodies, confirming that the new virus was a new 
serotype and not a variant of DENV-4. Interestingly, while the outbreak caused by the strain was 
associated with only a single hospitalized case, suggesting that disease caused by this DENV-5 
strain is mild, the viral titer of secondary infections in the macaque was four times higher than 
other serotypes.165,169 Previous comparisons of sylvatic strains with human adapted DENV in 
two surrogate human model hosts: monocyte-derived, human dendritic cells, and mice engrafted 
with human hepatoma cells, found that while sylvatic strains replicated at a lower titer, no 
overall difference between sylvatic and human-adapted strains was noted.234 This present 
spillover event thus appears to confirm that the adaptive barrier for emergence of sylvatic dengue 
is relatively low and raises questions about the adequacy of tetravalent DENV vaccines as well 
as the larger question as to whether even more yet undiscovered DENV serotypes may remain in 
the jungle.232 
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Within each DENV serotype, there is further genetic diversity in the form of clusters of 
variants or “genotypes.” Essentially defined by Rico-Hesse in 1990, through close comparison of 
a 240 base pair fragment from the E/NS1 gene region in both DENV 1 and 2, she delineated a 
number of genotypes, each defined as “a group of dengue viruses having no more than 6% 
sequence divergence.”108,181 All four serotypes of DENV have genotypes and often these follow 
different geographic distributions (Figure 4). For example, in DENV-2 the genotypes named 
“Asian 1” and “Asian 2” were only found in Asian populations. This however, may be an artifact 
as continued expansion and mixing of infected hosts and vectors may bring genotypes far from 
their putative geographic range. And indeed, some genotypes are found in multiple geographic 
localities; e.g. the “Cosmopolitan” genotype within DENV-2.107,182,225 
Regarding the origins of DENV, the historical and epidemiological evidence give reason 
to believe that DENV existed in Asia as long as 1,000 years ago, although probably in a sylvatic 
form.240 Indeed, the existence of sylvatic cycles of DENV transmission in both Africa and 
Southeast Asia involving nonhuman primate hosts and gallery forest vectors other than Aedes 
aegypti or Ae. albopictus suggest a zoonotic origin for the virus. Phylogenetic analysis suggests 
that each of the four serotypes independently passed over to humans, possibly more than once, 
but eventually establishing endemicity within humans some 125–320 years ago subsequent to 
sufficient human populations size.228,255 However, there has been some disagreement as to which 
continent might be the more likely locality of viral emergence.185,193,210 Given that DENV-1, 
DENV-2 and DENV-4 serotypes have been found in Asia193,194 while DENV-2 was the sole 
serotype to be found in Africa until the 1990s,185 the relative lack of susceptibility to DENV 
infection of the ancestral Ae. aegypti formosus from Africa,51 and the weight of phylogenetic 
analysis.227,240 the evidence seems to favor Asia as the more likely ancestral source.  
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Figure 4. Serotypes and genotypes representing genetic DENV diversity. Tree generated through 
maximum likelihood using 120 Envelope gene sequences (1485 bp). Approximate divergence times are 
shown in italics above key nodes. All horizontal branch lengths drawn to scale. From Holmes et al. 2003. 
History - Dengue Emergence and Resurgence 
Examining the actual historical record for the emergence of dengue as a disease is 
problematic, given the difficulties in distinguishing its symptoms from those resulting from other 
diseases such as chikungunya, measles, influenza, typhoid, leptospirosis, or malaria.183 Thus, 
there is no certainty when dengue was first recognized as a clinical disease. The most often cited 
first appearance is that found in a Chinese encyclopedia of disease symptoms and remedies, 
22 E.C. Holmes, S.S. Twiddy / Infection, Genetics and Evolution 3 (2003) 19–28
Fig. 2. Maximum likelihood phylogeny of 120 E gene sequences (1485 bp) representing the genetic diversity in dengue virus. In all cases the different
serotypes and genotypes of dengue virus are identified and the (approximate) divergence times (see text) are shown in italics above key nodes. The
GTR model of nucleotide substitution was used allowing a different rate of change for each codon position (parameter values available for the authors
on request). Bootstrap values (derived from 1 00 replicate NJ trees estimat d under the ML substitution model) are shown below selected nodes. All
analyses were undertaken using the PAUP* package (Swofford, 2002). The tree is rooted on DENV-4 sequences, as these are usually the first to diverge
in dengue phylogenies, and all horizontal branch lengths are drawn to scale.
Insights into the history of dengue virus can be also
obtained by reconstructing a molecular tim -scale of it
evolution. This was recently achieved by estimating rates
of nucleotide substitution using a maximum likelihood
method that analyses the amount of evolutionary change
that has occurred between viruses sampled at different times
(Rambaut, 2000). Employing this method to a large number
of envelope (E) gene sequences revealed that dengue virus
evoluti n often conforms to a mole ar clock, although
some lineage-specific rate differences were observed; mean
substitution rates (for all sites) ranged from 4.55 × 10−4
(DENV-1) to 9.01 × 10−4 substitutions per site, per year
(DENV-3) (Twiddy et al., 2003b). These rates are similar to
those reported in other vector-borne RNA viruses, although
slightly lower than those in RNA viruses transmitted by
other mechanisms (Jenkins et al., 2002), most likely because
of the fitness trade-offs, and hence selective constraints,
inherent when replicating in hosts as divergent as insects
and ma mals. Using these substit tio rates, the origin of
dengue virus (that is, the deepest split in the divergence of
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originally published during the Chin Dynasty (265 to 420 A.D.) and revised thereafter. Called 
“water poison,” the disease was thought to be connected with flying insects associated with 
water.78 We have records of other outbreaks with dengue-like symptoms in the French West 
Indies in 1635 and in Panama in 1699.24 If these were in fact dengue outbreaks then distribution 
of the virus was already widespread even before the 18th century, when the first known 
pandemic of dengue-like illness began.  
The appearance of a considerable number of reports from the late 18th century of 
simultaneous dengue-like epidemics in Egypt, India, the West Indies, and the southern United 
States30,78,183 certainly confirm the cosmopolitan nature of dengue distribution by this date. 
Although again, the possibility of diagnostic confusion with other diseases, particularly with 
chikungunya30 means that any such conclusions require caution. In any case, by early 1800 
dengue was widespread throughout urban tropical coastal cities of the world due to the global 
expansion of commercial shipping.250 The shipping vessels supporting expanded trade facilitated 
transport of vector breeding habitat along with humans, thus supplying a complete transmission 
cycle.79 With both the virus and mosquito vector introduced to coastal destinations around the 
world, dengue epidemics generally began to occur at 10–40 year intervals.164 
Halstead suggests that the term “dengue” was introduced into English medical literature 
from the Spanish West Indies during a 1827-1828 Caribbean epidemic of a disease producing 
rash with arthralgia. “Dengue” is in turn a Spanish corruption of the Swahili “Ki denga pepo”, 
meaning “seizure caused by an evil spirit.”92 As mentioned above, much confusion probably 
occurred between outbreaks of dengue and chikungunya with any febrile disease accompanied 
by rash being described by such terms as “Knokkelkoorts” from Jakarta in 1779 and “Breakbone 
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fever” from Philadelphia in 1780. 
Transmission of DENV by the mosquito vector Aedes aegypti had to wait until 
description in the early 20th century13,42 with discovery of a filterable, infectious agent in human 
blood9 and the infection with this agent of human volunteers205 and mosquitoes208 following 
shortly thereafter. Definitive identification of dengue was finally accomplished through isolation 
during the Second World War by two independent groups; Kimura and Hotta in Japan in 
1944110,126 and Sabin and Schlesinger in 1945 in the United States.196 
The waging of the Second World War in Asia and the Pacific marked a profound turning 
point in the emergence of dengue as a public health problem of worldwide scope.78,130 War 
disrupted normal water infrastructure, necessitating more personal water-storage, created bomb 
craters and spread refuse and debris through formerly pristine environments. All of these newly 
created mosquito-breeding opportunities occurred simultaneously with the increased transport of 
mosquitoes and their eggs into new geographic areas accompanied by movements of 
immunologically susceptible troops between regions of ongoing dengue endemicity. The result 
by the end of the war was not just to spread the virus and its vector over an area much greater 
than it had inhabited heretofore but also to bring different serotypes into contact with one 
another. 
Following the Second World War there were initially reasons for optimism in regards to 
dengue. For example, large-scale dengue epidemics in Central and South America appeared to be 
under control as a result of a vigorous and large successful campaign to eliminate the YFV and 
DENV vector Ae. aegypti. Unfortunately, these vector control programs were halted in the early 
1970s; by the 1980s incidence had increased, and by 1995 Ae. aegypti had returned to pre-
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campaign levels in the Americas once again.24,80,81 This same time period saw rapid human 
population growth throughout the tropics with a concomitant demographic shift from the country 
and into cities along with lagging infrastructure and unplanned development. All of these factors 
combined to create ideal habitat for Ae. aegypti and continued the introduction of novel DENV 
serotypes into immunologically susceptible human populations. Increasingly, all four serotypes 
came to be maintained in hyperendemic co-circulation in large cities throughout the tropics and 
subtropics of the world. It is during this same period of time and in the largest cities of Southeast 
Asia that the more serious manifestations of DENV infection first began to break out with 
increased frequency.78,148 The first well documented outbreak of what would eventually be 
known as dengue hemorrhagic fever occurred in Manila in 1953/1954, and was followed by a 
larger outbreak in Bangkok in 1958.92,104 Thus, the failure of mosquito control efforts in the latter 
part of the 20th century in combination with growing urbanization and transportation have 
contributed to the re-emergence of dengue to the scale of a global pandemic.  
Dengue Epidemiology 
Recent decades have seen a tremendous growth in dengue incidence and severity, marked by 
more frequent and severe epidemics. Previous to 1970 only nine countries experienced 
epidemics of severe dengue; by 1995 that number had increased more than four-fold and dengue 
is probably endemic in more than 100 countries in Asia, the Americas, the western Pacific, 
Africa and the eastern Mediterranean regions.90,249 
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Figure 5. Top Row: Comparison of DENV serotype distribution from 1970 to 2004.  
Bottom row: emergence of dengue and DHF 1950 - 2000, by incidence (a) and by country (b).  
All images MacKenzie et al. 2004.  
In terms of disease burden, many authors cite World Health Organization estimates of 
50–100 million infections annually worldwide with 500,000 persons needing hospitalization 
from DHF, and more than 15,000 deaths.183 More recent estimates however, have revised the 
number of infections significantly upwards to 390 million DENV infections per year, of which 
96 million manifest some degree of disease severity (an estimate three times that of the World 
Health Organization).22 Dengue is the most rapidly spreading mosquito borne disease in the 
world today with at least half of the world’s population living in regions at-risk for dengue 
disease transmission.249 For example, dengue disease incidence appears to have increased in 
Africa (although previous under-reporting may be a contributing factor),5 and outbreaks are 
increasingly reported in areas formerly free of the virus such as Hawaii, the Galapagos islands, 
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control have all contributed to the marked increase in epidemic activ-
ity. In 2004, over 2.5 billion people lived in risk areas for dengue infec-
tion (Fig. 6); it is estimated that between 50–100 million cases of
dengue fever, 500,000 cases of DHF/DSS and more than 20,000 deaths
occur each year129,138. Dengue is therefore the most important
arboviral disease of humans.
Prevention and control. Currently, the only way to prevent or control
dengue transmission is to control the principal vector mosquito,
Ae. aegypti138. Although successful control programs were imple-
mented in the American region in the 1950s and 1960s, the programs
were disbanded after epidemic activity ceased. In the 1970s and 1980s,
Ae. aegypti reinfested most of the countries where it had been 
eliminated139. These programs have never been successfully 
reimplemented.
At present, there is no vaccine for dengue viruses, although several
candidates are at various stages of development64,140,141. To be effec-
tive, a dengue vaccine must protect against all four virus serotypes. For
use in countries where dengue is endemic, a vaccine must be safe for
use in children 9–12 months of age, must be economical and should
provide long-lasting protective immunity (ideally >10 years).
Several approaches are being used to develop dengue vaccines. A
live, attenuated vaccine is thought to provide the most complete and
lasting immunity. At present, there are three such vaccine candidates
under development by Mahidol University–Aventis–Pasteur, by the US
Army–GlaxoSmithKline and by the National Institutes of Health
(NIH)64,140,141. Attenuation of the Mahidol and US Army candidates
was achieved by passage in primary dog kidney cells; the latter candidate
had a final passage in fetal rhesus lung cells142,143. The NIH has attenu-
ated its candidate vaccines by introducing a 30-nucleotide, nonlethal
mutation in the 3′ untranslated region144.
Several groups have also constructed chimeric viruses using various
infectious clones as backbones. A group at Acambis has inserted the
prM and E genes of the four DENV serotypes into the 17D yellow fever
backbone145. A group at the Center for Disease Control has con-
structed chimeras of DEN-1, DEN-3 and DEN-4 by inserting the prM
and E genes of these serotypes into an infectious clone of the Mahidol
PDK-53 DEN-2 LAV146. A NIH group has used an infectious clone of
their LAV DEN-4 candidate for the same purpose147. All of these
chimeric candidate vaccines seem promising in primate studies. The
17-D YFV chimeras have recently undergone a phase 1 trial in
humans, but results are not yet available.
The US Navy has developed a DEN-1 DNA candidate vaccine that
has shown promise in primate studies148, but the antibody levels and
persistence of antibody are of concern. Finally, Hawaii Biotech, Inc.,
developed a recombinant, subunit, tetravalent vaccine by inserting sub-
unit proteins representing the amino-terminal 80% of the E protein
for each serotype plus the entire NS1 protein of DEN-2 into modified
vaccinia Ankara recombinants grown in Drosophila melanogaster
cells149. Studies in primates have shown a robust neutralizing antibody
response.
In summary, there are at least six tetravalent candidate dengue vac-
cines that are in or near clinical trial in humans. The Pediatric Dengue
Vaccine Initiative funded by the Bill and Melinda Gates Foundation
was founded to facilitate bringing one or more of these promising can-
didate vaccines to fruition150.
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Figure 4 The global resurgence of dengue and dengue hemorrhagic fever
over the past half century, by incidence (a) and by country (b).
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control have all contributed to the marked increase in epidemic activ-
ity. In 2004, over 2.5 billion people lived in risk areas for dengue infec-
tion (Fig. 6); it is estimated that between 50–100 million cases of
dengue fever, 500,000 cases of DHF/DSS and more than 20,000 deaths
occur each year129,138. Dengue is therefore the most important
arboviral disease of humans.
Prevention and control. Currently, the only way to prevent or control
dengue transmission is to control the principal vector mosquito,
Ae. aegypti138. Although successful control programs were imple-
mented in the American region in the 1950s and 1960s, the programs
were disbanded after epidemic activity ceased. In the 1970s and 1980s,
Ae. aegypti reinfested most of the countries where it had been 
eliminated139. These programs have never been successfully 
reimplemented.
At present, there is no vaccine for dengue viruses, although several
candidates are at various stages of development64,140,141. To be effec-
tive, a dengue vaccine must protect against all four virus serotypes. For
use in countries where dengue is endemic, a vaccine must be safe for
use in children 9–12 months of age, must be economical and should
provide long-lasting protective immunity (ideally >10 years).
Several approaches are being used to develop dengue vaccines. A
live, attenuated vaccine is thought to provide the most complete and
lasting immunity. At present, there are three such vaccine candidates
under development by Mahidol University–Aventis–Pasteur, by the US
Army–GlaxoSmithKline and by the National Institutes of Health
(NIH)64,140,141. Attenuation of the Mahidol and US Army candidates
was achieved by passage in primary dog kidney cells; the latter candidate
had a final passage in fetal rhesus lung cells142,143. The NIH has attenu-
ated its candidate vaccines by introducing a 30-nucleotide, nonlethal
mutation in the 3′ untranslated region144.
Several groups have also constructed chimeric viruses using various
infectious clones as backbones. A group at Acambis has inserted the
prM and E genes of the four DENV serotypes into the 17D yellow fever
backbone145. A group at the Center for Disease Control has con-
structed chimeras of DEN-1, DEN-3 and DEN-4 by inserting the prM
and E genes of these serotypes into an infectious clone of the Mahidol
PDK-53 DEN-2 LAV146. A NIH group has used an infectious clone of
their LAV DEN-4 candidate for the same purpose147. All of these
chimeric candidate vaccines seem promising in primate studies. The
17-D YFV chimeras have recently undergone a phase 1 trial in
humans, but results are not yet available.
The US Navy has developed a DEN-1 DNA candidate vaccine that
has shown promise in primate studies148, but the antibody levels and
persistence of antibody are of concern. Finally, Hawaii Biotech, Inc.,
developed a recombinant, subunit, tetravalent vaccine by inserting sub-
unit proteins representing the amino-terminal 80% of the E protein
for each serotype plus the entire NS1 protein of DEN-2 into modified
vaccinia Ankara recombinants grown in Drosophila melanogaster
cells149. Studies in primates have shown a robust neutralizing antibody
response.
In summary, there are at least six tetravalent candidate dengue vac-
cines that are in or near clinical trial in humans. The Pediatric Dengue
Vaccine Initiative funded by the Bill and Melinda Gates Foundation
was founded to facilitate bringing one or more of these promising can-
didate vaccines to fruition150.
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control have all contributed to the marked increase in epidemic activ-
ity. In 2004, over 2.5 billion people lived in risk areas for dengue infec-
tion (Fig. 6); it is estimated that between 50–100 million cases of
dengue fever, 500,000 cases of DHF/DSS and more than 20,000 deaths
occur each year129,138. Dengue is therefore the most important
arboviral disease of humans.
Prev ntion and control. Currently, the nly way to revent or control
dengue transmission is to control the principal vector mosquito,
Ae. aegypti138. Although successful control programs were imple-
mented in the American region in the 1950s and 1960s, the programs
were disbanded after epidemic activity ceased. In the 1970s and 1980s,
Ae. aegypti reinfested most of the countries where it had been 
eliminated139. These programs have never been successfully 
reimplemented.
At present, there is no vaccine for dengue viruses, although several
candidates are at various stages of development64,140,141. To be effec-
tive, a dengue vaccine must protect against all four virus serotypes. For
use in countries where dengue is endemic, a vaccine must be safe for
use in children 9–12 months of age, must be economical and should
provide long-lasting protective immunity (ideally >10 years).
Several approaches are being used to develop dengue vaccines. A
live, attenuated vaccine is thought to provide the most complete and
lasting immunity. At present, there are three such vaccine candidates
under development by Mahidol University–Aventis–Pasteur, by the US
Army–GlaxoSmithKline and by the National Institutes of Health
(NIH)64,140,141. Attenuation of the Mahidol and US Army candidates
was achieved by passage in primary dog kidney cells; the latter candidate
had a final passage in fetal rhesus lung cells142,143. The NIH has attenu-
ated its candidate vaccines by introducing a 30-nucleotide, nonlethal
mutation in the 3′ untranslated region144.
Several groups have also constructed chimeric viruses using various
infectious cl nes as backbones. A group at Acambis has inserted the
prM and E genes of the four DENV serotypes into the 17D yellow fever
backbone145. A group at the Center for Disease Control has con-
structed chimeras of DEN-1, DEN-3 and DEN-4 by inserting the prM
and E genes of these serotypes into an infectious clone of the Mahidol
PDK-53 DEN-2 LAV146. A NIH group has used an infectious clone of
their LAV DEN-4 candidate for the same purpose147. All of these
chimeric candidate vaccines seem promising in primate studies. The
17-D YFV chimeras have recently undergone a phase 1 trial in
humans, but results are not yet available.
The US Navy has developed a DEN-1 DNA candidate vaccine that
has shown promise in primate studies148, but the antibody levels and
persistence of antibody are of concern. Finally, Hawaii Biotech, Inc.,
developed a recombinant, subunit, tetravalent vaccine by inserting sub-
unit proteins representing the amino-terminal 80% of the E protein
for each serotype plus the entire NS1 protein of DEN-2 into modified
vaccinia Ankara recombinants grown in Drosophila melanogaster
cells149. Studies in primates have shown a robust neutralizing antibody
response.
In summary, there are at least six tetravalent candidate dengue vac-
cines that are in or near clinical trial in humans. The Pedi tric Dengue
Vaccine Initiative funded by the Bill and Melinda Gates Foundation
was founded to facilitate bringing one or more of these promising can-
didate vaccines to fruition150.
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Figure 4 The global resurgence of dengue and dengue hemorrhagic fever
over the past half century, by incidence (a) and by country (b).
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Easter Island, Hong Kong, Buenos Aires, Florida, southeastern France, and Madeira Island.90,248 
In those countries where dengue has long been present, as in Southeast Asia, age shifts are 
occurring,48,88,172,218 causing reevaluation of dengue as a “childhood disease” and prompting 
changes in surveillance and treatment.  
Figure 6. Global disease burden of dengue, 2014. From Guzman and Harris 2015. 
The economic impacts of dengue are considerable and have a particularly pernicious 
effect on countries challenged with still emerging economies and developing health-care 
systems. Nevertheless, accurately estimating this impact is difficult; while case fatality rates are 
easily measured, dengue is a disease with a generally low rate of mortality but high rate of 
morbidity. Since most studies have focused on individual epidemics they do not take into 
account the larger indirect burden of the disease on a population resulting from lost productivity 
and time away from work or school owing to illness. Nonetheless, some estimates can be given. 
Estimates included in a review by Gubler in 2002 include: US $6 and $16 million in medical 
costs and control measures for a 1977 epidemic in Puerto Rico; US $12 million in medical costs 
alone for 1994 outbreak, also in Puerto Rico; and US $103 million for a 1981 Cuban epidemic, 
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of which nearly half was for mosquito control. A study in Thailand, estimated the annual 
economic burden of severe dengue in that country to range between US $31.5 and $51.5 
million.79 A survey of the economic and disease burden of dengue in 12 countries in SE Asia: 
Bhutan, Brunei, Cambodia, East-Timor, Indonesia, Laos, Malaysia, Myanmar, Philippines, 
Singapore, Thailand, and Viet Nam; estimated the annual economic burden was US $950 million 
or about US $1.65 per capita. Using a World Bank developed non-monetary composite index 
called ‘disability-adjusted life years’ (DALYs), the survey estimated 214,000 DALYs; 
equivalent to 372 DALYs per million inhabitants.202 
Unfortunately, the increased burden of dengue has increasingly been joined by the 
emergence of other arboviruses such as chikungunya, West Nile and Zika virus.173,50,59 Not only 
does this increase the complexity of clinical diagnosis but in the case of Zika, evidence is 
growing that exposure might prompt serological cross-reactivity with possible infection 
enhancement.50,122 While much of the news around dengue is gloomy, some optimism may be 
gained from the seriousness with which dengue and other arboviral diseases are now accorded; it 
was not so long ago that dengue was referred to as a “neglected tropical disease.” Certainly 
recent decades have seen an explosion of research and institutional attention.192 Full-length 
genomic sequences were completed for all four serotypes of DENV in the early nineties.83 And a 
particularly notable breakthrough has been the recent release of the first dengue vaccine. 
Developed by Sanofi-Pasteur, their tetravalent live attenuated vaccine, Dengvaxia, is composed 
of DENV structural proteins fused to a yellow fever 17D vaccine backbone. Dengvaxia passed 
its Phase III efficacy trials in 2014209 and as of 2016 the vaccine has been approved for use in 
more than six countries.247 (A further discussion of this and other dengue vaccines in 
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development follows in this Introduction.)  
Other promising technologies are emerging from recent developments in vector control, 
which are discussed in the next section.  
Mosquitoes and Transmission Ecology 
To understand the reemergence of dengue as the world’s single largest arboviral disease, 
the role of its mosquito vector must be understood. DENV is transmitted to humans by 
mosquitoes of the Aedes genus, although species (and even different populations) within the 
genus vary in their degree of vector competence. Transmission begins when the mosquito 
acquires DENV while feeding on the blood of a person infected with the virus. Following 
ingestion of viremic blood, extracellular virus arrives into the mosquito midgut and must bind to 
undefined receptors on the cellular surface of the midgut epithelium. If the virus can successfully 
infect and replicate within midgut epithelium cells then the viral infection spreads within the 
epithelium and disseminates from the midgut to secondary tissues. With secondary amplification, 
these new progeny virus are shed into the hemocoel (the cavity in which the hemolymph 
circulates, part of the open circulatory system of invertebrates), where DENV can subsequently 
disseminate and infect secondary tissues, including the salivary glands (and sometimes 
reproductive tissues for vertical transmission to offspring). Once sufficient virus replication has 
occurred in the salivary glands, virus is released into salivary ducts and upon the next 
probing/feeding event, the virus may be transmitted to a new uninfected vertebrate host via the 
saliva of the infected mosquito.31 However, transmission is complicated by the mosquito’s innate 
immune system and a number of tissue barriers associated with the midgut and salivary glands, 
i.e., the midgut infection barrier (MIB), midgut escape barrier (MEB), salivary gland infection 
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barrier (SGIB), and salivary gland escape barrier (SGEB).66 It is the combination of these 
obstacles and host cell receptivity for the virus that ultimately determines vector competence.  
Another important factor in transmission dynamics is the time period in which DENV 
incubates and goes through repeated cycles of amplification; there are two periods, one in the 
mosquito and the other in the human host (Figure 7). The period within the mosquito is termed 
the extrinsic incubation period (EIP), and is the time between when a mosquito takes a viremic 
blood meal and the time when the mosquito becomes infectious. Note that after EIP, the infected 
mosquito is capable of transmitting the virus to susceptible individuals for the rest of its life. 
Also, EIP is strongly dependent on temperature and thus influenced by variations in seasonal 
weather and climate. The intrinsic incubation period (IIP), by contrast, takes place within the 
host and is the time between a human being infected and the onset of symptoms due to the 
infection. A meta-analysis of previous EIP/IIP studies found that best-fitting temperature-
dependent EIP model estimated that 95% of EIPs are between 5 and 33 days at 25°C, and 2 and 
15 days at 30°C, with means of 15 and 6.5 days, respectively. The mean IIP estimate was 5.9 
days, with 95% expected between days 3 and 10 days.35 
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Figure 7. DENV intrinsic and extrinsic incubation periods. 
(http://www.cdc.gov/ncidod/dvbid/dengue/slideset) 
DENV is one of the few medically important flaviviruses that has an exclusive 
transmission cycle between mosquito and humans with no zoonotic hosts, i.e. urban transmission 
cycle.245 While a sylvatic (non-human primate) cycle does exist and may occasionally spill over 
into human populations, and is believed to be ancestral to the urban cycle, adaption of DENV to 
the human host and its vector to the human environment is so thorough that the sylvatic cycle is 
no longer required for maintenance.232,240 
While a number of mosquito species of the Aedes genus have been shown to be capable 
of transmitting DENV, Aedes aegypti, the YFV mosquito, is generally considered the primary 
vector although Aedes albopictus, the Asian tiger mosquito has an extensive range and is widely 
implicated with instigating dengue outbreaks as well. In addition, more geographically localized 
species such as Aedes polyenesiensis, and Aedes tabu may also play an important role in specific 
outbreaks. Nevertheless, Aedes (Stegomyia) aegypti is the major dengue fever vector everywhere 
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it occurs throughout the tropical and subtropical world.186 The reasons for this are many but the 
essential factor is the unusual evolutionary adaptions the species has made to associate with 
humans. Almost exclusively anthropophilic, Ae. aegypti prefers to feed on human blood175,214 
and is rarely associated with any habitat other than human dwellings. Adults prefer to rest within 
sheltered dark spaces inside houses, such under beds and within closets186 and as larvae and 
pupae, Ae. aegypti prefer breeding in artificial containers: generally household water containers 
such as barrels or cisterns, flower pots which are productive throughout the year, and various 
trash such as cans, bottles, etc. Other important behavioral factors are the species' preferred 
feeding times of dawn and dusk186 when humans are less likely to be behind netted beds, its 
imperceptible bite, and its shyness, which tends to make it more prone to biting multiple 
individuals in order to obtain a blood meal thus spreading the virus more widely.250 Finally, Ae. 
aegypti mosquitoes are competent for DENV, i.e., capable of infecting epithelial cells of this 
species' midgut wall and replicating to a high titer of 106 minimal infective doses (MID) per 
mL83 and surmounting such physiological obstacles such as the midgut barrier, in order to 
disseminate to the salivary glands where the virus can be passed onto a new human host. 86 
Surprisingly however, Ae. aegypti mosquitoes appear to have a relatively low susceptibility to 
oral infection, i.e., virus titers in the blood of the human host must exceed 105–107 virus particles 
per mL for infection and transmission to be sustained. It has been suggested in this regard that 
Ae. aegypti may act as a selection filter for maintaining viral virulence at a relatively high level, 
since only those virus strains that replicate in humans at a sufficiently high rate of efficiency are 
capable of producing the high viremias necessary for transmission by this mosquito.157 
Interestingly, Ae. albopictus is overall more susceptible to DENV midgut infection. Nonetheless, 
rates of virus dissemination from the midgut to other tissues are significantly lower in Ae. 
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albopictus than in Ae. aegypti. This factor, as well as the more anthropophilic host preferences of 
Ae. aegypti, may explain why those localities where Ae. albopictus predominates over Ae. 
aegypti have never experienced a typical explosive dengue epidemic with severe cases of the 
disease.132 
In those areas where large populations of Aedes mosquitoes persist, such as large, urban 
areas located in the tropics, one or more DENV serotypes are typically maintained endemically 
whereas in smaller or more isolated localities, where host herd immunity can build up, epidemics 
often result from the introduction of novel serotypes.77 DENV transmission shows a high degree 
of temporal and spatial heterogeneity based on seasonal and geographic variations in rainfall, 
relative humidity and temperature. Aedes survival is longer during the rainy season due to the 
high humidity, while temperature affects the maturation of mosquito life stages. Higher 
temperatures produce smaller females, which are forced to take more blood meals to obtain the 
protein needed for egg production.116 This of course increases the number of humans likely to be 
bitten by a single female and increases the probability of transmission. Temperature also 
determines the amount of time that ingested virus takes to reach the mosquito salivary glands 
ready for transmission as higher temperatures accelerate the extrinsic incubation period (see 
above for further discussion of EIP).96,243  
The high statistical correlation of household water storage containers with disease 
incidence68,71,223 is so well established that vector-control efforts are focused specifically on their 
removal. In some countries the presence of water storage containers may be so significant a 
predictor of Ae. aegypti infestation, that container abundance is found to mitigate any seasonal 
variations.146 Therefore, elimination or at least control of mosquito egress has always been one of 
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the highest priorities for minimizing the risk of DENV infection. Unfortunately, container 
control has a mixed record of success at best. One difficulty is that of surveillance. The localized 
presence of water storage containers renders the use of remote sensing ineffective except perhaps 
in more temperate regions61 and simply gaining access to properties to survey the containers can 
be time consuming, expensive and even hazardous.146 Furthermore, an increasing number of 
studies has demonstrated that larval abundance can be a poor predictor of adult abundance since 
container abundance is an inexact surrogate for larva abundance. This is because container 
indices do not address productivity, that is, the number of Ae. aegypti adults produced over 
time.178 Thus, even a single container can supply enough adults to cause significant DENV 
transmission. Finally, effective container control typically demands a high level of community 
participation, difficult to achieve, particularly in poor, urban areas where the challenges of daily 
life leave little time for the vague promise of more effective mosquito control.  
In fact, it is arguable that dengue has been successfully prevented exclusively through 
vector control on only three occasions. The first of these was the highly successful, vertically 
structured paramilitary eradication campaign directed by the Pan American Sanitary Board from 
1946–1970 that almost succeeded in eradicating Ae. aegypti from the Western hemisphere.79,198 
The second was also a rigorous, top-down, military-like vector control campaign in Cuba that 
was implemented in 1981 and relied upon intensive insecticidal treatment followed by reduction 
of available larval habitats and also included rapid diagnosis of dengue and treatment.69,172 The 
third program was in Singapore, and was based on entomologic surveillance and larval source 
reduction (i.e., reducing the availability of Aedes larval habitats) and included public education 
and law enforcement, the latter to discourage intentional or unintentional mosquito propagation. 
This program succeeded in achieving a 15-year period of low dengue incidence before seeing 
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resurgence in the 1990s.172 Thus, none of these programs was sustainable over the long-term. 
Nonetheless, new technologies in vector control have made an appearance with the 
potential to change the vector control equation. Genetic modification of Aedes aegypti with 
insertion of a dominant lethal gene (RIDL) developed by Oxford, UK–based Oxitec, offers a 
means to diminish this vector’s population levels through release of sterile males.4 Another 
approach, being studied by researchers at Monash University in Melbourne, Australia, has been 
to adapt the endosymbiotic bacterium Wolbachia from Drosophila to Ae. aegypti. This appears 
to both shorten the lifespan of the mosquito and block transmission of DENV.67,239 Both 
technologies have been tested in various field trials in various tropical locations, and results from 
both of these technologies are encouraging if preliminary with further trials ongoing.  
Ultimately, the transmission and incidence of dengue is a complex, multi-factorial 
process in which numerous factors affect disease incidence as much or more than vector 
abundance. Host immunity (both on the individual and population level), genetic variations in 
susceptibility in humans and mosquito and variations in virulence among different strains of 
DENV are just some of the other factors that must be considered. 
Dengue Pathogenesis 
In spite of decades of research into the causes of dengue pathology, we still have more questions 
than answers. It is clear that pathogenesis of dengue disease, both mild and severe, is determined 
by many factors, including those in the host, vector, and environment. Host immunity (both on 
the individual and population level), vector abundance, genetic variations in susceptibility in 
humans and mosquito and in virulence among different strains of dengue are just some of the 
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elements that must be considered in attempting to understand epidemic behavior. Research into 
dengue pathogenesis has been greatly hindered by the lack of an effective animal model. As non-
human primates are the natural hosts of sylvatic strains of DENV they can be infected by DENV 
and they do develop viremia. However, primate infections result in much lower viremic titers 
than those found in humans and never show signs of hemorrhage or shock.78 Several murine 
models of DENV infection have been recently described but results are still extremely 
preliminary and their applicability to human pathology remains controversial.190,253 In spite of 
these challenges, there are two leading theories as to the cause of morbidity from DENV 
infection, neither of which is mutually exclusive.  
Secondary heterotypic infection and the risk of severe dengue 
As previously mentioned, DENV has four genetically distinct serotypes. Infection with any one 
serotype offers relatively long-lasting immunity against reinfection by the homologous serotype 
but only temporally limited cross-immunity to the other three, generally lasting only 6 months.196 
After this time individuals infected with one serotype are fully susceptible to infection by any of 
the other three serotypes. 99 Moreover, secondary heterotypic infection appears to be a significant 
risk factor for severe dengue disease 98 although how the immune response to DENV protects 
against or contributes to severe disease is incompletely understood and the mechanisms 
suggested are controversial.53 In general, antibodies play an important role in immune protection 
against viral infection through neutralization by binding to virus particles, blocking their ability 
to bind to host cells and aggregating virions for elimination. However, in the case of DENV, 
while cross-reactive antibodies produced in response to a primary DENV infection recognize and 
do bind to newly infecting virus of a heterologous serotype, the concentration of those antibodies 
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fall below the threshold for neutralization. Instead, these antibodies appear to form antibody-
virus complexes, which are bound to and internalized by cells expressing Fcγ receptors (FcγR), 
i.e., cells of the monocytic/macrophage lineage. Thus, these “sub-neutralizing” antibodies appear 
to promote entry of DENV into FcγR cells in the process called ‘‘antibody-dependent 
enhancement’’ or ADE100 a mechanism observed in other flaviviruses including YFV, WNV, 
TBEV and JEV.52 
A key epidemiological observation is that while serotypes may have rarely co-existed in 
the past, increased urban development and transportation has resulted in greater areas of the 
world becoming hyperendemic with multiple DENV serotypes, such as in Southeast Asia in the 
sixties and South America in seventies. As hyperendemicity has increased, so have rates of 
heterologous secondary DENV infection and with them higher rates of severe dengue with 
hemorrhage and shock.75 Further support for this theory came from clinical observations in 
Southeast Asia in the 1960s and 1970s that demonstrated that dengue fever without 
complications occurred in foreigners who were non-indigenous to the area while much more 
severe dengue occurred in indigenous children.103 The theory of ADE explains that such severe 
disease in infants is a result of the transfer of DENV-specific maternal IgG antibodies across the 
placenta. As these anti-DENV antibodies diminish to lower levels, they predispose the infant to 
ADE by facilitating enhancement of a newly acquired primary DENV infection.103 Further 
evidence comes from passive administration of DENV-reactive monoclonal or polyclonal 
antibodies into IFN receptor-deficient mice256 as well as in non-human primates73 resulting in an 
increase of viral burden and disease severity. 
Over time, the ADE model has been further expanded to recognize that binding of DENV 
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antibody-antigen complexes to myeloid or mast cell Fcγ receptors may affect host immunity in a 
number of ways: increased release of cytokines such as IL-10 results in the skewing CD4+ T-cell 
responses.102 Alternatively, ADE may promote degranulation of vasoactive molecules that 
enhance capillary leakage.216 In mice, transfer of enhancing concentrations of antibody appears 
to promote ‘‘cytokine storms’’ and vascular leakage; again a result of interactions of the Fc 
region of antibody with Fcγ receptors.12  
In spite of such evidence, there are numerous documented cases of severe dengue with 
hemorrhagic and/or shock symptoms occurring after primary infection41,163,200 as well as cases in 
which, even upon secondary infection, no hemorrhagic fever or shock manifests.158,244 The 
specific mechanism by which ADE leads to severe symptoms is still in question as well. While 
ADE may enhance viral uptake, it is not clear that higher viremia is by itself a cause of more 
severe symptoms. For example, while average peak virus titers are higher in patients with severe 
dengue than in patients with dengue fever, these titers are several logs below peak levels by the 
time plasma leakage occurs.236 Conversely, many patients who have high virus titers do not 
develop plasma leakage.134,137 Such observations suggest that high viremic titers resulting from 
ADE may not be the only mechanism responsible for the pathogenesis associated with DENV 
infection. 
DENV strain variation and virulence 
In common with other organisms, DENV populations demonstrate genetic change as both a 
cause and consequence of evolution over time. As discussed in the section Dengue 
Phylogenetics and Evolution, evolution results from various forms of genetic variation, such as 
mutation, gene flow and recombination, being modified by those forces that change the relative 
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proportion of variants in populations over time, i.e., the random chance of genetic drift or non-
randomly through natural selection.19 What is less clear is whether such genetic change in DENV 
might lead to the phenotypic expression of such traits as increased virus replication and viremia, 
severity of disease (virulence), and greater transmissibility. As with other aspects of dengue 
research, correlating genetic changes in the DENV genome to specific phenotypic changes is 
difficult. The lack of good animal models for in vivo testing has been mentioned before. 
Epidemiological correlations with genetic difference are problematic because of the frequency of 
silent transmission and the variability of risk associated with uneven distribution of mosquito 
habitat and the resulting rates of transmission.217 An additional problem is that overall rates of 
virus isolation from patients with DENV infection are very low, particularly in the case of severe 
dengue with hemorrhage or shock. In most cases, by the time a patient begins to exhibit severe 
dengue, viremia is no longer detectable, probably because of the high levels of antibody present 
within the body at the time may inhibit isolation.87,168,190  
In spite of these challenges, it has been clearly demonstrated experimentally that DENV 
do vary in phenotypes related to virulence of the virus. For example, serial passage of DENV 
strains through tissue culture or suckling mice brains have produced viruses with attenuated 
virulence in humans196 and differential propagation has produced viruses with changes in 
temperature tolerance, plaque size, mosquito infectivity, mouse neurovirulence and the tropism 
of strains of DENV for various cell lines.101,190  
Good epidemiological evidence for natural variation in virulence is scarce since one of 
the attributes of the most useful epidemiological cases is that they should have occurred in 
remote and isolated areas where it can be shown that the outbreaks are due to infection from a 
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single DENV serotype and as a result of primary infections. The latter factor is important in 
order to distinguish the effects of strain variation from ADE resulting from secondary infection. 
The 1974 outbreak in Tonga (described below in the section Case Epidemiology) that serves as 
a natural experiment in DENV evolution and epidemic behavior is considered one of the classic 
examples because it is one of the very few cases in which these requirements are met. However, 
a number of other cases are frequently cited. They include an outbreak of DENV-3 in central 
Java, Indonesia in 1978, which showed dramatic attenuation, compared with an epidemic of the 
same serotype just two years earlier.87 Another example is the failure of successive epidemics in 
Iquitos, Peru – DENV-1 in 1990 followed 5 years later by DENV-2 – to result in severe 
symptoms in spite of substantial secondary infection.244 Our ability to analyze and compare 
outbreaks advanced significantly with the development of techniques allowing for partial, then 
whole genome sequencing and the use of these sequences to generate phylogenetic trees of 
evolutionary relationships among the viruses responsible for the outbreaks. Important early 
examples of such genetic epidemiology include an examination of the genetic relationships, 
distribution and evolution of DENV-1 and DENV-2 by Rico-Hesse (1990), which included one 
of the first sequences of sylvatic dengue, the delineation of geographically independent DENV-3 
subtypes and their evolution by Lanciotti et al. (1994), and a phylogenetic comparison by 
Chungue et al. (1993) of DENV-3 isolated from patients suffering severe or mild forms of 
dengue fever in French Polynesia.41,133,181 
One of the most thoroughly investigated cases for natural variation in DENV virulence is 
a shift in Central and South America from mild dengue fever to severe epidemics coincident with 
the replacement of the American genotype of DENV-2 with a seemingly more virulent Southeast 
Asian genotype of serotype-2.181 Since the late 1960s, DENV-2 in the Americas had only been 
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associated with classic dengue fever with no epidemics of DHF/DSS, despite co-circulation with 
other serotypes, in contrast with South-East Asia where severe dengue had been endemic since 
the 1950s.77,182,244 Beginning in the early 1980s however, a DENV-2 strain of higher 
pathogenicity originating from South East Asia began replacing the American subtype 
throughout Latin America with an attendant rise in dengue disease severity.81 Whole genome 
comparisons between the low-virulence American DENV-2 strain and high-virulence Asian 
strain revealed a number of structural differences throughout, particularly in the UTR of the 
latter.135 Further experimental support for this shift to an Asian DENV-2 of greater virulence has 
come from reverse engineering of the mutations that distinguish the two genotypes 
demonstrating lower viral output by the American.45 Further work showed greater susceptibility 
to infection by DEN-2 viruses of the SE Asian genotype than to those of the American genotype8 
and higher rates of replication by the SE Asian genotype in both human dendritic cells and 
mosquitoes.44 It should be noted that these investigations are relevant to the present study in as 
much as the DENV responsible for the South Pacific epidemic sweep were of the American 
genotype.213 
Other experimental support for epidemiological observations of viral virulence has 
included efforts to identify genetic markers of virulence and to characterize their phenotypic 
expression. For example, Mangada et al. (1998) did complete genome sequencing and 
characterization of 8 DENV-2 strains isolated from patients exhibiting different disease 
severities during an epidemic season in northeastern Thailand in 1993.151 While they found that 
the strain associated with shock symptoms showed the greatest divergence from other isolates, 
they were unable to identify any specific molecular markers associated with virulence, infectivity 
or cytopathic effect. In summary, there is as yet no evidence for a specific molecular basis for 
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virulence and/or epidemic potential, if only because we still have much to learn about the 
structure of DENV itself and its functions. 
Thus, while much progress has been made in elucidating the causes and mechanisms 
behind dengue pathogenesis, we are still far from any conclusive and comprehensive 
explanation. Both viral and host immune factors appear to play an integrated role in this process. 
Available evidence supports the hypothesis that severe dengue disease can more often be 
observed with some viral strains than with others and that it can occur in the absence of 
sequential infection. At the same time, there is abundant evidence that the risk of severe dengue 
is increased with secondary infections and that host immune responses must play a major role in 
capillary leakage. It may be the case that strain variation and ADE work in tandem to generate 
greater severity. For example, a comparison of low passage DENV-2 isolates from Thailand 
found evidence that strains associated with hemorrhagic symptoms had a tendency to cross react 
with more of a panel of DEN-4 monoclonal antibodies than those strains associated with 
classical dengue fever.160 Halstead also noted many years ago that different strains within 
serotypes ‘differed markedly in their reactions with dengue antisera’.95 Both observations 
suggest that some DENV strains from the same serotype could cause more severe disease than 
others because they have a greater ability to be enhanced by heterotypic antibodies. Thus, 
apparent increases in strain virulence might actually result from the virus generating a less robust 
immune response leading to enhancement.107,160  
Such a dynamic might work in conjunction with or even be the cause of a phenomenon 
frequently noted in dengue literature; that severity of outbreaks seems to correlate with a 
particular sequence in serotype or genotype exposure. For example, a prospective 
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epidemiological study in Rayong, Thailand found that all children exhibiting shock had 
secondary infections and the specific sequence determining the highest risk of shock was a 
primary infection with DENV-1 followed by DENV-2.197 Interestingly, in a table published in 
1980 that listed ten ‘simultaneous or sequential epidemics involving two or more dengue virus 
types but not associated with epidemic dengue shock syndrome’ only two were DENV-1 
followed by 2 and in those two cases the epidemics followed each other by more than 30 years.93 
Yet, a clinically mild outbreak of DENV-1 in Cuba in 1977, followed by DENV-2 in 1981, 
affected more than 300,000 persons, causing over 10,000 severe cases with 158 deaths.25 But on 
the other hand, the very same pattern of DENV-1 in Iquitos, Peru in 1990 followed 5 years later 
by DENV-2 was notable precisely because it did not result in severe symptoms.244 
In an intriguing side note to the 1981 Cuban DENV-2 epidemic, Kouri et al. (1989) 
observed that the responsible strain appeared “to have become more virulent with successive 
passages through the human host.”69 As evidence they noted that while the case fatality rate 
would have been expected to drop over the course of the epidemic due to improved case 
management, instead Cuba’s case fatality rate increased. They further argued that if one accepts 
a combined extrinsic and intrinsic incubation period of 15–20 days, then over the course of the 
Cuban 1981 outbreak the DENV-2 would have had time for approximately three human 
passages, which they claim as a possible explanations for the increased severity and case fatality 
rates.127 The concept of DENV gaining greater virulence as it goes through repeated “passages” 
through human hosts during epidemic outbreaks is interesting in as much as it offers a 
mechanism to explain the emergence of greater virulence. Yet, as previously noted, there is little 
evidence that strong positive selection plays a significant role in DENV evolution, in comparison 
to the role of importation leading to lineage replacement or localized genetic drift107,255 although 
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some evidence for localized adaptive evolution does exist.20,21 On the other hand, the importation 
of strains that then replace previous lineages means that adaptation must have occurred in a 
different location. Similarly, given the co-circulation of all four serotypes through most of the 
tropics and the rapid global movement of people, increased mixing of viral strains is inevitable. 
It has been suggested that this might possibly result in increased competition among DENV 
strains, “selecting for those that attain the highest levels of viremia, and hence maximum 
infectiousness.”107 
In any case, it is most likely that both viral and host factors are relevant to determining 
the risk of severe dengue disease but the specific interactions and relative importance of all these 
factors in determining the expression of clinical disease has yet to be established. 
Clinical Features and diagnosis of Dengue and Severe Dengue 
Infection with DENV results in clinical manifestations ranging from asymptomatic to mild 
febrile illness to severe shock and death. Of the more serious illnesses, two major syndromes 
have been defined, dengue fever (DF) and dengue hemorrhagic fever/dengue shock syndrome 
(DHF/DSS). The spectrum of illness is similar regardless of which of the four serotypes of 
DENV caused the infection, although there is some evidence that severe and fatal hemorrhagic 
disease is more often associated with DENV-2 and DENV-3 infections.78 In most tropical 
countries, any patient presenting with high fever with a history of mosquito exposure or living in 
an endemic area should be immediately suspected of DENV infection. Nonetheless, clinical 
diagnosis of dengue is problematic as symptoms can vary over the course of the illness and 
during the febrile phase, dengue resembles other arboviral infections, as well as measles, rubella, 
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enterovirus infections, adenovirus infections, and influenza.207 
 Regardless of clinical outcome, infection typically begins abruptly, with an incubation 
period lasting an average of 4–7 days (<14 days). Specific symptoms are frequently dependent 
upon the age of the patient. For example, in those areas where DENV is endemic, infections 
frequently result in undifferentiated febrile disease particularly in infants and young children. 
Serological studies have found that up to 90% of infected individuals were asymptomatic or 
minimally symptomatic.27,37 In those cases where fever does manifest, it is often characterized by 
nonspecific flu-like symptoms.153 
Classic dengue fever is a self-limiting febrile illness characterized by abrupt onset of 
high-grade fever (temperature of 38.9°C–40.6°C) associated with a variety of symptoms 
including headache (frequently retro-orbital), lumbosacral pain, conjunctival congestion and/or 
facial flushing. These initial symptoms can be followed by generalized myalgias or arthralgias 
that can worsen in severity over time. The constellation of symptoms of severe and 
incapacitating body ache, back pain, and arthralgia often is called “break bone fever.”121 Roughly 
50% of patients experience a transient, generalized macular or mottled rash within the first or 
second day, while a secondary rash, maculopapular or morbilliform and nonirritating, can appear 
coincident with or soon after defervescence, on the torso initially and then spreading 
centripetally to the face and limbs.171 Fever may last 1–2 days, may persist 6–7 days, or may 
have a biphasic (saddleback) course, although the latter is not the norm.183 Laboratory 
abnormalities may include thrombocytopenia, leukocytopenia, and a rise in liver enzymes along 
with a variety of hemorrhagic manifestations including petechiae and epistaxis, and a positive 
tourniquet test. The latter test can be easily performed using a simple tourniquet or blood 
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pressure cuff and has been reported to detect about four-fifths of patients with DENV 
infection.251 
Severe dengue or dengue hemorrhagic fever/dengue syndrome (DHF/DSS) describes 
DENV infections with more severe symptoms that typically begin with the sudden onset of a 
high temperature. This lasts 2–7 days, with accompanying chills, flulike constitutional 
symptoms, and a flushed face. As the fever subsides, patients may either recover or progress to a 
state of plasma leakage, which may in turn be transient or may progress to hypovolemia and 
profound shock with elevated hematocrit and hypoproteinemia, which if untreated, may progress 
to death within hours.246 Children with DHF frequently present with a sudden rise in temperature 
(>39°C and occasionally up to 40–41°C) along with facial flush, and at higher temperatures 
febrile convulsions may occur, particularly among infants. Those children with shock are often 
somnolent, exhibit facial petechiae, and show perioral cyanosis.121 Clinical evidence of 
accompanying plasma leakage includes serous effusion found postmortem, pleural effusion in 
radiographs, hemoconcentration, and hypoproteinemia.  
Hemorrhagic manifestations of severe dengue can include skin hemorrhages such as 
petechiae, purpura, and ecchymoses; bleeding from mucous membranes (epistaxis, gingival 
bleeding); and bleeding from the gastrointestinal, vaginal, and urinary tracts. As with pleural 
effusion associated with shock, these hemorrhagic symptoms usually occur after the fever 
subsides, with the gastrointestinal tract being the most common site of bleeding.78,121 
In patients that progress to shock, there are a number of signs of circulatory failure: the 
skin becomes cool, blotchy and congested; circumoral cyanosis is often observed; pulse becomes 
rapid. Initially lethargic patients may become restless; acute abdominal pain is frequently 
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observed. Many patients recover spontaneously or after fluid and electrolyte therapy. Patients 
with more severe plasma loss are in danger of profound shock leading to death without 
appropriate therapeutic management. The duration of shock is usually short; the patient may die 
within 8–24 hours or recover rapidly following appropriate volume-replacement therapy. With 
early diagnosis and prompt replacement of plasma, the severity of DHF/DSS can be substantially 
ameliorated.  
In terms of laboratory tests for dengue diagnosis, there are two general classes: the 
primary presumptive test, of which the most important is complete blood count. This can confirm 
the presence of increased hematocrit (hemoconcentration), atypical lymphocytosis and 
thrombocytopenia. The second class being confirmatory of dengue infection, which may be 
important in those cases where symptoms suggest the possibility of confusion with another 
pathogenic agent. Of the latter a variety of tests are available including reverse transcription 
PCR, viral isolation, and NS1 antigen rapid kits, but the most common are serological tests 
(typically ELISA) and focus on measuring either IgM or IgG.251 
Treatment for dengue is only palliative; there is no specific anti-viral treatment available 
for dengue. Nonetheless, early diagnosis and aggressive fluid replacement therapy with good 
nursing care can decrease case fatality rates to 1% or less.78 Fever is controlled with 
acetaminophen, with other nonsteroidal anti-inflammatory agents to be avoided due to their 
anticoagulant properties and risk of Reye syndrome in children. In most cases, patients testing 
positive for DENV infection do not require hospital admission or intravenous fluids unless they 
present with severe vomiting, dehydration, bleeding, altered mental status, clinical deterioration, 
or other evidence of severe dengue.121 In patients exhibiting mild hemorrhagic symptoms or 
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shock, normal saline or lactated Ringer’s solution can be used, but plasma or plasma expanders 
may be necessary in those with severe cases.78 
The majority of DF patients recover, even in cases of hemorrhage or profound shock.78 
Convalescence is usually short, with surviving patients recovering within 2–3 days, generally 
without sequelae, although some convalescence may be prolonged, with generalized weakness, 
bradycardia, ventricular extrasystoles, and mental status changes that can include lethargy, 
somnolence, and feelings of depression.121 
Diagnosis of dengue has gone through significant recent changes. Patients previously 
diagnosed according to World Health Organization guidelines either had DF or DHF. DF was 
defined as a febrile illness with at least two clinical findings; none of which were particularly 
specific, thus necessitating laboratory or epidemiological evidence for a confirmed diagnosis. 
The definition of DHF consisted of four clinical criteria: fever, a hemorrhagic tendency 
(spontaneous bleeding or a positive tourniquet test result), thrombocytopenia (platelet count, 105 
cells/mm3), and plasma leakage shown by pleural effusion, ascites, or 20% hemoconcentration. 
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Figure 8. Dengue classification according to the World Health Organization 
guidelines issued in 1975 and 1997. From Srikiatkhachorn et al. 2011 
However, the large numbers of patients with severe dengue disease exhibiting symptoms 
not matching those of the WHO system prompted calls for more inclusive case definitions.83 
Other criticisms included questions whether the case definitions, which were primarily 
developed using pediatric data from cases in Southeast Asia, were applicable to other regions 
and populations.211 The recent revision of the WHO dengue classification scheme states, “For the 
purpose of clinical management, WHO classifies dengue illness as (i) dengue with or without 
warning signs for progression towards severe dengue and (ii) severe dengue.”248 Patients who 
recover without major complications are classified as having dengue, whereas those who have 
any of the following conditions are designated as having severe dengue: plasma leakage resulting 
in shock, accumulation of serosal fluid sufficient to cause respiratory distress, or both; severe 
bleeding; and severe organ impairment.  
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The changes made in classification have not been without controversy. For example, an 
opinion paper by Halstead (2013) argued, “pathogenesis research should be conducted as much 
as possible on carefully defined categories of human disease response. This requires splitting, not 
lumping.”97 A group of authors defended the new guidelines, writing; “DF/DHF/DSS was too 
complicated to use in clinical or public health settings, yet was not sufficiently precise for 
detailed pathogenesis studies.” And that “D/SD brings clarity, clinical and epidemiological 
utility, and the potential for development of more precise definitions of clinical phenotype for 
pathogenesis studies.”63 A systematic review comparing the 1997 and 2009 WHO dengue case 
classifications, using 12 eligible studies (4 prospective), including ten expert opinion articles, 
was published by Horstick, et al. 2014.109 They summarized their findings as “The 2009 WHO 
classification has clear advantages for clinical use, use in epidemiology is promising and 
research use may at least not be a disadvantage.” 
 
Figure 9. Dengue classification according to the World Health Organization guidelines issued in 2008. 
Dengue is classified as dengue with or without warning signs and severe dengue.  
From Srikiatkhachorn et al. 2011 
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Useful summaries of relevant clinical features of dengue infection include Gubler 1997, 
Gubler 1998, Kalayanarooj et al. 1997, Kaushik et al. 2010, Oishi et al. 2007, and WHO 
2007.77,78,119,121,171,246 
Dengue Vaccines 
No specific anti-viral treatment is available for dengue. Aggressive fluid management to correct 
hypovolemia has reduced the case fatality rates of severe dengue to 1% or less but this is only 
palliative.78 Historically, prevention against dengue disease has focused on vector control and 
elimination but unfortunately, there is little evidence of long-term sustainable success for such an 
approach172 and even when such efforts have been successful, the primary impact appears to lie 
in suppressing mosquito population numbers rather than lowering the incidence of dengue 
disease.2 Thus, given the increasing scope and severity of dengue, efforts towards the 
development of a protective dengue vaccine are critical. And in theory, a vaccine for dengue 
should be readily achievable. DENV has no significant animal reservoir (while some spillover 
from sylvatic DENV has been reported165 there is no evidence that sylvatic DENV plays any role 
in maintaining transmission).232 Furthermore, DENV does not cause chronic infections such as 
with HIV or hepatitis C. Indeed, following infection with any one serotype, homotypic immunity 
appears to be quite long-lived if not life-long.238 Nonetheless, DENV has particular 
characteristics, detailed below, that present a challenge to the development of an effective and 
safe vaccine, many of which are corollaries to the advantages just enumerated.  
For example, the lack of an animal reservoir ironically presents a significant obstacle 
inasmuch as the clinical development of candidate vaccines is severely hampered by the lack of a 
relevant animal model. Mice are one of the most commonly used animal models in clinical 
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studies but wild-type mice exhibit little to no replication of DENV isolates. Moreover, non-
human primates exhibit few signs of severe dengue illness such as fever or shock.34,259 
A second obstacle is that an effective vaccine needs to prevent infection with all four 
DENV serotypes. While natural infection does induce long-lasting homotypic immunity, 
heterotypic immunity, while variable in duration, generally lasts only 6 months and thus only 
temporary.201 Development of vaccines with a tetravalent formulation that retains the 
immunogenicity of all four components has proven difficult, requiring the use of more 
complicated, multiple-dose immunization regimens.247 A third obstacle, and one connected to the 
second, is the possible complications of immune mediated enhancement of disease. Secondary 
natural DENV infection presents a sixfold higher risk of severe disease compared with primary 
infection,27 which is hypothesized to be due to heterotypic ADE. Thus, for a vaccine to be 
protective, it has to induce both strong and long-lasting neutralizing antibodies against all four 
DENV serotypes simultaneously yet not be so over-attenuated as to be unable to induce a 
protective immune response or indeed, to possibly enhance infection. The unique risk associated 
with dengue vaccines is that their attenuation or inactivation could possibly lead to 
subneutralizing concentrations of antibody and present a risk of enhancing disease rather than 
prevention.159 For example, vaccine induced ADE appears to have played a role in a trial of an 
experimental live-virus vaccine containing DENV-2. Volunteers in that trial previously given 
yellow fever virus vaccine exhibited higher antibody titers against DENV-2 than naïve patients 
and had evidence of higher and more frequent viremia.199 A fourth obstacle is a relative lack of 
data to predict the efficacy of candidate DENV vaccines in preventing severe dengue. 
Experimental challenge studies in humans that were conducted during and shortly after the 
Second World War made no effort to test the efficacy of candidate vaccines against symptoms of 
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severe dengue, such as DHF and DSS, simply because such pathologies were unrecognized prior 
to the late 1950s. Subsequent studies of candidate vaccines have analyzed efficacy only in 
experimental animal models, none of which faithfully reproduce the DHF syndrome seen in 
humans. As a result, selection of the most promising DENV vaccine candidates has necessarily 
relied on comparisons of vaccine- induced immune responses against observation of the 
protective immunity resulting from natural DENV infections.191 Nevertheless, a lack of reliable 
immunological markers distinguishing fully protected individuals from those at elevated risk has 
always meant that such observations are provisional at best.192 
Table 1. Dengue vaccines in clinical development (adapted from Sinha 2014) 
Developer Product description Stage 
Sanofi Pasteur  Dengvaxia®. Live attenuated tetravalent vaccine (Yellow Fever 17D/DENV chimeric viruses)  Licensed 
GlaxoSmithKline/ Walter 
Reed Army Institute of 
Research 
Live attenuated vaccine passaged through primary dog 
kidney cells and fetal rhesus lung cells Phase 3 
National Institutes of Allergy 
and Infectious Diseases/ 
Butantan Institute  
Live attenuated vaccine (targeted mutagenesis of DEN 
viruses and DENV/DENV intertypic chimeric virus)  Phase 3 
Takeda Pharmaceuticals / 
Inviragen  
Live attenuated DNA tetravalent vaccine (attenuated 
DEN2 PDK-53 virus and DENV/DENV intertypic 
chimeric viruses)  
Phase 2 
GlaxoSmithKline/Oswaldo 
Cruz Foundation/Walter 
Reed Army Institute of 
Research  
DENV1, purified inactivated virus vaccine  Phase 1 
US Naval Medical Research 
Center/Vical  
Vaxfectin DNA Vaccine (TVDV), expression of prM and 
E membrane proteins. Formulated with and without 
Vaxfectin adjuvant  
Phase 1 
In spite of these impediments, efforts towards dengue vaccine development have been in 
place since the 1920s, involving attenuating DENV in blood with ox-bile or grinding infected Ae. 
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aegypti mosquitoes in a salt solution and chemically pure phenol and formalin.154,208 During the 
Second World War, military physicians in the United States and Japan began efforts soon after 
the virus strains were isolated. Their studies demonstrated that DENV could be attenuated in 
humans after serial passage in suckling mouse brains and could elicit protective immunity 
against DENV challenge.110,196 Halstead (1980) cites investigations into developing live 
attenuated DENV-2 and DENV-4 vaccines that began in 1971 at the Walter Reed Army Institute 
of Research and the University of Hawaii, respectively.92 Walter Reed tested their vaccine 
candidate on human volunteers, derived from DENV-2 isolated from the serum of a patient with 
DF in Puerto Rico on 19 August 1969.14  
Sanofi-Pasteur Dengvaxia® 
While there are a number of candidate DENV vaccines in development (Table 1) the first 
to be successfully licensed is Dengvaxia®, otherwise known as chimeric yellow fever dengue-
tetravalent dengue vaccine (CYD-TDV), developed by Sanofi-Pasteur. This recombinant 
chimeric live attenuated tetravalent vaccine uses a yellow fever 17D vaccine strain as a backbone 
for which the PrM (pre-membrane) and E (envelope) structural genes are replaced with those 
from each of the four DENV serotypes195 (Figure 10a).  
 
Figure 10a) CYD-TDV structure: a yellow fever virus 17D vaccine strain backbone (in yellow) with prM 
and E gene segments from DENV 1-4. From Screaton et al. 2015 
Nature Reviews | Immunology
a  CYD-TDV (Sanoﬁ Pasteur)
b  LATV Δ30 (NIH)
c  DENVax (Takeda)
Δ30
Δ30
Δ30
Δ30
DENV1 C prM E Non-structural genes5′ 3′
DENV2 C prM E Non-structural genes5′ 3′
DENV3 C prM E Non-structural genes5′ 3′
DENV4 C prM E Non-structural genes5′ 3′
DENV1 C prM E Non-structural genes5′ 3′
DENV2 C prM E Non-structural genes5′ 3′
DENV3 C prM E Non-structural genes5′ 3′
DENV4 C prM E Non-structural genes5′ 3′
DENV1 C prM E Non-structural genes5′ 3′
DENV2 C prM E Non-structural genes5′ 3′
DENV3 C prM E Non-structural genes5′ 3′
DENV4 C prM E Non-structural genes5′ 3′
regard to responses to DENV2 (REF. 102). Heterologous 
priming and boosting has also been investigated in 
humans, in which CYD1 and CYD3 were used to prime 
and CYD2 and CYD4 used for boosting at 15 weeks103. 
In contrast to the primate study, the sequential bivalent 
immunization strategy was not superior to the repeated 
tetravalent immunization approach. It remains possible 
that the timing between priming and boosting and the 
serotype combinations used in these two studies may 
have influenced the outcome.
Of the other live attenuated vaccine candidates, a 
Phase I trial of the NIH LATV Δ30 vaccine, which has 
a 30-nucleotide deletion in the 3ʹ untranslated regions 
of the cloned cDNA (FIG. 4b), showed that seropositivity 
across all serotypes was over 90% after one dose of the 
vaccine; however, around 60% of vaccinees developed a 
rash and 73% experienced viraemia86,104. The tetravalent 
live attenuated vaccine DENVax (developed by Takeda) 
has undergone a Phase I trial87, in which more than half 
of the volunteers developed measurable antibodies to 
all four virus serotypes after a single dose87,105. Finally, 
despite the demonstration that the TDEN vaccine 
candidate developed by the Walter Reed Army Institute 
of Research (WRAIR) and GlaxoSmithKline induced 
antibody responses to the four serotypes in a Phase II 
trial, development has been stopped106.
Despite the difficulties, there remains a pressing need 
to pursue vaccine candidates as well as to test whether 
live attenuated vaccines can be improved to provide a 
more balanced protection, and whether these responses 
are durable will be determined by longer-term follow up 
of clinical trials.
New insights from monoclonal antibodies
A large number of mouse antibodies have been gener-
ated against dengue virus, and the epitopes for several 
of these have been mapped by systematic or random 
mutagenesis to the E protein107–116. More recently, human 
mAbs have been generated from dengue virus-infected 
patients; the main epitopes recognized by mAbs are 
described in this section (TABLE 2).
Antibodies targeting the fusion loop epitope of E protein. 
The fusion loop epitope (FLE) is a major epitope targeted 
by antibodies produced in both humans and mice. mAbs 
specific for the FLE are exemplified by mAb E53, which 
was originally isolated from West Nile virus-infected mice 
but is fully cross-reactive with dengue viruses117. Mutation 
of E protein W101 blocks the binding of antibodies 
directed to the FLE and reduces the reactivity of poly-
clonal human serum118–120. mAbs specific for FLE show 
good neutralization of dengue viruses grown in insect 
cells, which contain high levels of prM protein16. FLE-
specific mAbs bind better in the presence of prM protein 
which, by virtue of changing the virion architecture, better 
exposes the FLE13. The binding of FLE-specific mAbs to 
more mature virions produced in primary human cells, 
which contain lower levels of prM protein, and their sub-
sequent neutralization is not particularly efficient, with 
neutralization levels typically failing to exceed 60–80% 
even at high antibody concentrations16. The induction of 
antibodies specific for FLE, although commonly gener-
ated in humans and often cross-reactive between sero-
types, may not therefore be the ideal response to target 
by vaccines. Another antibody, 1C19, which recognizes 
the BC loop (amino acids 73, 78 and 79) close to the FLE, 
potently neutralized all four serotypes, suggesting that the 
epitope may be a good target for vaccines. However, it is 
not clear whether the epitope for 1C19 is prM-dependent 
in common with other FLE-specific mAbs, as the epitope 
for 1C19 lies close to the FLE121.
Figure 4 | Dengue vaccines. a | The Sanofi Pasteur vaccine CYD-TDV contains four 
chimeric live flaviviruses, each derived from the genome of the yellow fever virus 17D 
vaccine strain (shown in yellow) with the precursor membrane (prM) and envelope (E) 
gene segments replaced by the corresponding gene segments of each of the four 
dengue virus serotypes (DENV1 to DENV4). b | The US National Institutes of Health (NIH) 
live attenuated tetravalent vaccine (LATV) contains a mixture of four recombinant 
dengue virus genomes; the DENV2 component is a chimeric dengue virus derived  
from a DENV4 genome with prM and E gene segments replaced by those of DENV2.  
The vaccine strains were attenuated by deleting 30 nucleotides (Δ30) from the 
3′|WntTansNatedTeIionoHtJedenIWeXiTaNIenoOec | The DENVax vaccine from  
Takeda contains a mixture of four recombinant DENV2 genomes, each derived from  
the genome of an attenuated DENV2 virus with prM and E gene segments replaced  
by the corresponding gene segments of DENV1, DENV3 and DENV4.
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Sanofi-Pasteur tested the vaccine extensively in large trials in southeast Asia and Latin 
America among cohorts of adults and children who were either immunologically naive against 
DENV and other flaviviruses before vaccination or who had some degree of pre-existing 
flavivirus immunity due to vaccination against YFV or JEV or natural exposure in endemic 
areas.89 Based on these tests, the WHO Strategic Advisory Group of Experts (SAGE) on 
immunization recommended in early 2016 that Dengvaxia be used in countries with high DENV 
endemicity based on the vaccine’s safety and expected public health benefit; particularly when 
used in high transmission intensity regions with approximately 70% seroprevalence at 9 years of 
age. On the other hand, based on independent modeling65 it appears that in very low transmission 
intensity settings (seroprevalence 10% at 9 years) vaccination of 9 year-olds was likely to 
increase dengue hospitalization rates. Thus, the recommendation of WHO is that the vaccine 
CYD-TDV not be used when seroprevalence is below 50% in the age group targeted for 
vaccination nor in children under 9 years of age.247  
Based on the WHO’s projection of a 10%–30% reduction in symptomatic and 
hospitalized dengue illness over 30 years, as of 2016 Dengvaxia is now commercially available 
in the Philippines and Indonesia and approved for use by Mexico, Brazil, El Salvador, Costa 
Rica, Paraguay, and other countries.60,254  
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CHAPTER 2: EXPERIMENTAL BACKGROUND 
Case Epidemiology 
The studies described in this dissertation are based on DENV-2 isolates from a series of 
outbreaks that occurred in the South Pacific in the early 1970s, which were notable – for the 
purposes of this study – in abruptly shifting from a distinctly virulent character to one that was 
quite attenuated85. Because the epidemiology of these outbreaks was relatively well documented, 
and serological and clinical data are available for all isolates used in this study, a close 
examination of this epidemiological evidence seems warranted and is described below. 
Outbreaks of dengue were known to occur among the Pacific islands, if only on an 
occasional basis, such as in the late 1800s and early 1900s in such countries as Australia, New 
Caledonia, and Fiji. Later, dengue appeared in Fiji, Tonga, and both islands of Samoa during the 
1930s47 . 
However, the frequency and size of dengue outbreaks increased sharply across the Pacific 
with the Second World War, as movements of troops and materials brought increased human 
population densities as well as expanded vector distribution. Large epidemics of dengue erupted 
among troops of both armies76 and there were major epidemics in at least twelve of the nineteen 
South Pacific territories.47 Retrospective serological surveys in many of these areas indicated that 
these epidemics were largely due to the DENV-1 serotype. All available evidence indicates that 
following the war there were no dengue epidemics for the next 20 years41. 
The next appearance of dengue began with a mild but widespread epidemic in French 
Polynesia in 1964 affecting several thousand people (approximately 50% of the population at the 
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time) due to DENV-3. No major hemorrhagic manifestations were seen. DENV-3 was 
responsible for another outbreak in Tahiti in 1969, even more mild than that previous.47 
Figure 11. Map of those South Pacific islands - Fiji, New Caledonia, Niue, Tahiti and Tonga - from which 
DENV-2 was isolated and analyzed in this study. From: U.S. Central Intelligence Agency, 2007. 
Fiji 
The DENV-2 isolates with which this dissertation concerns itself were derived from a specific 
set of outbreaks that swept across islands of the South Pacific in the early 1970s (Figure 11). 
There is some evidence to suggest that the DENV strains involved in these outbreaks were 
genetically related to outbreaks in Puerto Rico that took place between 1969 and 1973. Thus the 
virus could have been introduced into the South Pacific from the Caribbean (or vice versa)220,181. 
The South Pacific epidemic sweep began with nearly simultaneous outbreaks in Fiji and Tahiti 
and smaller neighboring islands beginning in early 1971. The first clinical case in Fiji was 
diagnosed in March, although subsequent serological tests of young people in the surrounding 
area suggested that initial infections had occurred several weeks before the diagnosed case. 
Sporadic cases were reported over the next few months but only in May 1971 was formal 
notification made of a dengue outbreak. The number of cases remained high until the end of 
August, and then declined to a minimum of three cases in January 1972, whereupon cases 
increased again each month to a second peak of 79 cases in April. Notification ceased in April 
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1973 with a total of 3,413 cases150. 
While many cases showed the classic dengue fever syndrome, a majority of cases were 
quite mild with serological tests indicating additional large numbers of subclinical infections as 
well. Only three individuals (all adults) demonstrated hemorrhagic manifestations although none 
were ever proven to be due to DENV infections. Hemagglutination inhibition (HI) antibody titers 
in all cases were much higher to DENV-2 than to DENV-1. Seventy-three percent of 
notifications were from people over 20 years of age, in spite of this cohort only constituting 26% 
of the population, and 35.4% of these individuals had anti-DENV antibodies before the onset of 
the epidemic. The age distribution of the outbreak suggested that pre-existing antibodies might 
have played a role in enhancing subsequent infection. Regarding mosquito populations, with the 
exception of one neighboring island, dengue outbreaks only occurred in those areas where the 
Aedes aegypti mosquito was present. 
Tahiti 
Concurrently with the epidemic in Fiji, another outbreak, also of the DENV-2 serotype, took 
place on the island of Tahiti. The first clinical diagnoses in Tahiti were made in May 1971 with a 
peak of cases in late June/early July and lasting until September of the same year. Estimates 
based on hospital and employment records indicate that at least half of the Tahiti's population of 
approximately 80,000 persons was affected, with the majority affected being adults. More than 
50 isolates were obtained, though only one from a DHF case, all of which were DENV-2. 
Although most patients exhibited symptoms of classic dengue fever such as headache, 
muscle pain, morbilliform eruption, etc., there were a small but significant number of patients 
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who exhibited DHF of unusual severity.158 188 Of these hemorrhagic patients, 33 experienced 
symptoms serious enough to warrant hospitalization and 3 died. All were older, all but three had 
antibodies showing a previous DENV infection, i.e., a secondary antibody response, and the 
DHF was remarked as being “distinctly hemorrhagic” as opposed to manifesting as dengue 
shock syndrome. Because, as mentioned above, DENV-3 outbreaks were known to have 
occurred in Tahiti in 1964-1965 and then again, on a smaller scale, in 1969, the DHF was felt to 
be compatible with the theory of sequential infection, also known as ADE. 
New Caledonia 
An outbreak of DENV-2 occurred on the island of New Caledonia from October 1971 to May 
1972 affecting approximately 40% of the population, which at the time was around 60,000 
persons. Hemorrhagic cases were described as “frequent”143 with one death of a young male 
believed to have had a primary DENV infection some years before. 
Niue Island 
In early 1972 a DENV-2 epidemic that exhibited much greater manifestations of DHF severity 
took place on Niue Island15. Located roughly 300 miles east of Tonga and 350 miles southeast of 
Samoa with an area of about 100 square miles, Niue Island at the time was relatively isolated, 
receiving one plane a week and one boat a month. The first case of DENV-2 was laboratory-
confirmed in March 1972 although several febrile illnesses suffered by Europeans in February 
were retrospectively suspected to have been dengue. The largest number of cases occurred 
March – June and tapered off until September. Out of a total population of approximately 4,600 
persons, (all of whom but ~ 150 were Polynesian) the number of people seen by the local 
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department of health and confirmed as having DENV was 790. There were 12 deaths, seven of 
which were among children between the ages of 2–14 years. Most patients exhibited signs and 
symptoms associated with classical dengue infection: a fever (sometimes of “saddle-back” 
configuration), prostration, headache, backache, retro-orbital pain, and in some cases, a 
morbilliform rash. However, a small but significant number of patients exhibited DHF/DSS with 
such symptoms as abdominal pain, hepatomegaly, hematemesis, epistaxis, ecchymosis, shock 
and coma. Unusually, in a number of patients ecchymosis progressed to ulceration. 
Given the severity of the outbreak on Niue Island, a retrospective study was carried out in 
August 1972. Six hundred and thirteen individuals were queried as to the state of their health 
since February 1972 and whether they believed they had had dengue. Of these 275 answered 
affirmatively (44.8% of the total 613 individuals), with 70 having experienced hemorrhagic 
manifestations (25.4% of cases, 11.4% of the total 613 individuals). A serological study carried 
out at the same time collected sera from all 8 surviving severe cases who had not left Niue 
Island, from all available household contacts (4 years of age or older) of the severe and fatal 
cases (73 total), and from a random sample of persons of various ages who lived in different 
parts of the island, for a total of approximately 500 samples. HI and plaque-reduction 
neutralization tests were carried out for both DENV-1 and DENV-2. 
The results showed that the outbreak was caused exclusively by DENV-2. The data 
further showed that all infected persons under the age of 25 had contracted a primary dengue 
infection during the recent outbreak while most infected persons over the age of 30 experienced 
an infection of the secondary type. The latter correlated with epidemics of DENV-1 known to 
have taken place on many Pacific islands during the Second World War. In regards to clinical 
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outcomes, no striking differences were observed between those individuals experiencing primary 
infection versus those experiencing secondary either with respect to the percent reporting illness 
or the percent of illnesses with hemorrhagic manifestations. Such results prompted the authors of 
the original report to conclude that the observations on Niue were not compatible with the theory 
of sequential infection and ADE.15 
Any possible role in regards to vector was also considered. Although Aedes aegypti was 
likely to have inhabited Niue Island at the time of the outbreak (it had not been recorded 
beforehand but was found subsequently), it was far less prevalent than the endemic species 
Aedes cooki. Since there is no surface water on the island, the probable source for the mosquitoes 
were cisterns kept for household water supplies. There was no noticeable increase in the number 
of mosquitoes either before or during the outbreak. 
To summarize the status of the DENV-2 outbreaks on those South Pacific islands during 
the period from 1971 through 1972, i.e., Fiji, Tahiti, New Caledonia and Niue, all had gone 
through explosive epidemics typified by severe disease and high rates of virus isolation. 
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Smaller in scale and less documented were outbreaks characterized by mild disease 
manifestations and poor virus isolation rates as seen in Samoa and a few smaller islands during 
this same period of time.84 A sense of the differences in outbreak character between islands can 
be seen below (Figure 12). 
 
Figure 12. Graphic comparison of the number of reported DENV-2 cases on each island per year in 1971 
- 1972. From: The South Pacific Commission Dengue Newsletter. July, 1974 v. 1. 
Kingdom of Tonga 
The Kingdom of Tonga remained unaffected by the epidemics taking place on neighboring 
islands in 1971–1972. Made up of more than one hundred islands, of which about thirty are 
inhabited, the total population of Tonga in this period was estimated to be approximately 90,000. 
The nearest neighboring territories are the Samoa islands, roughly 450 miles to the north, Fiji to 
the west and Niue Island to the east, both about 300 miles distant. Given the progression of 
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epidemics on all of these neighboring islands, public health officials in Tonga had reason to 
anticipate an epidemic of corresponding severity on their island. In addition, high rainfall over 
the fall and winter of 1973 had led to greater than usual populations of Aedes aegypti as well as 
A. tabu thus heightening concern.85 ⁠ 
Beginning in August 1973, human plasmas collected in the course of a filariasis survey 
were tested for dengue HI antibodies in order to detect silent infections. In general, individuals 
over the age of 40 showed seropositivity against DENV-1 while younger persons did not. 
However, there were two or three individuals in their late 20s with antibodies against DENV-2. 
As these individuals had never left Tonga this finding suggested the arrival of DENV-2 on the 
island before August 1973.47 Nonetheless, no clinical signs of DENV infection appeared until 
late December 1973/early January 1974. Subsequent serological studies in March confirmed the 
presence of DENV-2. With a large dengue outbreak seemingly imminent, it was decided to take 
advantage of the circumstances to gather data on the duration and magnitude of viremia in 
effected individuals. Accordingly, records of cases at the major hospital were reviewed for 
dengue-like illnesses and house-to-house surveys carried out in a local village and two local 
schools. 
Surprisingly, no major outbreak occurred. The incidence of cases built up slowly to a 
noticeable level in mid-February, with the number of people seeking medical attention at the 
hospital peaking at 165 in March and 127 in April. Case numbers fell sharply thereafter, with 
dengue ceasing to be recognized by the end of October. Among those individuals who were 
either hospitalized or seen as outpatients, almost all had remarkably mild clinical manifestations 
of short duration and the majority had primary infections. Incidence of hemorrhage was 
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extremely low. Of those few patients with secondary infections, all were over 40 years of age.85 
Given the difficulty of determining numbers of those infected and rates of transmission, 
surveys consisting of interviews and blood samples were conducted in a local village that 
appeared to be a focal point of infections in April as well as in local schools.47 Of the 412 
villagers interviewed, around 20% had a history of dengue-like illness within two months of the 
survey with the highest rates of reported illness among persons 5–19 years old. Among 100 
school children surveyed, 8% of primary and 13% of secondary school children reported having 
dengue-like illness or fever in the previous two months.85  
Isolation of the virus was attempted in 18 patients and all successful isolations were of 
DENV-2. However, even under conditions that ought to have been ideal, both the isolation rate 
and virus content of positive sera were quite low. Some patients were identified on day of onset 
with mild illness and followed for as long as 8 days, with blood samples taken daily and 
mosquitoes allowed to feed on them. Nevertheless, the majority of these patients, confirmed with 
DENV-2 infections by seroconversion, had undetectable levels of viremia. When virus was 
detectable, viremia was at a low titer (≤ 106 MID50) and of only 1–3 days duration.78 Thus, 
viremia levels among those tested were found to vary broadly in both magnitude and duration. 
Retrospective serological assays using plaque-reduction neutralization demonstrated that, with 
the exception of one individual with no neutralizing antibodies, all patients less than 40 years of 
age had antibody patterns compatible with DENV-2 while those tested who were over 40 had 
patterns suggestive of DENV-1 infections. 
In summary, this study derives from epidemiological observations of a series of 
outbreaks of DENV-2 in the South Pacific in the early 1970s, which had a virulent character 
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initially but then appeared attenuated upon their emergence in Tonga.85 The outbreaks began, 
after an absence of almost 30 years, almost simultaneously in both Fiji and Tahiti in early 
1971,158, 150, 188 then spread to New Caledonia and Niue Island in 1972,143, 15, 188 and then Tonga 
in late 1973.85 The outbreaks in Tahiti, New Caledonia, and Niue Island all spread rapidly, 
infecting from 40 - 50% on New Caledonia and Tahiti and up to 90% on Niue. These outbreaks 
were of severe classical dengue fever and associated with high rates of viremia. Rates of DHF on 
these islands were also high, especially on Niue Island where there were 12 deaths, and were 
recorded as being of a more distinctly hemorrhagic form as opposed to manifesting as dengue 
shock syndrome.15, 47 Yet in contrast, the outbreak of DENV-2 in Tonga was extremely mild with 
almost no DHF and associated with very low viremia.85 
It is instructive to contrast this DENV-2 outbreak in Tonga with a subsequent outbreak on 
the same islands in 1975 but this time involving DENV-1. The latter virus' progression through 
the population of Tonga was explosive; the incidence of hemorrhage higher, and there was a case 
fatality rate of 12 persons (compared to none previously.) Among the few (n = 11) serum 
samples collected from this outbreak, DENV-1 was isolated from 4 of 6 patients with primary 
infections, including one 26-year-old female fatality with DHF. DENV-1 was also isolated in 
one of the four patients with secondary infections. Thus, primary and secondary infections were 
roughly equal.85 
To review then, all islands affected by dengue outbreaks from 1971 to 1974 and for 
which serological testing was conducted and/or isolates collected had outbreaks of DENV-2. 
Further, all islands experienced both primary and secondary infections, the latter as a result of 
previous dengue infections no more recent than 1950. However, with the possible exception of 
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Fiji, no particular difference was seen in disease severity between the primary and secondary 
infections. 
Those islands from which DENV-2 were isolated previous to Tonga experienced sudden 
outbreaks that showed a rapid increase in the number of people affected, resulting in 40–50% of 
the populations becoming infected, and which were characterized by disease of unusual severity. 
In Tonga however, DENV-2 exhibited near-silent transmission as it circulated around the island 
for almost a year among a population that was fully susceptible without being detected, resulted 
in less than 1% of the population exhibiting retrospective serological evidence of infection, and 
could only be characterized as remarkably mild with the virus seemingly attenuated. And again, 
a significant difference between these outbreaks was their relative rates of virus isolation. 
Because the public health systems in Tahiti and New Caledonia were so overwhelmed with the 
number of sick patients, they were actually unable to draw as many serum samples as might have 
been preferred. Nonetheless, virus isolation rates were extremely high. By contrast, in Tonga 
where preparations had been made for a large outbreak, patients showed low viremia and virus 
isolation success rates were very low. Indeed, in most cases, DENV infections were identified by 
plaque reduction neutralization antibody tests rather than by clinical symptoms. Interestingly, a 
subsequent outbreak of DENV-1 in 1975 was dramatically greater in severity, as judged by 
symptoms, numbers of cases, and virus isolation rates. Table 2 summarizes these differences. 
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Table 2. Epidemic DENV-2 in the South Pacific (adapted from84,213) 
Country Year Nature of outbreak 
Severity of 
disease Est. case numbers 
Virus isolation 
rate (%) 
Tahiti 1971 Explosive Severe 40,000 (50% of pop) > 75 
Fiji 1971 Explosive Severe 
3,400 acute; 
20,000 subacute 
> 75 
New Caledonia 1972 Explosive Severe 25,000 (40% of pop) > 75 
Niue  1972 Explosive Severe 2,070 (45% of pop) NA 
American Samoa 1972 Smoldering Mild 30 57 
Tonga 1974 Silent Mild 
24 hospitalized;  
100+ subacute 
 (~ 0.05% of pop) 
33 
Tonga (DENV-1) 1975 Explosive Severe 40,000 (50% of pop) 45 
Possible factors in the variation in South Pacific DENV-2 epidemic severity 
The transmission and incidence of DENV, and the epidemic response to infection represents a 
complex matrix of interactions among multiple populations of hosts, vectors, and pathogens. 
Thus, in order to better understand the apparently dramatic attenuation observed in the outbreak 
on the island of Tonga versus those on the other islands of the South Pacific epidemic sweep, it 
is necessary to delineate the various factors that may have played a role. 
Epidemiology 
The epidemiology of the series of outbreaks constituting the South Pacific epidemic sweep of 
DENV-2 from 1971 to 1974 has been reviewed in the previous section. It bears emphasizing 
however, that much of the unique character of this series of outbreaks is due to the unusual 
degree of geographic isolation of the human populations affected. All the islands described, 
except Tahiti, were relatively inaccessible at the time and, again with the exception of Tahiti, had 
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not experienced DENV for 25–30 years.85 
Entomology 
The possible role of mosquitoes in the differential expression of DENV-2 between islands 
warrants discussion. As previously mentioned, while other Aedes mosquitoes have been shown 
to be competent for the DENV, Ae. aegypti is considered the primary vector of transmission.132. 
While no information is available from the 1971 outbreak on Tahiti, Aedes aegypti was found in 
all areas of confirmed infection in Fiji with the exception of the neighboring island of Rotuma. 
There, only the endemic species Aedes rotuma was detected.150,47 In New Caledonia Ae. aegypti 
mosquitoes were found to be abundant in all areas where dengue was occurring143 while in Niue, 
although Ae. aegypti had not been reported previously, it was found subsequently and was 
assumed to be present during the outbreak.47, 15 
A number of Aedes species, including Ae. aegypti, and Ae. tabu, were known to be 
present on Tonga during both the 1974 DENV-2 and 1975 DENV-1 outbreaks although overall 
numbers were lower in 1975 and while each species' relative numbers varied between Tongan 
island groups, these differences did not correspond to epidemic intensity.85 Attempts to infect 
both Ae. aegypti and Ae. tabu by feeding on dengue patients were successful in only one case 
and subsequent examination of salivary glands found no presence of DENV-2. Interestingly, 
infectivity evaluations using the Tonga strain as a basis for vaccine development also found that 
the strain failed to infect the midgut or head of Ae. aegypti while they noted that DENV-2 New 
Guinea prototype strain had been shown to be highly infectious.23 
Thus, evidence for vector influence on differences in epidemic behavior is lacking. Ae. 
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aegypti was found on almost all islands in which dengue outbreaks occurred. While vector 
competency has been shown to vary between species, as well as between different geographic 
populations of the same species, no correlation has been established between these variations and 
clinical outcome, nor have subsequent dengue outbreaks with different serotypes been observed 
to follow the same geographic pattern.186 
Serology and host genetics 
Much of the pathophysiology associated with DENV infection is thought to be a direct 
consequence of immune response.17 It is worth asking therefore whether the dissimilar outbreak 
epidemiologies were owing to variations in host response, due for example to differences in 
exposure history on the various islands or to possible genetic differences. 
Beginning in the 1960s with pioneering seroepidemiological studies by Halstead and 
colleagues in Thailand there has been growing attention paid to the increased risk of severe 
dengue disease, such as DHF, following secondary infection with a novel serotype; that is, a new 
DENV infection in an individual who had previously experienced one or more DENV infections 
of a different serotype.94 Exposure to the initial infection generates antibody recognition but 
there is evidence to suggest that structural differences between DENV serotypes are sufficiently 
large that the cross-reactive antibodies are poorly neutralizing and even enhancing. Thus through 
the process of ADE, antibodies generated by during primary infection may promote entry of 
DENV into host cells during secondary infection leading to greater viral burden and more severe 
disease.98 
While sequential infections with heterotypic serotypes are routine in hyperendemic 
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countries, the South Pacific at this time was a special case. As has been mentioned repeatedly, 
this area was unusually isolated, not just from other parts of the world but also from other islands 
in the region. Inter-island traffic at this time was infrequent. In addition, and in consequence of 
its long isolation, most of these islands – with the exception of Tahiti – had no record of prior 
dengue outbreak for the past 20–30 years. Accordingly, all islands, with the possible exception 
of Tahiti, had similarly low seropositivity rates from previous infections. Thus, there is little 
evidence for some contribution of secondary infection to the epidemiological pattern seen in the 
South Pacific sweep. As described in the section on Niue Island – site of perhaps the most severe 
outbreak in the South Pacific DENV-2 sweep – retrospective serology found that all infected 
persons under the age of 25 had contracted a primary DENV infection. While on the other hand, 
most infected persons over the age of 30 had an infection of the secondary type, the latter 
correlating with epidemics of DENV-1 that took place during the Second World War. Yet 
significantly, in regards to clinical outcomes, no striking differences were observed between 
those individuals experiencing primary infection versus those experiencing secondary infection, 
either in terms of the percent reporting illness or the percent of illnesses with hemorrhagic 
manifestations.188,15 Similarly with Tonga, site of the least severe outbreak, clinical severity was 
not seen to correlate with secondary vs. primary infection, either in the 1974 DENV-2 outbreak 
nor, and perhaps more surprisingly, in the subsequent DENV-1 outbreak in 1975, which was 
much more severe both in terms of numbers of patients and severity of symptoms. In neither 
outbreak was there any evidence of correspondence between clinical severity and secondary 
infection.85 
Other host factors that have been suggested to contribute to a higher risk of severe 
dengue include age, race/ethnicity, nutritional state, and underlying chronic diseases such as 
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asthma.91 As to the latter possibility; there were numerous cases of patients with pre-existing 
conditions whose character might have increased their susceptibility to hemorrhagic symptoms. 
Yet no overall pattern of pre-existing conditions could account for the differences in disease 
severity seen between islands such that would explain the attenuation seen in Tonga. In regards 
to race/ethnicity – there is in fact some evidence for host genetic differences in dengue disease 
susceptibility – for example, it has been suggested that individuals of African descent may have 
greater resistance to DENV infection. 203,204 Yet again, there appears to be no obvious 
correspondence between differences in the host genetics of the South Pacific island populations 
affected and the pattern of DENV-2 outbreaks described. As previously mentioned, affected 
island populations were either primarily Polynesian (Tahiti, Niue, Tonga) and/or Melanesian 
(New Caledonia, Fiji). As an example, the population of Niue was the most affected in terms of 
severity of symptoms and proportion of people infected, whereas Tonga was the least affected; 
yet both islands are primarily populated by Polynesians. And again, patterns of ethnicity do not 
bear out upon subsequent dengue outbreaks as for example, the dramatically different epidemic 
outcomes on Tonga itself between the attenuated DENV-2 outbreak of 1974 and the 1975 
DENV-1 outbreak which was associated with high morbidity. 
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Phylogenetics of the South Pacific DENV-2 Sweep 
Introduction 
In an article published in 1978, Dr. Duane Gubler stated, 
“The most striking feature of the 1974–1975 dengue experience in the Kingdom of Tonga 
was the contrast between the severity of the clinical manifestations and the explosive 
nature of the outbreak in 1975 as compared with 1974.”85 
After reviewing (and rejecting) various alternative explanations for this contrast he wrote, 
“The most likely explanation, therefore, for the difference in dengue manifestations in the 
2 [years] is that in 1975 the dengue type virus circulating in Tonga was by nature more 
virulent than the dengue type 2 viruses present in 1974.”85 
Nevertheless, he was forced to conclude, 
“Since it is very probable that both dengue type 1 and dengue type 2 viruses spread from 
one island to another, the reason or reasons for the differing virulence of the infection on 
different islands remains a mystery.” 85 
In hopes of resolving this mystery, and given the evidence for variations in DENV virulence (as 
reviewed above) we performed a comparative genetic analysis of the samples of DENV isolated 
from the outbreaks that made up the 1971–1974 South Pacific sweep. Because this genetic 
analysis served as the foundation for the phenotypic research described in this dissertation, it is 
worth summarizing in some detail. 
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Based on the epidemiological and serological data from these outbreaks (reviewed in the 
Epidemiology section above) and the lack of a reasonable alternative explanation for the 
attenuation seen in Tonga outbreak (see the section “Possible factors in the variation in South 
Pacific DENV-2 epidemic severity” above) it seemed reasonable to suggest that the attenuation 
seen on Tonga might be a result of genetic changes in a population of DENV-2 in the course of 
its transmission from human populations on neighboring islands. 
Thus, genetic analysis was carried out with the objective of delineating the evolutionary 
relationships among the virus samples collected from the South Pacific series of outbreaks with 
the goal of establishing whether genetic variation among those strains led to the eventual 
attenuation observed on the island of Tonga. 
With these samples in hand, the following investigations were performed, based on 
specific hypotheses with their rationale included, the approach taken, the method used, and the 
results acquired therein.213 
Phylogenetic analysis of South Pacific evolutionary relationships. 
Hypothesis: DENV isolated from the 1971–1974 South Pacific sweep have a high degree of 
sequence homology to the degree that they cluster together as a distinct clade within the 
genotypes of the DENV-2 serotype reflecting a single infectious origin.  
Rationale: Contemporary observers of the 1971–1974 South Pacific dengue outbreaks15, 85, 158 
assumed that they were due to viruses undergoing in situ evolution rather than the consequence of 
multiple introductions into the region. Nonetheless, with no method of proving such a supposition, 
multiple questions remained, questions that whole-genome sequencing is designed to answer: 
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• What was the likely evolutionary and geographic origin of the DENV-2 responsible 
for the South Pacific sweep? 
• Was there a single virus ancestor common to all the outbreak isolates or would their 
sequences reveal the existence of more than one source? 
Approach: In order to examine the evolutionary relationships between the 20 South Pacific DENV 
isolates and more specifically, to provide them with a genotypic context and examine whether in 
situ evolution rather than multiple source introduction occurred during the South Pacific sweep, a 
phylogenetic tree was generated that included 54 publicly available sequences representative of all 
genotypes within serotype 2. Additional verification was provided through multiple node support 
analysis. 
Methods: The 20 low-passage South Pacific sweep DENV-2 isolates (see Table 3, page 110) were 
used to infect C6/36 cells. Viral RNA was extracted using the QIAamp viral RNA mini kit 
(Qiagen), reversed-transcribed with SuperScript III Reverse Transcriptase (Invitrogen), and 
amplified by PCR using PfuUltra II Fusion HS DNA polymerase (Stratagene), using primers 
designed for 2X coverage of the entire ORF. PCR-ampliﬁed DNA fragments were run out on 1% 
agarose gel and puriﬁed using QIAquick Gel Extraction kits (Qiagen). Puriﬁed DNA fragments 
were sequenced at the UH Manoa Advanced Studies in Genomics, Proteomics and Bioinformatics 
sequencing facility, using an Applied Biosystems 3730XL DNA Analyzer. Sequence editing, 
alignment and assembly of completed genomes were done using Sequencher 4.7 (Gene Code 
Corp.) with alignments verified in Se-Al 2.0 (Rambaut, Oxford Evolution Group). To provide 
genotypic, geographic and temporal context, 54 publicly available sequences spanning all known 
DENV-2 genotypes and representing a comprehensive and diverse assemblage of DENV across 
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the serotype were added; this included whole genome nucleotide sequences from Zhang et al 
(2006)257 and envelope gene sequences from Twiddy et al (2002)225. In addition, envelope gene 
sequences from sylvatic DENV-2 strains were used as outgroups to root the tree. All additional 
sequences were aligned with the South Pacific DENV isolates, as detailed above. Evolutionary 
relationships among isolates were inferred through two methods of tree building: maximum 
likelihood (ML) and Bayesian inference. For ML, sequence alignments were imported into 
PAUP* 4.0b10215 and RAxML212 for phylogenetic analysis. In order to verify ML tree topologies 
and node support Bayesian posterior probability values were generated for each node using 
MrBayes113,187. In addition, 100 ML bootstrap replicates were implemented in the RAxML 
BlackBox web server 212 as an additional measure of node support. Node support values and 
topologies generated from all three methods–PAUP*, MrBayes and RAxML BlackBox–were 
virtually identical.  
Results: A key question regarding the outbreaks on each island was whether they might have been 
caused by strains that were genetically and evolutionarily unrelated. Given the geographic isolation 
of these islands, even greater at that time than today, a series of unrelated outbreaks would have 
been unlikely. Nevertheless, there was always the possibility that the dramatic differences in 
epidemic behavior seen between Tonga and the other islands were simply due to Tonga having 
experienced the introduction of a different DENV-2 strain from elsewhere. The ML-generated 
phylogenetic tree (Figure 13) unequivocally confirmed that a) the viruses isolated during the South 
Pacific epidemic sweep were of the same evolutionary lineage; b) these same isolates all belonged 
to the DENV-2 American genotype, which includes New World isolates dating back to the 1950s, 
and c) all stemmed from a single introduction into the region from the Americas. Both the 
Bayesian posterior probability and ML bootstrap support values provided an assessment of 100% 
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support for critical nodes on the tree, confirming both the robustness of the tree and the placement 
of the South Pacific isolates within the American DENV-2 genotype. 
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 Figure 13. ML tree of isolates from South Pacific sweep placed within other representative DENV-2 
genotypes, including whole genome (Zhang et al. 2006) and E gene sequences (Twiddy et al. 2002). E 
gene sequences from sylvatic DENV-2 strains used as outgroups to root tree. Node numbers are 100 
replicate bootstrap values under the ML substitution model and derived from RAxML program. 
DENV-2 GENOTYPES
American/Asian
Cosmopolitan
American
South Pacific isolates
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Asian I
Sylvatic root
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Phylogenetic analysis of Tonga clade for signs corresponding to attenuation 
Hypothesis: Genetic sequences derived from DENV isolated from patient blood draws on the island 
of Tonga are expected to form a distinct clade within a phylogenetic tree of the South Pacific isolates, 
and in so doing, demonstrate a distinctive genetic basis for the clinical attenuation unique to the 
outbreak on Tonga.  
Rationale: Having ruled out variations in vector transmission efficiency, human immunity and 
secondary infection with a heterotypic serotype as possible causes of the attenuation observed on 
Tonga, Gubler et al. (1978) suggested that strain variation was the most likely factor to fit the 
evidence.85  
Approach: Evolutionary relationships between South Pacific isolates were examined by generating a 
phylogenetic tree along with verification through multiple node support analyses. The goal, as in the 
previous experiment, was to answer the following questions: 
• Would the clinical similarity seen among Tonga patients be reflected in the similarity 
of the sequences among the Tonga DENV isolates? Would viruses isolated from 
patients on Tonga show greater genetic homology with one another than they do with 
DENV-2 isolated from patients on the other South Pacific islands? Or, in other words, 
would the viruses isolated from dengue patients on Tonga show sequence homology 
great enough to form a monophyletic group on a phylogenetic tree? 
Methods: Phylogenetic analysis was carried out as described above. As with the full serotype 
tree described above, evolutionary relationships among the South Pacific DENV-2 isolates were 
inferred using a ML method in the phylogenetic program PAUP*. However, this second tree 
consisted only of South Pacific isolates rooted with four American genotypes as an outgroup, 
 
80 
thus allowing for a test of the hypothesis of Tonga forming a unique and distinct clade apart from 
the other South Pacific sequences. 
Results: The ML-generated phylogenetic tree consisting of only the 20 whole-genome South 
Pacific isolates plus the American genotype sequences for rooting (Figure 14) clearly revealed 
that the Tonga sequences clustered into a distinctly monophyletic clade lending support to the 
hypothesis that there is a genetic correlation to the clinical attenuation. In addition, this ML tree 
of (Figure 14) provides a host of evidence; including clustering of the Tonga clade with a 1971 
Tahiti strain, the high shared-branch node probabilities, and the high percent identity between the 
Tahiti and Tonga strains, that the Tonga clade is clearly derived from earlier Tahiti strains and 
not the result of a separate infection event. 
Amino acid substitutions in Tonga clade that correlate with patterns of attenuation. 
Hypothesis: Samples of DENV isolated from patients on Tonga will show evidence of nucleotide 
substitutions leading to amino acid replacements shared across the clade with these amino acid 
changes as the basis for the distinct attenuated phenotype of Tonga DENV.  
Rationale: As with other RNA viruses, DENV lacks the proofreading enzymes used by DNA-
based organisms to enhance the fidelity of genome replication. Yet, genetic diversity in DENV is 
relatively low in comparison with other RNA viruses; DENV strains belonging to the same 
serotype vary by no more than 10% at the nucleotide level and 4% at the amino acid level. The 
constraints on DENV evolution probably reflect the need to preserve critical determinants 
involved in virus-cell interactions across two very diverse phyla (Arthropoda and Chordata).157 
Nonetheless, we know that minor amino acid changes can result in significant changes in viral 
epidemic potential as has been recently illustrated by the chikungunya virus where a single 
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mutation in the envelope protein gene resulted in enhanced infection and accelerated viral 
dissemination in Ae. albopictus mosquitoes, conferring a selective advantage over infection in 
Ae. aegypti. 222 Given our inference of an underlying genetic basis for the observed phenotype of 
attenuated virulence, genetic alteration of the protein sequence warrants investigation.  
Approach: Nucleotide substitutions detected under phylogenetic analysis were mapped for amino 
acid changes. 
Methods: The 20 whole-genome sequences derived from the South Pacific DENV-2 epidemic 
sweep plus American genotype sequences for rooting (see Figure 14) were analyzed using a 
parsimony approach implemented in the program MacClade.149 Beginning with an assumption of 
minimum evolution, MacClade mapped the most parsimonious distribution of amino acid 
changes onto the branches of the ML phylogenetic tree made up of the 20 South Pacific isolates, 
noting amino acid changes that occurred on branches both antecedent and within the Tonga 
clade.  
Results: Mapping of the distribution of amino acid changes onto the Tonga clade allowed for the 
identification of 3 distinct substitutions specifically associated with and acting as 
synapomorphies for the Tongan isolates; in NS4A which saw a change from an isoleucine to a 
methionine at residue 46 (I464AM) that defines the entire Tonga clade including the attenuated 
vaccine strain, Tonga 74, as well as a Tahiti strain isolated in 1971 and presumably sharing 
ancestry with the Tonga strains; in the pre-membrane (prM) gene region which had a histidine 
to arginine substitution at residue 54 (H54pMR) and defines all naturally isolated Tongan samples; 
and in NS2A which experienced a serine to glycine substitution at residue 83 (S832AG) and 
defines a subset of Tonga isolates (see Figure 14). 
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Figure 14. Phylogenetic tree of the South Pacific DENV-2 epidemic sweep illustrating the three amino 
acid changes defining the monophyletic Tonga clade. 
Whether these amino acid substitutions can account for the attenuation observed among 
DENV-infected Tonga patients is open to question, and even if so, the mechanism by which 
substitutions could lead to attenuation is unknown; nevertheless, our attempt to correlate specific 
amino acid substitutions with the epidemic attenuation offers insights into DENV genes whose 
functions still remain under investigation. 
NS2A and NS4A have both been implicated in the inhibition of the interferon-mediated 
antiviral immune response through interference of STAT1 function162 albeit to a lesser extent 
than NS4B. Nonetheless, the antagonistic effects of these proteins did appear to be stronger when 
all three proteins were co-expressed. Working with WNV, Liu et al. (2004)141 also found NS2A 
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to be a major inhibitor of IFN whose effects could be reduced 15- to 50-fold through a single 
amino acid substitution (Ala30 to Pro [A30P]). Interestingly, Umareddy et al. (2008) found that 
such inhibitory effects were strongly strain dependent (though not serotype-specific), suggesting 
a molecular basis for strain variations in epidemic potential.229 
prM, a precursor to the M protein, is thought to promote infectivity of mature virions upon 
rearrangement of virion surface structure upon proteolytic cleavage.36 Leitmeyer et al. (1999)135 
identified two amino acids in the prM protein - prM-28 (Glu3Lys) and prM-31 (Val3Thr) - that 
distinguished the more virulent Southeast Asian genotype of DENV-2 from the American and 
noted previous experiments26 that demonstrated the induction of protective antibody in mice 
models upon exposure to the prM protein in combination with the membrane (M) protein. 
The specific amino acid changes themselves bear examination. The change from histidine 
(H) to arginine (R) in the pre-membrane protein replaces an aromatic amino acid with a straight-
chained molecule capable of forming multiple H-bonds. Both amino acids are polar but arginine 
is much more hydrophilic (it is the most hydrophilic of all amino acids) and while both amino 
acids have a positive charge, arginine is more positive, while relatively small shifts in 
physiological pH are capable changing the average charge of histidine. 
In NS2A, while serine (S) is relatively neutral in terms of hydrophobicity, glycine (G) is 
decidedly hydrophobic. Perhaps more important, serine is a polar amino acid with a hydroxyl 
side chain while glycine is non-polar and structurally is the smallest of the amino acids. 
Finally, the change from isoleucine (I) to methionine (M) in the NS4A protein replaces the 
most hydrophobic of all amino acids (I) with one considerably less so. Both amino acids are 
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nonpolar and neutral in charge although the substitution replaces a hydrocarbon side chain with a 
sulfur-containing one.166 
Whether any of these amino acid substitutions would be likely to modify the proteins that 
they are found within is unknown although even small structural differences might have an 
important effect on protein secondary structure. 
South Pacific isolates tested for recombination and/or positive selection. 
Hypothesis: We hypothesize that genetic and phenotypic variation among the South Pacific 
isolates will be the result of nucleotide substitution, rather than recombination, and that any 
amino acid replacements are more likely to be fixed under conditions of genetic drift rather than 
positive selection.  
Rationale: Recombination is the formation of new, covalently linked combinations of genetic 
material from either two separate genomes or between different sites on the same genome 55. In 
the case of dengue, natural recombination is thought to result from the co-infection of a single 
individual human or mosquito host by different viruses, which may be of different DENV 
subtypes, serotypes or even more than one species of Flavivirus252. The existence of recombinant 
DENV and their role in DENV evolution remain controversial1,180 and the existence of a 
recombinant among the South Pacific isolates would be unusual. However, since recombination 
between strains can conjoin sequences with distinct and individual lineages, it can profoundly 
affect the topology of a phylogenetic tree, increasing the danger of misinterpretation. Thus, the 
detection and quantification of recombination is a necessary task in genetic analysis. Similarly, 
given the stochastic nature of the DENV transmission event, seasonal fluctuations in vector 
populations, and the isolating effect of islands to generate numerous population bottlenecks, any 
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fixation of amino acid replacement is much more likely to be a result of drift rather than positive 
selection.18 But again, as with the relative unlikelihood of recombination, even though positive 
selection is not expected to have played a role in the South Pacific sweep, the significance of 
positive selection and the relative ease of testing for it makes it worthwhile to carry out. 
Approach: As a test of positive selection, the ratio of non-synonymous substitutions (dN) to 
synonymous substitutions (dS), i.e., dN/dS, is an accepted and frequently used surrogate 74. 
Phylogenetic codon-based tests to detect recombination were used to test all South Pacific 
sequences. 
Methods: To determine whether amino acid changes amongst the South Pacific isolates had been 
fixed by positive selection rather than random genetic drift, we estimated relative rates of 
nonsynonymous to synonymous nucleotide substitution (dN/dS) across coding portions of a 
multiple alignment that included the South Pacific isolates as well as the four American genotype 
outgroup sequences. We utilized two methods to assess the extent of adaptive evolution among 
the taxa in this alignment; PARRIS (rates across the alignment) and GABranch (rates on 
individual branches) (DataMonkey.org). Tests for recombination among the South Pacific 
DENV-2 isolates were carried out using the GARD detection method (also in DataMonkey.org). 
In the event that breakpoints were found, alternative phylogenies were explored by generating 
neighbor joining trees with bootstrap resampling (100 replications) in PAUP* for the multiple 
alignments of South Pacific sequences on either side of the breakpoint under the same model of 
evolution.  
Results: Analysis of rates of nonsynonymous (dN) to synonymous (dS) substitution identified no 
significant positive selection pressure on amino acid substitutions throughout the South Pacific 
outbreaks or specifically on the Tongan clade. Tests for recombination tentatively identified an 
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incongruous Tahiti isolate which was removed from the list of compared sequences and thus 
played no role in further phylogenetic analysis. 
Viral demographics: DENV-2 population changes across the South Pacific sweep 
Hypothesis: We hypothesize that the evidence for genetic variation leading to attenuation will be 
revealed in changing DENV demographics. That is, we predict that the number of DENV will 
increase as the virus moves across the susceptible island host populations, but then as a result of 
attenuation, the introduction of the virus into Tonga will be accompanied by a drop in viral 
population numbers.  
Rationale: We suspected that a source of evidence for viral genetic variation leading to the 
attenuation on Tonga might be found in tracking changes in DENV demographics. That is, we 
would expect that the number of DENV would be found to increase as the virus moved across 
susceptible island host populations but then as a result of attenuation the introduction of the virus 
into Tonga would be accompanied by a drop in viral population numbers. Given the lower 
viremia among Tonga patients remarked upon by Gubler et al. in their 1978 paper,85 impairment 
of replication efficiency in the causative viruses might be a likely cause of the observed 
attenuation and this should be observable in demographic tests. 
Approach: Coalescent based methods of phylogenetic analysis as implemented in the BEAST 
program provide a statistical means of comparing relative population sizes over time and these 
were carried out. 
Methods: Effective population size for a virus like DENV is essentially equivalent to the 
effective numbers of infections that go on to produce subsequent infections. Virus effective 
population sizes (Ne) over the timespan of our study were estimated as a function of relative 
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virus genetic diversity amongst sequences isolated at different points in time, with most isolates 
in our study dated to month and day of sampling. Relative genetic diversity (Net, where t is the 
generation time, set to 2 weeks for DENV) is an indicator of effective population size under a 
neutral evolutionary process based on coalescent theory.  
We used a Bayesian Markov Chain Monte Carlo (MCMC) inference framework in the 
program BEAST to independently estimate relative genetic diversity and Ne while incorporating 
uncertainty in the phylogeny by integrating across tree topologies.57 Within BEAST we used the 
Bayesian Skyline model, employing a relaxed uncorrelated lognormal molecular clock model 
and a codon model of substitution.72 Statistical uncertainty in mean Ne estimates is reflected in 
95% Highest Probability Densities (HPD). MCC topologies were generated in the TreeAnnotator 
program and were identical to topologies generated by the other tree estimation methods.  
Results: Our coalescent-based reconstruction of the demographic history of the American 
genotype DENV-2 in the South Pacific based on estimates of relative genetic diversity (Net) over 
time suggests that viral effective population sizes (Ne) experienced a decline representing a 
genetic bottleneck when introduced from the Caribbean. This was followed by an increase in 
diversity suggestive of exponential growth during first establishment in the South Pacific in 
1971, followed by a brief decline starting around 1972 that did not reach former population lows 
and then what appears to be a period of slow or neutral growth beginning late 1973 (Figure 15). 
These changes in population size are consistent with epidemiologic data of large initial 
case numbers in 1971 and 1972 – as in Tahiti, Fiji and New Caledonia – followed by diminishing 
case numbers in American Samoa in 1972 and Tonga in 1974.158, 15,82,85 
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Figure 15. Maximum clade credibility tree of isolates from the South Pacific sweep on a temporal scale, 
aligned with the effective virus population size estimates (Bayesian Skyline plot) based on genetic 
diversity, both generated in BEAST 57. E gene sequences from American genotype strain of serotype 2 
used as outgroup to root the tree. Node numbers are posterior node probabilities. Bold values are inferred 
amino acid substitutions that may correlate with strain attenuation. Corresponding Bayesian skyline plot 
shows mean effective number of infections (Ne) over the same time scale (solid black line, left-hand axis) 
with shaded area representing 95% high probability densities. 
Summary 
This previous research involved carrying out whole-genome phylogenetic analysis of the DENV-
2 isolates collected during this South Pacific sweep, comparing them with other publicly 
available DENV-2 sequences – all of which were representative of the temporal and geographic 
variation available within the DENV-2 serotype - in order to identify the genetic variations 
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within the South Pacific isolates, particularly those changes in amino acid composition that 
correlated with the attenuation of the DENV-2 outbreak in Tonga, and in so doing elucidate the 
relative contribution of virus strain variation to the epidemiology of the South Pacific outbreaks. 
Our phylogenetic analysis revealed: 
• All South Pacific DENV isolates were found to fall within a single clade and a single 
genotype demonstrating their common evolutionary origin. 
• All Tonga DENV isolates were found to cluster into a single monophyletic clade 
suggesting that there is a genetic correlation to the clinical attenuation seen among 
patients infected with DENV-2 on the island of Tonga as compared to other islands. 
• 3 distinct amino acid substitutions were associated with the Tongan DENV-2 isolates 
and found in the prM, NS2A and NS4A proteins. 
• No positive selection was detected in the South Pacific phylogeny suggesting evolution 
through genetic drift. 
• A recombinant breakpoint was detected in the South Pacific DENV-2 phylogeny with 
the recombinant sequence suspected to have originated in Tahiti. 
• Viral demographics show an increase in Tonga DENV-2 populations suggesting that 
attenuation was not accompanied by decreased transmissibility. 
Thus, the results derived from the analysis in this case study strongly suggest a genotypic basis 
for the attenuation seen in the 1974 outbreak in Tonga. Having discussed this research as an 
introduction to that which is the focus of this dissertation, I now shift from analysis of the South 
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Pacific DENV-2 isolate’s genotype to an analysis of their phenotype in order to determine 
whether the attenuation seen on the island of Tonga is due to the amino acid substitutions which 
has resulted in downstream altered function, and/or whether epidemic attenuation is due to 
reduced transmission or higher asymptomatic rates. 
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CHAPTER 3: OBJECTIVE & SPECIFIC AIMS 
Introduction 
The four serotypes of dengue virus (DENV-1, DENV-2, DENV-3 and DENV-4) cause a wide 
spectrum of clinical disease, ranging from febrile illnesses to life-threatening hemorrhagic fever. 
Worldwide incidence has increased alarmingly to where DENV is now the most common 
mosquito-borne viral disease in the world.22 A variety of known risk factors for serious dengue 
disease have been identified, such as viral strain variation, vector competency, and secondary 
infection by a heterologous DENV serotype, but the mechanisms by which DENV causes disease 
that could account for such variability in both clinical symptoms and epidemic intensity remains 
unclear. As discussed in the previous chapter, we have focused on a possible role for DENV 
strain variation in determining epidemic potential or virulence. To do this we focused on a 
simplified transmission arena and demonstrated a possible link between strain variation and 
epidemic severity by carrying out phylogenetic analysis of a DENV-2 sweep among South 
Pacific islands that took place in the early 1970s. We found that DENV-2 isolates from an 
outbreak on the island of Tonga revealed three unique amino acid substitutions in the prM, 
NS2A and NS4A gene regions that defined the Tonga clade by distinguishing them from all 
other DENV-2 isolates and may provide a structural basis for the distinctive epidemiological 
attenuation observed during the Tonga outbreak. That there is a molecular basis for such 
differences in epidemic potential is still unclear however. While a number of studies have 
attempted to identify specific structural differences that correlate with clinical and/or epidemic 
outcome135,44,45,38 definitive evidence continues to be elusive. 
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Objective, Hypothesis and Aims 
The objective of this dissertation research is to better understand the role of virus evolution in 
DENV epidemic dynamics and disease severity. Based on the apparent correlation between the 
apparent clinical attenuation of symptoms among DENV-infected patients on the island of Tonga 
with a unique set of amino acid substitutions that define the Tonga clade, we hypothesize: 
evolutionary changes in the DENV genome can give rise to significant variations in disease 
severity and epidemic potential between different populations of DENV.  
In Aim 1, we will explore the relationship between genetic changes in DENV-2 epidemic 
strains and their phenotypic effects using in vitro models. Phenotypic differences between strains 
will be measured on the basis of viral productivity (number of virus produced, i.e. viral titer), 
infection efficiency (number of infected cells), and replication rate (rate of virus production per 
cell). In addition, the specific mutations characterizing the Tonga synapomorphies suggest 
additional measurements to examine the proportion of infectious virions and possibly the viral 
effects on host immune response. DENV-2 isolates from the entire South Pacific sweep will be 
compared for phenotypic differences in both human and mosquito cells. 
In Aim 2, we will use in vivo models to investigate the effects of genetic changes on 
phenotypes relevant to the DENV mosquito vector such as infection and replication. At the 
conclusion of these studies, we will have expanded our knowledge of various DENV 
phenotypes, including replication and dissemination dynamics, examined variations introduced 
into such dynamics by genetic changes between strains, and developed new tools for further 
examination into DENV pathogenesis. 
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Significance 
Given that DENV transmission takes place exclusively between the human host and Aedes 
vector, no animal model is available for direct examination of viral strain variation. This study is 
unique in that it takes advantage of a natural experiment in which many, if not most, of the 
confounding factors in dengue disease dynamics could be excluded except for virus evolution, 
thus allowing for a clearer examination of the effects of strain variation and genetic change on 
DENV epidemic severity. The correlation between genetic change and outbreak variation 
identified in DENV-2 isolates from Tonga thus provide a unique opportunity for comparing 
phenotypes of epidemic potential and/or virulence. Such phenotypic comparisons have the 
potential to elucidate the mechanisms by which DENV strains produce variations in disease 
outcome and have far-reaching impacts on DENV surveillance, vaccine development, and the 
study of viral evolution. 
Specific Aims 
Given the complexities and multifactorial nature of DENV pathogenicity, and in light of our 
previous research having provided strong evidence for viral genetic change as the basis for the 
attenuation of dengue symptoms seen in Tonga in 1974, this PhD research will focus specifically 
on the contribution of DENV strain diversity to virulence/epidemic potential. 
This focus will clearly require a more full characterization of the DENV samples isolated 
from the islands of the South Pacific sweep. To understand what changed in the Tonga virus 
lineage that made it less virulent than it had been in Tahiti, Fiji, and the other islands of the 
South Pacific, we propose to compare the South Pacific DENV-2 isolates within both human and 
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mosquito cell lines as well as within live mosquitoes.  
Thus, our long-term goal is to use insights gained from DENV evolution to better 
understand epidemic dynamics and DENV emergence. The objective of the proposed research is 
to ascertain if phenotypic effects from DENV genetic variation are responsible for epidemic 
intensity and disease severity. Our study is unique in that it takes advantage of a natural 
experiment in which many, if not most, of the confounding factors in dengue disease dynamics 
could be excluded, except for virus evolution, thus providing an opportunity for comparing 
phenotypes of epidemic potential and/or virulence. Such phenotypic comparisons could have far-
reaching impacts on DENV surveillance, vaccine development, and the study of viral evolution. 
Specific Aim 1 
Determine the relationship between genetic changes in DENV-2 epidemic strains and their 
phenotypic effects using in vitro models. 
Hypothesis: Unique genetic substitutions (synapomorphies) associated with attenuated DENV 
strains from the island of Tonga will reveal measurable phenotypic differences in comparison 
with strains from the other islands in the South Pacific sweep in in vitro assays. Approach: We 
propose to look for phenotypic differences among strains isolated from the South Pacific 1971–
1974 DENV-2 epidemic sweep. Phenotypes to be measured include those of viral productivity 
(number of virus produced per unit volume such as plaque forming units per milliliter, i.e. viral 
titer) and replication rate (rate of virus production over time). Additional measurements may 
include the proportion of infectious virions (because prM mutation might result in more 
immature virus particles) and possibly the viral effects on host immune response (since NS2A 
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and NS4A mutations might result in diminished interferon suppression). Isolates from the entire 
South Pacific sweep will be compared for phenotypic differences, as correlates of epidemic 
potential, in both human and mosquito cells. 
Specific Aim 2 
Determine the relationship between genetic changes in DENV-2 epidemic strains and their 
phenotypic effects using in vivo models. 
Hypothesis: Synapomorphies associated with attenuated DENV-2 strains from the island of 
Tonga will exhibit measurable phenotypes similar to those to be examined in vitro: viral 
productivity and replication rate.  
Approach: We propose to infect genetically diverse colonies of Ae. aegypti with DENV-2 
isolated from the 1971–1974 South Pacific sweep to compare their ability to infect, replicate, and 
disseminate. Using time course experiments, infections will be carried out through direct 
inoculation and measured by MID50 and qPCR.  
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CHAPTER 4: MATERIALS & METHODS 
Samples 
Sixteen low-passage DENV-2 samples were used in this analysis; all were obtained from the 
collection of Dr. Duane J. Gubler and acquired by him during the South Pacific sweep (Table 3). 
Viral passage history (Pass) refers to the number of passages in C6/36 cells; those passages followed 
by an asterisk indicate that virus was initially isolated in adult Aedes (specific species unknown). All 
sequencing was carried out with the passages as listed in Table 3, as was plaque assay, focus forming 
assay and SYBR Green qPCR. The Choy plaque assay, MID50 and TaqMan qPCR used samples 
with an additional passage in C6/36 and the MID50 assay used one further passage in Ae. aegypti. 
Maintenance of cell cultures  
C6/36 cells, an Aedes albopictus clone of whole larval tissue (ATCC, Manassas, VA), were 
maintained in DMEM (Gibco, ThermoScientific, Waltham, MA), 5% fetal bovine serum, 
NaHC03, non-essential amino acids, and sodium pyruvate in 28?C incubator. Vero cells, derived 
from kidney epithelial cells from an African green monkey (ATCC, Manassas, VA), were 
maintained in M-199 media (Gibco, ThermoScientific, Waltham, MA), 5% fetal bovine serum, 4 
mM L-glutamine, 100 X penicillin/streptomycin and 7.5% NaHCO3 in humidified 5% CO2 at 37?
C. BHK cells, a kidney cell line derived from 1-day old Syrian golden hamsters (Mesocricetus 
auratus), were maintained in RPMI (HyClone, Bangkok, Thailand), 10% fetal bovine serum, 
plus L-glutamine, non-essential amino acids, penicillin and streptomycin in humidified 5% CO2 
at 37?C.  
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Table 3. Epidemiological data on the isolates used in this study.  
Strain ID Passa Date of 
Onset 
Isolation: 
Date/Time 
Diseaseb Age Race Sex Travel History Notes 
Tahiti 10000 2* 4/12/1973 4/15/1973 DF n.d. n.d. F n.d.  
Tahiti 7848 2*  1971 DF n.d. n.d. n.d. n.d.  
Fiji 1021 4  1971 DF n.d. n.d. n.d. n.d.  
Fiji 1422 3  1971 DF n.d. n.d. n.d. n.d.  
New 
Caledonia 
9137 
2* 12/31/1971 12/31/1971  n.d. 60 C? M n.d.  
New 
Caledonia 
9297 
2* 1/26/1972 1/27/1972 
8:15 A.M. 
headache, joint pain 49 C F Born in France, 
in NC 1.5 years 
 
Samoa S-
5277 
2* 6/21/1972 1972 Febrile acute 50 P M Never out of 
Am. Samoa  
 
Samoa S-
5279 
2* 6/21/1972 1972 Afebrile acute 50 P M Never out of 
Am. Samoa  
Repeat 
of S5277 
Samoa S-
5285 
2* 6/21/1972 1972 Febrile acute 26 P F Never out of 
Am. Samoa  
 
Samoa S-
5373 
2* 6/22/1972 1972 Febrile acute 33 P M   
Tonga 14616 2* 4/16/1974 4/16/1974  
P.M. 
Febrile, myalgia, 
arthralgia, no rash 
nor hemorrhage 
16 P F Never out of 
Tonga 
 
Tonga 14619 2* 4/16/1974 4/16/1974 
7:30 P.M. 
Febrile 16 P F Never out of 
Tonga 
Repeat 
of 
S14616 
Tonga 14620 2* 4/16/1974 4/17/1974 
8:30 A.M. 
Febrile, myalgia, no 
rash nor 
hemorrhage 
19 P F Never out of 
Tonga 
 
Tonga 14639 2* 4/17/1974 4/18/1974 
2:30 P.M. 
Fever, headache 16 P F Never out of 
Tonga 
 
Tonga 14644 2* 4/16/1974 4/19/1974 
11:30 A.M. 
Afebrile, headache 
no rash nor 
hemorrhage 
16 P F Never out of 
Tonga 
repeat of 
S14616; 
5th blood 
Tonga 14694 2* 4/25/1974 4/26/1974 
10:15 A.M. 
Febrile, 
hematemesis, 
melena, no other 
sign of bleeding  
15 P F Never out of 
Tonga 
 
n.d. = no data, DF = dengue fever, C = Caucasian, P = Polynesian, a = Viral passage history,  
b = All patients were classified as having classical dengue fever (DF).  * = First passage in adult 
mosquito 
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Virus replication 
DENV-2 samples used in this research were passaged in C6/36 cells as follows: T-25 flasks were 
seeded with C6/36 cells in 9 mL of DMEM-10 and allowed to grow 2–3 days before replacing 
the media with a 200–300 µL inoculant of DENV-2 at a standard MOI of 0.1 in DMEM-2. 
Exceptions were made of viruses that had unusually low titers; i.e., Tonga strains 14619 and 
14620 (MOI 0.01), and 14639 (which had an exceptionally low titer of 6.18E+03 pfu/mL and 
thus was infected with an MOI of 0.005) or for which very small volumes were available.  
In some cases, due to prior bacterial contamination, virus was inoculated using 0.2 µM syringe 
filters for sterilization. Following incubation of cells with virus for 1 hour at 28° C, an additional 
5 mL of DMEM-2 was added and the flask returned to incubate in humidified 5% CO2 at 37?C. 
Cell health was checked under inverted microscope every 2–3 days and pH adjusted (if 
necessary) with NaHCO3 drops to revert to red color. Generally after 5 days, a sample of cells 
are scraped off and tested for successful viral infection using DFA. With confirmation of 
successful infection, all cells are scraped from flask, mixed with FBS at 23% (v/v) and spun 
down at 2,000 rpm for 5 min. 600 µL of super were aliquoted and frozen down to -80°C. 
Direct Fluorescent Assay (DFA) 
Cells were checked for successful DENV infection using direct fluorescent assay as follows: 
Using a plastic cell scraper to loosen C6/36 cells from bottom of flask, 200–500 µL of cell 
solution were pipetted from flask into a 1.5 mL tube, spun 5 min at approximately 1200 rpm to 
form pellet, then vortexed in 500 µL 1 X PBS to resuspend. Cell solution was then applied to 
glass slide, 10 µL/well, 2 wells/cell sample (with a negative control on each slide) and allowed to 
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air dry for 30 min, followed by immersion in ice-cold acetone within Copeland tray for 15–20 
min at –20°C. 4G2 mouse monoclonal-antibody (mAb) was applied to each well at a dilution of 
1:300, the slide placed in a moistened Petri dish humidity chamber in 37°C incubator for 30 min, 
immersed in PBS, then rinsed with distilled water. After a drop 1 µL of mounting media on each 
well, a glass slip was applied to the slide and it is examined with an epi-fluorescent microscope. 
Depending upon percentage of cell fluorescence: 0% - check again in two days, 10% - check 
again tomorrow, 60 – 70% - freeze infected cells tomorrow, 100% - freeze now at -80°C. 
Plaque Assay 
As an initial attempt to determine the viral titer of the samples of DENV-2 isolated from 
the 1971–1974 South Pacific sweep, plaque assays were performed as previously described. 11,155 
Briefly, Vero cells were grown in 6-well plates in DMEM media supplemented with 10% fetal 
bovine serum (FBS) until almost confluent. Preparatory to infection, serial dilutions of viral 
supernatant are prepared, 10-1 to 10-7, in cold DMEM media supplemented with 5% FBS and 
then each well is inoculated with 200 µL of the appropriate virus dilution, with all reps of each 
dilution on a single plate (most often with 2 reps per dilution). Inoculum was allowed to incubate 
for 1 hour at 37°C and 5% CO2, followed by each well of infected cells being overlaid with 3 mL 
of 1% agarose. After approximately 7 days, a second 3 mL layer of 1% agarose plus 2% neutral 
red was added to each well, followed by another 24 hours of incubation. The resulting plaques 
were counted over a light box with PFU/mL calculated using the following formula: 
(Average plaque count between reps) x (fraction of 1 mL) x (inverse of dilution) 
Example: the average number of plaques at 10-2 dilution was 36 and at 10-3 was 12. The 
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amount of virus used to infect each well was 200 mL or 1/5 of 1 mL. Using the formula given:  
(36 x 5 x 102 = 1.8 x 104) + (12 x 5 x 103 = 6.0 x 104) / 2 = Average pfu/mL = 3.9 x 104. 
Focus-Forming Assay 
Because the results from working with plaque assays were unsatisfactory, we attempted to 
measure DENV infectivity titer using the focus-forming assay (FFA). Rather than relying on 
measurements of cytopathology as a surrogate of viral quantity, the FFA detects virus directly 
through use of horseradish peroxidase (HRP)-labeled anti-flavivirus antibodies. Briefly, the 
method is as follows; Vero cells (as with plaque assays described above) are grown to near 
confluence in 96-well plates in DMEM with 10% FBS. DENV samples are diluted in 2% FBS in 
DMEM from 10-1 to 10-7 and then 50 µL of each dilution is added replicate wells, and allowed to 
incubate at 37°C for 90 minutes with gentle rocking, followed by 150 µL of an overlay mixture 
of 2% methylcellulose plus 2X DMEM. After further incubation at 37°C in 5% CO2 for 4 days, 
the overlay is removed, wells washed 5 times with PBS and 200 µL of methanol/acetone added 
to each well for 10 minutes. After monolayers are allowed to dry completely, 200 µL of antibody 
dilution buffer are added to each well and allowed to incubate at room temperature for 30 min, 
followed by 50 µL of primary antibody (4G2 antibody, 1:2,000 dilution) incubated at 37ºC for 1 
hour, 2 washes with PBS, then 50 µL of secondary antibody (HPR- conjugated goat anti-mouse 
IgG, 1:2,000 dilution) to each well and for 1 hour at 37ºC, followed by 2 washes with PBS and 
50 µL of TrueBlue peroxidase substrate (KPL, Inc., Gaithersburg, MD, USA) for 10 minutes at 
room temperature with rocking (making sure that blue foci are visible). Substrate is then 
discarded and the plate washed with ddH2O. After thorough drying, the foci are counted and 
quantified in a digital ELISPOT reader (Cellular Technologies Limited, Cleveland, OH, USA).  
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Quantitative Polymerase Chain Reaction (qPCR) 
Unlike PFA or FFA, qPCR avoids the complications resulting from viral variations in plaque- 
forming ability or growth in different cell lines by directly measuring viral RNA concentration. 
Thus, given our inability to titrate all DENV-2 isolates from the South Pacific sweep, particularly 
the DENV-2 isolated from patients from the island of Tonga, using either PFA or FFA, we 
carried out quantitative PCR using the SYBR Green method at the University of Hawaii at 
Manoa and the TaqMan method at Mahidol University, Bangkok School of Tropical Medicine. 
Regardless of the method, qPCR begins with RNA extraction as follows. 
RNA Extraction 
Viral RNA was extracted from South Pacific DENV-2 isolates using the QIAamp viral RNA 
mini kit (Qiagen, Valencia, CA) at the University of Hawaii at Manoa and the GenUP Total 
RNA kit (biotechrabbit GmbH, Hennigsdorf, Germany) at Mahidol University, Bangkok School 
of Tropical Medicine; in both cases following the manufacturer’s instructions. In both cases, 
RNA was derived from the cell-free supernatant fraction of DENV-2-infected C6/36 in order to 
avoid incompletely transcribed/packaged RNA and the majority of immature virus particles. The 
extracted RNA was eluted in 60 µL of RNase-free water and stored at -80°C. 
SYBR Green qPCR 
Protocol for qPCR at University of Hawaii at Manoa was as follows: extracted RNA was 
converted to cDNA through reverse-transcription using iScript Reverse Transcription Supermix 
kit (BioRad, Hercules, CA) following manufacturer’s instructions. Briefly, 5X iScript reaction 
mix and iScript reverse transcriptase were combined with nuclease-free water in a master mix on 
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ice, then aliquoted into 0.5 µL microcentrifuge tubes; one for each RNA template plus a negative 
control. Immediately after adding RNA template to master mix, tubes were loaded into a thermal 
cycler and run as follows: 5 min at 25°C, 30 min at 42°C, 5 min at 85°C, and hold at 4°C. 
Finished cDNA was either quantified through qPCR immediately or stored at -20°C for later 
analysis. 
Primer set used for qPCR is specific to the DENV 3’–noncoding (3’NC) region and was 
developed for detection of all DENV serotypes. The forward primer is DC10418 (10418-
TTGAGTAAACYRTGC TGCCTGTAGCTC) and the reverse primer is CDC10590 
(GGGTCTCCTCTAACCTCTAG TCCT-10564).39 Viral titer was measured as genome 
equivalents/mL against the cDNA generated from the lab-adapted, high-titer DENV-2 strain 
DAKARA whose titer had been previously established through repeated plaque assay and FFA 
at 2.5x107. DAKARA cDNA was serially diluted 5x (100–105) on ice to create a standard curve 
in sufficient quantities to run in duplicate. The cDNA of sample and standard was amplified 
using the iQ SYBR Green Supermix kit (BioRad, Hercules, CA) for 40 cycles (5 sec at 95°C, 30 
sec at 63.4°C, and 30 sec at 72°C) on BioRad CFX96 iCycler.  
TaqMan qPCR 
Rather than using the SYBR Green method, at Mahidol University, Bangkok School of 
Tropical Medicine, we used TaqMan to carry out qPCR, utilizing the KAPA PROBE FAST One-
Step qRT-PCR Kit (Kapa Biosystems, Inc., Wilmington, MA). As a one-step quantitative PCR 
kit, a separate step of producing cDNA was avoided. Primers and probe are specific to the 
DENV-2 envelope region117 with sequence and position as follows:  
 
103 
DEN-2 F   CAGGTTATGGCACTGTCACGAT  1605  
DEN-2 C   CCATCTGCAGCAACACCATCTC   1583  
DEN-2 probe  CTCTCCGAGAACAGGCCTCGACTTCAA 1008 
Viral titer was determined through comparison with a standard curve established by a 
serial dilution of RNA from a strain of DENV-2 lab-adapted by Dr. Pornsawan Leaungwutiwong 
at Mahidol University and designated D2 (16681), MK2-3, C6/36-1, Sm-2, C6/36-5, 20 Feb 13 
The titer of this standard was established with repeated plaque assays at PFU 2.3x105. 
Quantitative PCR run for 44 cycles (2 min at 95°C, 15 sec at 95°C, and 1 min at 60°C) on 
BioRad CFX96 iCycler. 
Mosquito inoculation  
Inter-thoracic inoculation of DENV into mosquitoes is a long-standing means of determining 
viral titer, particularly valued for its sensitivity, as well as a method for “rescuing” low-titer 
DENV isolates86,189. Working at Duke-National University of Singapore (NUS), we carried out 
both functions; beginning with the establishment of an initial seed bank of virus samples isolated 
from the South Pacific DENV-2 sweep, followed by their titration in order to compare with other 
titration methods. 
All mosquitoes used in experiments were either Aedes aegypti or Ae. albopictus from a 
colony at the Duke-NUS Graduate Medical School. The original colony was established in 2010 
with specimens collected in Ang Mo Kio, Singapore, and supplemented weekly with field-
collected mosquito eggs which were collected from the Geylang area of Singapore, reared to 
adulthood, sorted by species and introduced into the laboratory populations (10% of colony), to 
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maintain genetic diversity. Generally, for reasons of safety, only male mosquitoes were initially 
inoculated. However, given their smaller size, survival post-inoculation was unacceptably low, 
so female Ae. aegypti were generally used. 
In order to carry out inoculations, needles of a sufficiently small diameter to ensure 
minimal mosquito mortality are required. Needles were prepared by stretching borosilicate glass 
capillary tubes (internal diameter 0.4 mm; outside diameter 0.7 to 1.0 mm; 30 in length) through 
a Narishige PC-10 Dual-Stage Glass Micropipette Puller (Narishige Group, Tokyo, Japan) to 
draw to a fine point. The resulting needles were sorted and marked with 1 mm divisions using a 
rubber stamp for accurate and consistent inoculum delivery then mounted in a metal holder 
connected by flexible tubing to a large syringe (Figure 16).  
 
Figure 16. Glass needle stamped with 1 mm lines and mounted in syringe delivery system. Photo 
courtesy Current Protocols in Microbiology (2005). 
To securely contain small numbers of deliberately infected mosquitoes, small “infection 
chambers” consisting of cardboard ice cream containers were used (i.e., white cardboard tubes 
with slide on cardboard caps, often called “Neptune cans”) (Science Supplies WLE Corp., Fort 
Lee, NJ). These were modified for use by replacing the top caps with mosquito netting and 
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cutting a small door in the side of the tube for transferring mosquitoes in and out. 
The inoculation of Aedes mosquitoes, whether for developing of seed pools or titration, 
requires extremely careful handling as the escape of even a single infected individual can present 
a considerable risk to those working in the insectary, as well as the possibility of escape into the 
outside environment. Therefore, all work was undertaken in dedicated mosquito insectary 
facilities rated at BSL-2 at both JABSOM and Duke-NUS, mosquitoes were kept in containment 
at all times (described in more detail below) with inoculations and mosquito sorting carried out 
in sealed glove boxes, all inoculation and virus handling was completely separated from 
mosquito rearing and particularly during inoculation, mosquito numbers were carefully 
accounted for. 
Successful inoculation with minimal mortality requires that mosquitoes be immobilized 
during injection. While there are a number of methods for knocking down mosquitoes, we found 
it most convenient to chill containers of mosquitoes under crushed ice. Thus mosquitoes are 
aspirated from their rearing cage into a plastic collection canister, which was immediately 
plugged with cotton wool and then placed within zip lock bag and buried in ice for a minimum of 
20 min to knock out (KO) mosquitoes. While waiting for mosquito KO a serial dilution of the 
virus was prepared within the inoculation room biosafety cabinet (BSC) and then transferred, 
along with the KO mosquitoes, into the inoculation room glove box. KO mosquitoes are 
transferred from collection canister to 50 mL blue top tube, then sorted by sex and roughly 
counted; approximately 60 females are transferred to another tube under dissecting scope and put 
back on ice, while males are returned to colony cage. 
Within glove box, glass needle is inserted into syringe delivery apparatus, 20 µL of virus 
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dilution are pipetted onto parafilm, then drawn up into needle. Blue top tube with mosquitoes is 
taken off ice, and a single female shaken out onto dissecting scope stage and arranged to lie on 
back. With the needle carefully inserted into the neck membrane, 1 mm virus is injected 
(equivalent to 0.17 µL volume), and then mosquito is transferred to cardboard infection chamber 
(described above). After 10 mosquitoes are inoculated per isolate dilution, the chamber door is 
plugged with cotton ball and sealed shut with tape (Figure 17 and 18) 
 
Figure 17. (Left) Virus inoculum of 0.17 µL is injected into the membrane anterior to the mesepisternum of 
the Ae. aegypti female. (Center). The inoculated mosquito is transferred from microscope stage using 
needle and placed in infection chamber for virus incubation. (Right) Inoculated mosquitoes are stored at 
28◦C for 10 - 14 days to obtain optimal virus replication. Photo courtesy Current Protocols in Microbiology 
(2005). 
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Figure 18. Mosquito inoculation system inside glove box in insectary at  
Duke-NUS Graduate Medical School, Singapore. 
Four infection chambers (each for a separate viral dilution) can be placed into a 
BugDorm-1 cage (MegaView Science Co., Ltd., Tatchung, Taiwan) along with flasks of water 
and 10% sucrose with wicks to the chambers in order to maintain mosquito survival during virus 
incubation. Cages were then placed within a controlled-environment chamber at 27°C. Water and 
sucrose levels are checked daily and wicks replaced every 5 days to prevent bacteria and fungal 
build up. At 10 dpi mosquitoes are sacrificed by placing infection chambers in -80°C freezer for 
15 min and then tested for infection with indirect fluorescent assay (IFA). 
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Testing that infection has taken place, whether through injection or oral feeding, in 
general relies upon crushing the head of the mosquito on a glass slide and staining these tissues 
with fluorescein isothiocyanate-tagged anti-DENV antibody; the principle being that the 
presence of virus in the head verifies that virus replication has occurred and led to dissemination 
throughout the body. 128,155 Head squash and antibody staining (usually as IFA) was carried out 
as follows: 12-well slides are labeled using dark pencil. Wells are numbered 1–6 on top and 7–
12 on bottom. Both negative and positive controls are included on each slide if available (Any 
uninfected mosquito was used as a neg. control. Positive control mosquitoes were those 
inoculated with the high-titer DENV-2 virus DAKARA beforehand – generally – and stored at  
-80°C). Mosquitoes were immediately transferred from -80°C freezer, placed one per slide well 
and head removed using a razor blade. Bodies were stored in labeled microcentrifuge tubes at  
-80°C for future testing and possible virus isolation.  
Each mosquito head was crushed within its well using a quick side-to-side motion with 
pestle, removing exoskeleton. After all heads are crushed slides are submerged in -20°C. acetone 
for 10 min then air-dried inside BSC. After placing slides inside a petri dish lined with damp 
paper towel, 25 µL of antibody is pipetted onto each well, the slides are incubated at 37°C, 
followed by a rinse 1x PBS and air drying in BSC; first primary antibody, then secondary with 
FITC. Finally, a 5-µL drop of mounting fluid is placed onto each slide well then gently covered 
with a glass cover slip and viewed under fluorescent microscope. The titer of infectious DENV 
measured by this mosquito inoculation technique gives a mosquito infectious dose at 50%, i.e., 
MID50, as calculated by the method of Reed and Muench, which essentially calculates the 
minimum dilution of virus required to infect 50% of inoculated mosquitoes.40,177,189 
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Seed pools were produced as follows: 50 Ae. aegypti mosquitoes were inoculated per 
each South Pacific viral DENV-2 isolate (with interthoracic injections as described under MID50 
but using no dilution of virus). Infections were confirmed at a minimum of 14 dpi through head 
squashes and IFA of 10 mosquitoes per virus pool. Upon verification of successful infection, 30 
mosquitoes per pool were macerated using MP Biomedicals Fast-Prep (MP Biomedicals, LLC, 
Santa Ana, CA) in 1.25 mL of homogenization media. Viral supernatant was centrifuged to 
remove most mosquito body parts, with further purification using a 0.2 µm syringe filter, then 
aliquoted at 100 µL per vial. Remaining 20 infected mosquitoes per pool were stored at -80°C. 
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CHAPTER 5: INFECTIVITY TITERS OF DENV-2 ISOLATES 
DETERMINED IN VITRO  
Introduction 
None of the South Pacific DENV-2 isolates that we had carried out phylogenetic analysis 
on had ever been measured for their titer, or if they had, those records had been lost. Given the 
lack of infectivity titer data, sample measurements were taken from the cell supernatant of all 
isolates in our stock using plaque assays, focus-forming assays, and quantitative PCR.  
Plaque Forming Assays 
Plaque assays are a standard virological method and were used routinely in the Department of 
Tropical Medicine at the University of Hawaii by a number of investigators working with West 
Nile virus. Plaque assays can utilize a number of different cell lines to detect plaques; in our lab 
in Hawaii we used Vero cells, which work well with West Nile.  
Details are provided in the Materials & Methods chapter but general method is 
represented in the flowchart below. 
 
Seed 6-well plate 
with Vero cells
Infect cells with 
10-fold serial 
dilution of virus
10-1 - 10-7
Overlay infected 
cells with agarose
Day 7 
Overlay 2nd 
agarose layer with 
neutral red
Wait 3 days for 
plaques to appear
Count plaques
Calculate titer
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Focus-Forming Assays 
While plaque assays are a longstanding method of virus titration, it has been found to be less 
than optimal for measuring DENV amounts, primarily because, as a number of papers have 
pointed out, DENV can be poorly cytopathic, and it can be particularly difficult to get good 
plaques from low-passage DENV isolates.7,151 In addition, plaque formation can be restricted by 
the phenotype and passage history of the DENV strain and by the type and age of cells used in 
the plaque assay.179 
An alternative titration method, the focus-forming assay (FFA) avoids this problem, 
since rather than detecting virus indirectly through cell lysis; FFA labels virus particles directly 
using a horseradish peroxidase-labeled immunoassay. An additional advantage of the method is 
that foci are high contrast, allowing for easier identification and even automation of counting 
thus increasing throughput. Given that the results from working with plaque assays were 
unsatisfactory (see Results section below), the FFA thus recommended itself to us for trial as 
possibly a more sensitive approach to measuring DENV infectivity titer.  
Quantitative PCR 
Other techniques available to estimate the concentration of DENV, in addition to plaque 
assay and FFA, include mosquito inoculation and qPCR. Each technique presents a different set 
of problems when attempting to compare titers between different virus strains. Viral infectivity 
assays measure a restricted phenotype and, therefore, may not accurately reflect the number of 
infectious particles if viral strains differ in their ability to form infectious plaques or to establish 
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infection in the mosquito by intrathoracic inoculation. Moreover, results may be difficult to 
reproduce because of variation among lots of cell lines or populations of colonized mosquitoes. 
QPCR may circumvent many of these limitations by directly measuring the concentration of 
viral RNA; however, it will also measure viral RNA that is not fully transcribed or packaged 
while replication is occurring in the cell.125,231,241 
In any case, given our inability to titrate all of our DENV-2 samples using either the 
plaque or focus-forming assays, particularly those samples isolated from the outbreak on Tonga 
(see Results section), we decided to attempt qPCR; first, with the SYBR Green method at the 
University of Hawaii and later the TaqMan method at Mahidol University, Bangkok School of 
Tropical Medicine. 
In both cases, measurements of viral titer using qPCR relied upon using the lab-adapted, 
high-titer DENV-2 strains as a standard. These strains had the advantage of having produced 
high and consistent titers in numerous plaque and FFA and allowed us to correlate qPCR cycle 
number with plaque forming units as genome equivalents per mL.  
Because the qPCR assays carried out at the University of Hawaii and at Mahidol 
University were of two distinct types; SYBR Green and TaqMan respectively, were conducted at 
widely different times and worked with different samples of the South Pacific isolates, they will 
discussed in separate chapters; this chapter will deal exclusively with SYBR Green qPCR carried 
out at the University of Hawaii at Manoa while Chapter 11 will review TaqMan qPCR assays 
performed at Mahidol University, Bangkok School of Tropical Medicine. 
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University of Hawaii SYBR Green qPCR 
QPCR always begins with RNA extraction; followed by a two-step process to convert RNA to 
cDNA and then determine the copy number of each of the stock samples of virus isolated from 
the South Pacific sweep (details can be found in Chapter 4: Materials & Methods).  
 
In the initial qPCR trials we attempted to use a primer targeting the nonstructural gene 5 
(NS5) but given that this showed a high rate of non-specific binding (exhibited as a secondary 
peak on the melt curve) no further trials were carried out. The primer ultimately chosen for the 
SYBR Green assay was adopted from Chien et al.39 and targeted the distal end of the 3’–
noncoding region of the DENV, which is highly conserved, even among different geographic 
isolates, while also effective at distinguishing DENV from other related flaviviruses.111,112 
The amplification protocol used was adopted from one successfully used by my colleague 
Ms. Panpim Throngsipong, as follows: 
 
Nonetheless, the protocol did require optimization, as our initial qPCR trials based on her 
SYBR-Green qPCR with  
DENV-2 standard 
Bio-Rad iQ SYBR Green 
Supermix
RT-PCR to cDNA
Bio-Rad iScript cDNA 
Synthesis Kit
Extract sample RNA
QIAmp Viral RNA Mini Kit
FlaviMelt.tmo
Cycle Cycle Descript. Repeats Step Process RampRate
Dwell
Time Hold
Set -
Point Gradient Range
Melt
Curve
+
Temp - Temp + Time - Time
1 Initial Denaturation 1 1 MAX 03:00 95.0
2 Anneal\Extend 40 1 Denature MAX 00:15 94.0
2 Anneal MAX 00:30 50.0
3 Extend MAX 00:45 72.0
3 Melt Curve 70 1 MAX 00:10 60.0 0.5
4 Cool 1 1 MAX 4.0
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FlaviMelt
protocol were unsatisfactory. For example, when only using a dilution series of the qPCR 
standard (the lab-adapted DENV-2 strain DAKARA) the correlation coefficiency value was R2 > 
0.98 and the amplification efficiency was within the ideal range of 90–105% with amplification 
curves well spaced. However, with the addition of unknowns, all efficiencies were much poorer 
and amplification curves appeared “retarded,” i.e., the exponential phase was greatly diminished. 
After considerable attempts at testing the ratio of primer to template and increasing the annealing 
temperature above that originally recommended, I eventually optimized my qPCR to achieve an 
R2 = 1.0 and amplification efficiency = 102.8% with the following protocol: 
 
As mentioned above, our qPCR measurements relied upon using a lab-adapted, high-titer 
DENV-2 strain as a standard and this was DAKARA at the University of Hawaii at Manoa. 
Upon the suggestion of Dr. Moti Chapagain, a large quantity of DAKARA virus was grown in 
flasks of C6/36 and pooled. Samples from this pool were titrated using the focus-forming assay 
on four separate occasions resulting in an average titer of 2.76E+07 ffu/mL (SD = 0.17). RNA 
was then extracted from the same pool of DAKARA, reverse transcribed to cDNA, aliquoted 
into 0.5 mL microcentrifuge tubes, frozen down and stored at -20°C, with individual tubes being 
used for each qPCR run to avoid cDNA deterioration through repeated freeze/thaw.  
To accurately calculate the amount of DAKARA cDNA to use in creating the serial 
dilution for the qPCR standard curve, we calculated as follows (further information can be found 
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in lab notebook 10 June 2011 and in file “Standards Calc.numbers”). For purposes of simplicity, 
the average titer of the DAKARA DENV-2 strain was 2.5E+07 pfu/mL or 2.5E+04 pfu/µL.  
RNA extraction 
!"#	%&	'()*+,(-* 5	tubes = 700	µ8	 = total viral super needed 
(2.5E+04 pfu/µL) 700	µ8 = 1.75E+07 pfu total titer	
So total amount of viral RNA extracted = (50 µL eluate/tube) (5 tubes) = 250 µL 
Thus, extraction results in 1.75E+07 pfu/250 µL RNA 
cDNA conversion 
Use 5.74 µL RNA per reaction to make 20 µL cDNA: !.:;<=#:	>?@A;#%& 	= 	 B;.:"	%&  
x = 4.02E+05 pfu / 20 µL cDNA or  
x = 2.01E+04 pfu / µL or 
x = 1.0E+05 pfu /5 µL  
Thus, the DAKARA serial dilutions 100 – 10-4 were made with 5 µL cDNA in 45 µL ddH2O. 
To convert qPCR results into pfu equivalents, we created a spreadsheet to carry out the 
following calculations: 
1. The qPCR software “BioRad iCycler iQ Real-Time PCR Detection System” produced a SQ 
Mean (average estimated Starting Quantity) for each duplicate unknown based on it’s Ct 
value compared with that of the standard curve generated from the DAKARA dilution series. 
For example, SQ Mean of the isolate Tonga 14616 = 2.3E+02 
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2. The SQ Mean is then multiplied by the ratio of cDNA produced to the amount of cDNA used 
in the qPCR reaction to get the equivalent amount of pfu. 
 (SQ Mean 2.3E+02) (Ratio of total cDNA to added cDNA 10) = 2.3E+03 
3. This is then divided by the amount of cDNA (equivalent to the original virus particles) by the 
quantity of RNA eluate used to make the cDNA. 
2.3E+03 / 5.74 µL of RNA used to make cDNA = 4.01E+02 
4. Next we multiply the number of µL of RNA extracted by the number of plaque forming units 
per µL of extraction eluate. 
(4.01E+02) (50 µL of RNA from extract) = 2.0E+04 
5. This calculation derives average pfu/µL by dividing the total pfu/µL of the viral RNA 
extracted by µL of virus stock. 
2.0E+04 / 140 µL used in RNA extract = 1.4E+02 pfu/mL 
6. The final calculation converts average pfu/mL to average pfu/µL. 
(1.4E+02) (1000) = 1.43E+05 pfu/µL 
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Results 
Plaque Assay 
While the titer of available lab-adapted strains of DENV-2 (i.e., DAKARA and NGC 1056) 
could be readily measured through the plaque assay method, the majority of the South Pacific 
DENV-2 isolates simply did not generate visible plaques (Figure 19). The Fisher exact test 
statistic value was 1, thus not significant at p < .05, illustrating our plaque assay’s poor utility. 
Figure 19. Titers of stock South Pacific sweep isolates and lab-adapted DENV-2 standards (*) using 
plaque assay. Log scale. 
Focus-Forming Assay 
Our results from focus-forming assays showed that while this assay was able to measure most of 
the South Pacific DENV-2 isolates, it was incapable - despite repeated attempts - of detecting the 
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majority of those samples isolated from the Tonga outbreak (Figure 20). Nonetheless, Fisher's 
exact test gives a p-value = 0.002747 showing that FFA was an effective measurement method. 
 
Figure 20. Titers of stock South Pacific sweep isolates and lab-adapted DENV-2 standards using both 
plaque and focus forming assay (FFA). Note lack of bars for the majority of Tonga isolates. Log scale.  
Quantitative PCR 
Results from SYBR Green qPCR tests conducted at University of Hawaii at Manoa 
demonstrated that all South Pacific samples, including those from Tonga, at the very least 
contained DENV RNA (Figure 21).  
Choy Plaque Assay 
Subsequent to our attempts, successful plaque assays for Tonga isolates 14619, 14620, 14639 
and 14644 were carried out using BHK-21 cells by our colleague Dr. Ming Ju Milly Choy at 
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Duke-NUS Graduate Medical School, Singapore (Figure 21).  
 
Figure 21. Comparison of titers of stock South Pacific isolates and lab-adapted DENV-2 standards  
( * ) using plaque assays, FFA and qPCR. Log scale.  
Discussion 
Based on the negative results from the plaque forming and focus forming assays, we were 
beginning to have some doubts as to whether the Tonga isolates had survived passage. The qPCR 
assay however, demonstrated that all of the South Pacific samples, including those from Tonga, 
at the very least contained DENV RNA. As expected, absolute values for genome equivalents 
were much higher than that for the focus forming assays (Figure 21). In some cases, such as the 
isolate Fiji 1021, genome equivalents are almost three orders of magnitude higher than the titer 
measured in focus forming units. 
On initial observation, the ability of a particular DENV-2 isolate to form plaques did not appear 
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to correlate with high titer. That is, the field-acquired isolates from the South Pacific DENV-2 
sweep that did form plaques exhibited a variety of titers but in all cases less than the lab-adapted 
DENV-2 strains (Table 4 below shows the average pfu for each plaque forming strain from a 
minimum of two assays). 
Table 4. Average PFU for each plaque forming isolate 
DAKARA NGC 1056 Tahiti 10000 Fiji 1422 Tonga 14616 
2.46E+07 3.70E+06 6.03E+05 7.84E+04 1.43E+03 
 
As noted in the Results section, we were unable to detect the majority of the Tonga 
DENV-2 isolates using either the plaque or focus forming assays (both of which used Vero 
cells). However, as mentioned above, Dr. Ming Ju Milly Choy at Duke-NUS Graduate Medical 
School, Singapore was successful at measuring the titer of some Tonga isolates using a plaque 
assay with BHK-21 cells. Her results, as illustrated in the chart in Figure 21, allow for 
comparisons with our other titration methods. Judging from her data as well as our own qPCR 
results, it is clear that the isolates from the Tonga outbreak exhibit a distinct difference in titer 
from other isolates, regardless of assay. Furthermore, if one refers back to the phylogeny of the 
South Pacific epidemic sweep (Figure 14) the Tahiti/Fiji/New Caledonia virus isolates are not 
dissimilar genetically – in the tree they are generally mixed together unlike the Tonga viruses 
which all lie within a single genetically distinct clade. Thus in comparing the two categories: 
Tonga versus Tahiti/Fiji/New Caledonia, one sees a distinct difference in titers, a difference that 
may possibly relate to the former’s attenuated epidemic phenotype (Table 3). 
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CHAPTER 6: TIME-COURSE EXPERIMENTS FOR 
REPLICATION DYNAMICS IN VITRO 
Introduction 
To more accurately assess the phenotypic effects of the Tonga synapomorphies on virus 
replication rate in the mosquito vector, C6/36 (Aedes albopictus) cells were infected with 11 
South Pacific isolates. Six-day viral growth curves according to genomic equivalents to pfu/mL 
by qPCR are shown below (Figure 22). 
Results 
 
Figure 22. Comparative replication kinetics from an experimental infection of C6/36 cells using isolates 
from the South Pacific sweep. G.E. PFU/mL measured in genome equivalents from quantitative PCR. 
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Discussion 
The experimental infection confirmed first, that in spite of the initial failure of plaque or focus 
forming assays in mammalian cell culture to detect the majority of Tonga isolates including 
14619 and 14694, these isolates are indeed viable and infectious in mosquito cell culture. The 
detectable viral genome on day 0 of Tonga 14694 and other isolates is probably a result of 
inadequate washing immediately following initial infection (in an attempt to mitigate against 
poor monolayer adherence), particularly as both of their titers dropped on day 2. But aside from 
that decrease, the trend for all virus isolates is to show a daily increase in titer. 
Second, it is interesting that of the three Tonga strains tested, Tonga 14616, the only 
Tonga strain initially capable of both forming plaques as well as being detectable by focus 
forming assay, showed a titer nearly as high or higher than that of the non-Tonga strains.  
Nonetheless, taken together, the experimental infection showed no obvious correlation 
between Tonga replication rate/productivity and epidemic attenuation in as much as the Tonga 
isolates showed no consistent replication pattern among themselves nor in comparison with 
isolates from islands with more severe outbreaks. However, these results are quite preliminary. 
As mentioned, C6/36 growth and adherence of the monolayer across wells was inconsistent and 
this may have skewed the resulting viral titers. These studies will be repeated using this 
experience as a guide to improve future results. 
Finally, since the beginning of this year we have passaged all the DENV-2 isolates from 
the South Pacific sweep in C6/36 cells. Most have been passaged at a standard MOI of 0.1 with 
the exception of those viruses that had unusually low titers and for which very small volumes 
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were available. These exceptions were all Tonga strains: 14619 and 14620 (MOI 0.01), and 
14639 (which had an exceptionally low titer of 6.18E+03 pfu/mL and thus was infected with an 
MOI of 0.005). While only a personal anecdotal observation, we have been struck by the 
difficulty in growing the Tonga isolates, their consistently poor fluorescence using the Direct 
Fluorescent Assay to assess DENV-2 infections in C6/36 cells (data not shown) and their 
consistently low qPCR titers even after passage. 
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CHAPTER 7: MOSQUITO INOCULATION FOR MID50 
Introduction 
Arguably the most sensitive quantitative assay for DENV and certainly one of the most 
affordable, mosquito inoculation is particularly helpful for “rescuing” DENV from samples taken 
from patients with low viremia, viral isolates with a very low titer, or viruses with low infectivity 
in cell cultures.40,155 It also has the great advantage of requiring a small volume of sample in 
comparison with most other titration methods.189 While inoculations may be a less “natural” 
model of natural infection than infection through oral feeding of blood containing virus, 
mosquitoes are generally more susceptible to infection with arboviruses from inoculation as 
opposed to feeding.33,189 This may possibly be because inoculations bypass the mosquito midgut 
barrier.66 In any case, positive results from this method may provide a useful comparison to 
negative results from oral infections. And again, as previously mentioned, inoculations have the 
advantage of requiring considerably smaller volumes of virus than that necessary for oral 
infections.  
Titration through mosquito inoculation essentially involves the following steps:  
 
Mosquitoes are collected from lab colonies, anaesthetized on ice, serial dilutions of virus 
are injected directly into the thorax of at least 10 mosquitoes per dilution, allowing viral infection 
to take place for 10–14 days and then a 50% threshold of a minimum infectious dose, i.e., MID50 
Harvest, crush 
heads on slide, 
apply antibody, 
detect signal 
Prepare serial 
dilution of virus 
100 - 10-5 
Chill Ae. aegypti 
on ice to knock 
out 
Inject Ae. 
aegypti with 
virus; 10 per 
dilution 
Supply with 
water & sucrose 
for  
10 dpi 
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40,177,189 is detected using head squash and IFA technique.128 See the Materials and Methods 
section for more detail. 
Our introduction to in vivo work with live Aedes albopictus mosquitoes commenced in 
August 2009 in the JABSOM insectary (University of Hawaii at Manoa, Honolulu, Hawaii, 
USA) under the tutelage of Dr. Brett Ellis. This involved learning and adapting methods for 
mosquito containment and safe-handling practices, waste management, collection of wild adults 
and eggs, mosquito care (including egg hatching, larval rearing, adult blood feeding), and harvest 
and preservation of eggs.  
In November 2009, Dr. Shannon Bennett’s lab carried out an experimental oral infection 
of Ae. albopictus using DENV-1 isolates from a 2001 DENV-1 outbreak in Hawaii. While the 
aim of this experimental infection differed from the current research project in as much as the 
infection was to examine Ae. albopictus gene expression, many of the methods used were the 
same as those to be used in this project and thus provided valuable experience. Briefly, wild-
stock Ae. albopictus mosquitoes collected from across the island of Oahu were fed an infectious 
meal of human blood mixed with one of four Hawaii DENV-1 strains or a negative control with 
four replicates per treatment and an average of 50 blood-fed females per replicate. Infected 
mosquitoes were sacrificed in a time series up to 14 days and dissected into midgut, salivary 
glands and remaining carcass. 
In September 2012, in vivo work for this doctoral research was shifted to Duke-NUS 
Graduate Medical School (Emerging Infectious Disease Program, Duke-National University of 
Singapore) where it was possible to work with both Ae. aegypti and Ae. albopictus. Our first 
priority was to establish and maintain genetically diverse populations of both mosquito species to 
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ensure that transmission dynamics closely mirror those under natural conditions. After 
consultation with the National Environment Agency – Singapore’s government agency dealing 
with mosquito control – traps to collect eggs were set up in locations known to have high Aedes 
abundance. From January 2013 through August 2014, egg papers were collected on a weekly 
basis, eggs hatched and reared to adulthood, sorted by species, and introduced into the laboratory 
populations. 
For all of the advantages of direct inoculation, the technique does require training and 
considerable practice. While some attempt was made at JABSOM using Ae. albopictus, real 
training began at Duke-NUS, primarily with the assistance of Milly Choy, Dr. Duane J. Gubler, 
and Dr. Ian Mendenhall, using both Aedes albopictus and Ae, aegypti. Initial practice only used 
PBS (no virus) and focused on maintaining mosquito survival 10–14 days post inoculation, then 
moved to using high titer DENV-2 isolates with known MID50 value. This trial inoculation 
required the preparation of a 6-step serial dilution of virus (undiluted to 10-5) with 10 mosquitoes 
per dilution.  
A few points should be noted: at first our inoculations were only carried out in male 
mosquitoes for reasons of safety but it eventually became clear that the survival rate of male 
Aedes was unsatisfactory and therefore inoculations were shifted exclusively to female Ae. 
aegypti. Indeed, mosquito survival post-inoculation was a persistent problem given the length of 
time necessary for DENV incubation (10–14 days) and we found that survival could be impacted 
by any number of factors: excessive age of individual mosquitoes, excessive time spent 
anaesthetized during inoculation, too much inoculant, or any interruption in mosquito’s access to 
sucrose or water during the incubation period. Thus, many inoculation assays might be rendered 
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unusable after waiting more than a week for results. One strategy for compensating for this 
possibility was to inoculate 50% more mosquitoes than that needed for the assay. Such problems, 
along with the extensive training and practice necessary to inoculate a great number of 
mosquitoes within a reasonable amount of time, need to be carefully weighed against the 
technique’s many advantages as a means of measuring viral titer. A further note is that while we 
had originally hoped to do oral infections in Singapore in order to make a comparison of 
dissemination rates of the South Pacific DENV-2 isolates in Ae. aegypti, we found working with 
colleagues at Duke-NUS that it was difficult to achieve successful oral infection even with high-
titer, lab-adapted strains of DENV. Given time constraints, therefore oral infections were not 
pursued. 
In any case, given the low titers exhibited by most of the Tonga isolates from the South 
Pacific DENV-2 sweep, it was thought to be beneficial to amplify the virus in mosquitoes 
through parenteral inoculation 189 with the goal of generating a seed bank of all DENV-2 
isolates from the South Pacific sweep produced under consistent standards for further work. In 
addition to the higher titers achieved through this technique, it also has the advantage of avoiding 
artificial adaptation of the virus to cell culture. Seed pools were produced as described in the 
Methods section. The resulting seed bank of DENV-2 isolated from the South Pacific sweep was 
then assayed for titer using the parenteral inoculation/MID50 method described above with the 
results shown in Figure 23 and Table 5; both below in the Results section. 
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Results 
 
Figure 23. Comparison of titers using plaque assays, FFA, qPCR and MID50 of stock South Pacific 
sweep isolates and lab-adapted DENV-2 standards (*). Log scale. 
Table 5. Comparison of titers using plaque assays, FFA, qPCR and MID50 of  
stock South Pacific sweep isolates and lab-adapted DENV-2 standard DAKARA.  
Isolates marked “negative” were tested but gave no results. 
Source ID Plaque FFA Choy SYBR qPCR MID50 
* DAKARA 9/7 2.46E+07 2.76E+07  2.50E+07 4.10E+04 
Tahiti S-10000 6.03E+05 4.55E+05  8.90E+05 3.31E+07 
Tahiti S-7848 negative 1.94E+04  9.64E+05 2.22E+07 
Fiji 1021 negative 1.13E+04  8.40E+06 1.24E+06 
Fiji 1422 7.84E+04 1.49E+05  7.16E+05 8.05E+07 
New Cal 9137 negative 1.77E+04  5.68E+05 7.51E+06 
New Cal 9143 negative 1.51E+06  3.53E+06 4.86E+07 
New Cal 9297 negative 9.30E+04  7.09E+06 2.34E+07 
Samoa S-5277 negative 1.31E+06  1.24E+07 2.58E+05 
Samoa S-5279 negative 9.47E+05  1.21E+07 5.88E+05 
Samoa S-5285 negative 8.67E+05  7.90E+06 2.42E+05 
Samoa S-5373 negative 2.17E+05  4.12E+06 2.48E+06 
Tonga 14616 1.43E+03 1.34E+04  2.73E+05 2.58E+05 
Tonga 14619 negative negative 3.50E+03 1.53E+05 2.61E+05 
Tonga 14620 negative negative 1.10E+03 1.03E+05 3.09E+04 
Tonga 14639 negative negative 2.10E+04 6.18E+03 4.50E+04 
Tonga 14644 negative negative 1.20E+05 4.88E+05 2.48E+05 
Tonga 14694 negative negative  6.53E+05 8.63E+06 
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Our use of mosquito inoculation to measure titer in terms of MID50 was successful in as 
much as the technique was able to achieve measurable results with all samples, including those 
isolated from patients from the DENV-2 outbreak on the island of Tonga, although, not 
unexpectedly, those results varied from other titration methods previously used, see Figure 23. 
Discussion 
Given the sensitivity of MID50, we expected higher titer numbers than those acquired 
from running plaque or focus forming assays but lower numbers in comparison with copy 
number from qPCR as the latter detects not just infectious virions but also noninfectious 
immature virions and defective virus particles. Thus, qPCR detects virions that for a variety of 
factors are unable to carry out infectivity, such as limited cell-binding capacity, inefficient 
cellular uptake of virions, or defects in membrane fusion properties, viral replication, or virus 
assembly; all of which can create PFU-to- particle ratios as great as 1:4,000.231 Numerous studies 
have repeatedly shown just such a pattern although typically such comparisons have been 
between plaque assays and qPCR10,46,179.  
In the case of plaque assays and MID50, both are measuring infective particles. And while 
comparisons have been fewer in number, in general they have shown MID50 results to be around 
2 logs higher than that from plaque assays.189  
One of the few studies to compare qPCR with MID50 was by Choy et al. 201340 and they 
also found a consistently higher, but variable ratio of qPCR-generated RNA copy numbers to 
infectious virus titer from MID50. They found copy number/mL to be up to 5 logs higher than the 
same virus measured by MID50. Our results are variable in that regard (Table 6 below). For 
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example, our experimental standard DAKARA was almost 3 logs lower in titer in MID50 in 
comparison with qPCR (and indeed all other assays) while other South Pacific DENV-2 sweep 
isolates showed a variety of results; some with higher MID50 values than from qPCR, others just 
the opposite. Intriguingly the Tonga isolates, as a group, appeared to show the least variation in 
titer between qPCR and MID50. 
Table 6. Log difference in titers between SYBR Green qPCR and MID50 
Source ID SYBR qPCR (G.E. pfu/mL) 
MID50 
(MID50/mL) 
Log difference  
(G.E. pfu/mL: 
MID50/mL) 
* DAKARA 9/7 2.50E+07 4.10E+04 -2.8 
Tahiti S-10000 8.90E+05 3.31E+07 1.6 
Tahiti S-7848 9.64E+05 2.22E+07 1.4 
Fiji 1021 8.40E+06 1.24E+06 -0.8 
Fiji 1422 7.16E+05 8.05E+07 2.1 
New Cal 9137 5.68E+05 7.51E+06 1.1 
New Cal 9143 3.53E+06 4.86E+07 1.1 
New Cal 9297 7.09E+06 2.34E+07 0.5 
Samoa S-5277 1.24E+07 2.58E+05 -1.7 
Samoa S-5279 1.21E+07 5.88E+05 -1.3 
Samoa S-5285 7.90E+06 2.42E+05 -1.5 
Samoa S-5373 4.12E+06 2.48E+06 -0.2 
Tonga 14616 2.73E+05 2.58E+05 -0.0 
Tonga 14619 1.53E+05 2.61E+05 0.2 
Tonga 14620 1.03E+05 3.09E+04 -0.5 
Tonga 14639 6.18E+03 4.50E+04 0.9 
Tonga 14644 4.88E+05 2.48E+05 -0.3 
Tonga 14694 6.53E+05 8.63E+06 1.1 
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Figure 24. Log difference comparison of titers between qPCR (bottom) and MID50 (top)  
assays of stock South Pacific sweep isolates and lab-adapted DENV-2 standard DAKARA. 
By the same token, our MID50 results appear to confirm observations from previous 
assays, that in general, DENV-2 isolated from the Tonga outbreak are lower in titer, as a group, 
than DENV-2 isolated from other islands during the South Pacific sweep. A notable exception is 
the Tonga 14694 isolate which has a distinctly high genome equivalent/mL value and one of the 
highest MID50 values of any isolate. While the titer of this specific isolate should be retested for 
confirmation, given that earlier tests showed no sign of positive selection213 some degree of 
variability in titer among DENV-2 isolated from the 1974 Tonga outbreak should not be 
surprising.  
As a further illustration of the low titer shared by the majority of Tonga isolates, we see 
in displaying MID50 results along the phylogenetic tree delineating genetic relatedness (Figure 
25) that the majority of low titer DENV-2 isolated from the South Pacific sweep are concentrated 
-3.0
-2.3
-1.5
-0.8
0
0.8
1.5
2.3
3.0
* D
AK
AR
A 
9/
7
Ta
hi
ti 
S-
10
00
0
Ta
hi
ti 
S-
78
48
Fi
ji 1
02
1
Fi
ji 1
42
2
Ne
w
 C
al
 9
13
7
Ne
w
 C
al
 9
14
3
Ne
w
 C
al
 9
29
7
Sa
m
oa
 S
-5
27
7
Sa
m
oa
 S
-5
27
9
Sa
m
oa
 S
-5
28
5
Sa
m
oa
 S
-5
37
3
To
ng
a 
14
61
6
To
ng
a 
14
61
9
To
ng
a 
14
62
0
To
ng
a 
14
63
9
To
ng
a 
14
64
4
To
ng
a 
14
69
4
Log Differences in Titer
 
 
132 
within the Tonga clade and as a group they demonstrate generally lower titer than those isolates 
from the other South Pacific outbreaks. 
 
Figure 25. MID50 titers of each isolate mapped onto phylogenetic tree for purposes of comparison across 
clades.  Time
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Low Titer   
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* Isolates used 
in time course 
experiment
*
*
Tonga 14619
Tonga 14620
Tonga 14639
Tonga 14644
Tonga 14639
Tonga 14639
Tonga 14704
American Samoa 5279
American Samoa 5277
American Samoa 5285
New Caledonia 9297
Tonga 74 (vaccine strain)
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2.61E+05
3.09E+04
4.50E+04
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*
*
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Fiji 1021
Fiji 1422
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*
New Caledonia 9137
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Tahiti 10000 3.31E+07 *
Tahiti 125 NA
Tahiti 78 NA
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CHAPTER 8: TIME-COURSE EXPERIMENTS FOR 
REPLICATION DYNAMICS IN VIVO 
Time Course Experiment: I 
An attempt was made to compare replication dynamics of DENV isolated from Tonga (which 
have consistently exhibited low titer) with DENV isolated from other South Pacific sweep 
islands which had more severe outbreaks and which consistently exhibit titers one and two logs 
higher. 
Ae. aegypti mosquitoes were inoculated for this time course experiment with the 
following four representative South Pacific isolates (MID50 titers are included for reference): 
Table 7. South Pacific isolates and MID50 titers used in in vivo time course experiments. 
Tahiti 10000 New Cal 9297 Tonga 14616 Tonga 14619 
3.31E+07 2.34E+07 2.58E+05 2.61E+05 
MOI was normalized through the 100x dilution of high-titer isolates and viral dilutions used to 
inoculate 10 mosquitoes per isolate. Five mosquitoes were harvested per isolate on days 3–7 for 
a total of approximately 40 infected mosquitoes. Harvested mosquitoes were pooled, 
homogenized and purified of debris through centrifugation, then inoculated into Ae. aegypti for 
MID50 titration, which as described previously involves: serial dilution of the homogenate, 
inoculation of 10 mosquitoes per dilution (3 to 4 dilutions necessary per isolate, i.e., 30–40 
mosquitoes per isolated). Inoculated mosquitoes held for 10 days, then harvested and assayed for 
infection using head squash and IFA. 
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Results: I 
A preliminary head squash/IFA of the mosquitoes used for MID50 titration of Day 3 Tonga 
14616 and Tahiti 10000 were completely negative and showed no signs of infection, i.e., no 
fluorescence was exhibited in any of the head squashes. A subsequent qPCR test of half the 
homogenates showed lack of infection in all Tahiti 10000 and New Cal and Day 3 Tonga 14616. 
Discussion 
A number of causes for lack of infection are possible:  
• Our 100x dilution of the Tahiti and New Caledonia samples in order to normalize MOI 
may have lowered MOI too much or somehow interfered with infection. 
• Virus samples may have degraded from excessive freeze/thaw (samples were stored in 
freezers at Duke-NUS that were shared with others and thus there is always the risk that 
samples could be moved by others and accidentally left out to thaw). 
• There might have been mistakes made in dilution and/or injection. 
To test for virus degradation and the effect of diluting the virus for normalizing MOI, 
I used the same media that I had previously used for dilution and ran another qPCR. 
• All samples were positive so the stock virus was not degraded and dilution had no significant 
effect. However, only infection would ensure samples were capable of replication.  
• Time course experiment was therefore repeated but unfortunately, we lacked time to 
titrate inoculated mosquitoes with MID50. 
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Time Course Experiment: II 
Given the failure of the previous time course experiment (see above) to successfully infect Ae. 
aegypti with Tahiti and New Caledonia DENV-2 isolates (even though qPCR demonstrated that 
both isolate stocks and their dilutions had copy numbers equivalent to previous assays) it was 
decided to attempt again direct inoculation of Ae. aegypti females with normalized isolates 
diluted in DMEM-10, harvesting / freezing at -80°C at 3 time points, i.e, Days 3, 7, 10 with 10 
mosquitoes per time point.  
 
 
Table 8. MOI calculations for normalizing infectious titer for South Pac DENV-2 time course exp. 
 
 
Results 
Details on the method of SYBR Green qPCR used to measure these infected mosquitoes as well 
as the results are discussed in the following Chapter 9. 
Tahiti 10000 
New Cal 9297 
Tonga 16 
Tonga 19 
Virus normalized 
to minimum  
MID50 
Inject 30 Ae. 
aegypti females 
with 0.17 mm3 per 
each isolate 
Harvest/freeze 10 
mosq at dpi 3, 7 
and 10 
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CHAPTER 9: VIRAL LOAD OF DENV-2 ISOLATES 
DETERMINED BY QPCR II 
Introduction 
Titration assays using qPCR carried out at Mahidol University, Bangkok School of Tropical 
Medicine, had the primary goal of titrating mosquitoes infected (by the intrathoracic method) at 
Duke-NUS as part of time course experiments (discussed in the previous Chapter 8.). As 
mentioned, these mosquitoes were originally planned by us to be titrated by means of MID50 but 
the time needed proved to be insufficient due to the need to move to Thailand. As methods used 
for carrying out qPCR at Mahidol were completely different from those used at University of 
Hawaii, a more full description is warranted. It also bears mentioning that in learning and 
carrying out this later qPCR, we are greatly indebted to the generous instruction and use of 
equipment by Dr. Pornsawan Leaungwutiwong and her laboratory staff, in particular Mr. Narin 
Thippornchai and Ms. Siriporn Cheattanadee, in the Department of Microbiology and 
Immunology at Mahidol University. 
Table 9. Comparison of major differences between University of Hawaii and Mahidol qPCR methods: 
 University of Hawaii at Manoa Mahidol University 
RNA Extraction Qiagen QIAamp viral RNA mini kit Biotechrabbit GenUP Total RNA kit 
Chemistry SYBR Green TaqMan 
Primer (Probe) 
gene target  
3’ Non-Coding Region  
(Chien et al. 2006) 39 
Envelope 
(Johnson et al. 2005) 117 
Reverse 
transcription Two-step One-step 
Standard Lab-adapted DENV-2 “DAKARA” tested by me using PFU and FFU 
Lab-adapted “D2 (16681), MK2-3” 
independently tested using PFU and FFU 
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Standard 
Standard curve of Mahidol University qPCR was based on lab-adapted DENV-2 strain acquired 
from Dr. Pornsawan and identified as “D2 (16681), MK2-3, C6/36-1, Sm-2, C6/36-5, 20 Feb 
13.” Previous plaque and focus-forming assays in her lab had established an average pfu of 
2.3E+05 per mL. 
RNA Extraction 
Since Dr. Pornsawan’s laboratory carried out qPCR of clinical samples for DENV detection and 
viremia measurement on a routine basis, protocols were completely worked out and required no 
optimization on my part. However, although Dr. Pornsawan’s laboratory routinely uses the 
Qiagen QIAamp viral RNA mini kit for RNA extraction, as a means of saving funds, the use of a 
different and less expensive kit from another manufacturer was explored; the Biotechrabbit 
GenUP Total RNA kit. In using both kits to extract RNA from the same standard and then 
running all RNA under the same qPCR conditions, a threshold cycle of less than one (Ct < 1) 
was found in comparing results. Thus encouraged, a test run of the standard curve was conducted 
to ensure that methods were free of error. 
Unfortunately, although amplification curves of the standards were evenly spaced, 
suggesting that the qPCR itself was successful, high Ct values lead me to believe that my RNA 
extraction was suboptimal. Dr. Pornsawan offered to have her staff attempt to repeat both the 
extraction (using the Qiagen kit) as well as the qPCR to check whether the problem was with 
either the virus standard or my lab technique. Unfortunately, her staff instead simply extracted 
RNA from the DENV-2 standard for me using the Qiagen kit (rather than the Biotechrabbit 
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GenUP Total RNA kit) so that I could use this RNA as my standard for all subsequent qPCR 
assays. As we will see however, this may have led to subsequent problems since I used the 
Biotechrabbit GenUP Total RNA kit to extract RNA from samples while continuing to rely upon 
RNA extracted by the Qiagen kit for my standard curve.  
Quantitative PCR assay of MID50 homogenate 
My initial efforts at using qPCR at Mahidol were to test mosquitoes that had been inoculated in 
two separate MID50 assays at Duke-NUS. The first assay - named MID50-1 – had come out 
lower than expected so had been followed up by another assay attempt - MID50-2. My goals in 
this qPCR then were: 1) confirm positive infection in mosquitoes from both previous assays, 2) 
test my new TaqMan protocols on at least the standard 3) test whether the later MID50 assay 
(MID50-2) was higher than the first as had been suggested by the respective MID50 results.  
Table 10. Results of qPCR assay of MID50 homogenate 
 Tahiti  10000 
New Cal  
9297 
Tonga 
 14616 
Tonga  
14619 
MID50-1 2.42E+05 2.95E+05 2.24E+05 1.87E+05 
MID50-2 - 2.52E+05 2.13E+05 2.25E+05 
 
Results confirmed successful infection of mosquitoes with viable virus. And Ct values 
showed minimal variation within replicates suggesting that my qPCR methodology was 
improved. Mean PFU values did vary somewhat between the earlier attempt at MID50 (MID50-
1) and the later (MID50-2). Note that measurements of the Tahiti and New Caledonia isolates 
from MID50-1 came out an average of 2 logs lower than from MID50 assays carried out a year 
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previously (although Tonga measurements were approximately the same). Thus MID50-2 was to 
see if the low titer of MID50-1 was a handling error or whether it suggested that my samples had 
deteriorated. Here it appears that if anything, G.E. PFU/mL values decreased in the later MID50 
assay except with Tonga 19. (This exception might be due to shuffling of MID50 tubes when 
they were packed for shipment and accidental swapping of the Tonga 19 MID50-1 and MID-2 in 
inventory). In any case, all qPCR measurements are fairly similar which is even more odd. 
Quantitative PCR assay of mosquitoes infected in Time-Course Experiment II 
Treatment of mosquitoes inoculated as part of the second attempt at carrying out time-course 
experiments is illustrated in the following flow chart: 
 
All mosquitoes for each of 4 isolates and 3 harvest days were homogenized as pools 
(n=12). However, my lab notes regarding the number of mosquitoes per pool turned out to be in 
error which meant that while most pools had 7 mosquitoes other pools had as few as 4, thus 
requiring normalization of subsequent copy number results. 
Table 11. Results of qPCR of mosquitoes infected in Time Course Experiment II 
 Day 3 Day 7 Day 10 
Tahiti 10000  9.21E+01 5.88E+02 2.14E+03 
New Cal 9297  3.41E-02 1.05E-01 8.64E-02 
Tonga 14616   5.46E+00 1.79E+02 1.22E+02 
Tonga 14619   2.91E+01 8.20E+01 2.24E+03 
4 isolates x 
3 harvest days  
=  12 pools  
Homogenized each 
of 12 pools 
TaqMan qPCR with  
DENV-2 standard 
KAPA Probe Fast 1-
Step qRT-PCR Kit 
Extract RNA using 
GenUP Total  
RNA Kit 
0E+00
8E+02
2E+03
2E+03
3E+03
Day 3 Day 7 Day 10
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The results from the qPCR of pooled mosquitoes infected as part of the second time- 
course experiment were difficult to interpret. Unlike the first time course experiment, this 
titration did show evidence that mosquitoes were successfully infected at least with the Tahiti 
10000 and Tonga 14619 (in contrast to the first time course in which infection failed in all days 
Tahiti 10000 and New Cal and Day 3 Tonga 14616). 
However, this limited comparison of Tahiti versus Tonga shows no indication that the 
Tahiti 10000 isolate replicates faster than Tonga 14619, a result that would seem to contradict 
the results of previous replication experiment (Figure 22, upper left). In addition, viral loads 
determined by qPCR were still surprisingly low (considerably lower titers than those seen in the 
previous qPCR assay), which may have been an artifact of the assay (the dilutions for 
normalization) or possibly due to problems with the original inoculation.  
Quantitative PCR of stock South Pacific DENV-2 
Given the uncertain results from qPCR of mosquito samples infected with South Pacific DENV-
2 isolates, I turned to original samples of the isolates that had been grown in C6/36 cells. While 
not the same passage as those samples previously tested by SYBR Green, they were only one 
passage later. The goal was to compare these qPCR results with those gained from the SYBR 
Green qPCR at University of Hawaii and the measurements for MID50 at Duke-NUS. 
Table 12. Passage history of assayed South Pacific isolates 
 Isolate 
Harvest  
day Passage Isolation Volume 
Harvest  
date 
Tahiti 10000 10 3  0.5 mL 2/28/12 
New Cal 9297 10 3 Mosq C6 1.0 mL 2/28/12 
Tonga 14616 10 3 Mosq C6 0.5 mL 2/28/12 
Tonga 14619 11 3 Mosq C6 0.5 mL 3/30/12 
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Results 
Table 13. Results of qPCR of stock DENV-2 isolates  
 
 
 
 
 
 
As the table shows, while Ct values are consistent across replicates, the resulting pfu 
values do not appear to have any particular correlation with those from my SYBR Green qPCR 
assays. Also, unlike the SYBR Green qPCR, the TaqMan assay results show little difference in 
G.E. pfu values between what are ordinarily low-titer isolates such as the Tonga versus isolates 
those from the islands of Tahiti or New Caledonia. 
Discussion 
There were a number of problems with my qPCR titration of the mosquitoes infected in the time 
course experiments but the basic problem was that my TaqMan qPCR showed no apparent 
correlation with the results of other assays and in particular with my previous qPCR assays using 
SYBR Green. There are a number of possible reasons for this: 
1. Using different primers may have contributed a significant source of variability in my results. 
The TaqMan primer/probe targeted the E protein – perhaps the most variable protein in 
DENV – whereas my SYBR Green probe was specific to the 3’NCR, which is very highly 
Isolate Sample Ct-1 
Sample 
Ct-2 
Ct 
Mean 
TaqMan 
Mean 
SYBR 
Green 
Tahiti 
10000 19.79 19.72 19.75 1.18E+05 8.90E+05 
New Cal  
9297 20.13 20.22 20.18 8.84E+04 7.09E+06 
Tonga  
14616 19.36 19.35 19.35 1.55E+05 2.73E+05 
Tonga  
14619 22.30 22.99 22.64 1.68E+04 1.53E+05 
1E+00
1E+01
1E+02
1E+03
1E+04
1E+05
1E+06
1E+07
Tahiti 10000 New Cal 9297 Tonga 14616 Tonga 14619
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conserved. 
2. The choice of using TaqMan rather than SYBR Green seemed to promise more accurate 
results. However, apart from the inherent problems with comparing titration results when 
using different methods, the choice of TaqMan might have actually further decreased assay 
accuracy in using primer/probes of poor specificity.  
Of the two widely used real-time RT-PCR formats, SYBR Green I based assays are less 
expensive, more flexible, and less susceptible to false negatives due to single nucleotide 
polymorphisms in the probe sequence than assays that use TaqMan. Although a single 
point mutation in the probe region can reduce target detection by 47% in TaqMan assays, 
SYBR Green I is a nonspecific dsDNA binding dye that only requires design of 
oligonucleotide primers for PCR to measure fluorescence emission.179 
3. As previously mentioned, when I attempted to use the Biotechrabbit GenUP Total RNA kit 
to extract RNA from my standard and my qPCR results appeared less than optimal, I then 
opted to use RNA extracted using the Qiagen QIAamp viral RNA mini kit. However, I 
subsequently used the Biotechrabbit kit for extraction of the time course mosquitoes. This 
meant that I had never actually verified that my Biotechrabbit extractions were optimal and 
meant that Ct values of standards and unknowns were not really comparable.  
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CHAPTER 10: SUMMARY OF RESULTS  
AND DISCUSSION 
Spearman’s Correlation 
The Spearman’s Correlation Coefficient was applied to measure the statistical correlation 
between the various methods used over the course of this research to measure viral 
titer. Spearman’s is a nonparametric measure of the strength of association that exists between 
two variables, in this case between any two methods of viral quantification.  
For context, the chart (previously shown in Figure 23, Chapter 7) is included below to 
illustrate all titrations created during the course of this research. 
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A matrix showing the results of Spearman’s Correlation test between paired data between 
methods (from Table 6; the standard DAKARA was not included) is shown in Table 14 below. 
Table 14. Spearman’s Correlation Test of titration data. N = no. of samples, Rs = Spearman's Correlation 
Coefficient (strength of association) and p = statistical significance. Colors indicate strength of association 
(Rs) where red = High, yellow = Moderate, blue = Low X = no comparison, and - = same method.  
Tests run in IBM SPSS Statistics for Mac v20. 
 MID50 SYBR qPCR 
Choy PFU 
(BHK-21) FFA (Vero) PFU (Vero) 
MID50 - 
N=17 
Rs=0.288 
p=0.262 
N=4 
Rs=0.400 
p=0.600 
N=12 
Rs=0.025 
p=0.94 
N=3 
Rs=0.500 
p=0.333 
 SYBR qPCR - 
N=4 
Rs=0.400 
p=0.600 
N=12 
Rs=0.455 
p=0.138 
N=3 
Rs=1.000 
p=0.000 
  Choy PFU (BHK-21) - X X 
   FFA (Vero) - 
N=3 
Rs=1.000 
p=0.000 
    PFU (Vero) - 
      
Given the variety of methods used over the course of this research to measure the viral 
titer of DENV-2 isolated from the South Pacific epidemic sweep, it is reasonable to speculate on 
how well these methods agree with one another. The Spearman’s Correlation Test allows us to 
make some comparisons and the table above provides a graphic illustration of the strength of 
correlation between methods. Because there are a different number of samples associated with 
each method, Rs is not strictly comparable. Thus, note that those method comparisons with high 
Rs (red) also have few samples.  
In general Rs values match expectations, e.g., since PFU (plaque assays) and FFA (focus 
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forming assays) utilize similar methods and both grow virus in Vero cells it is not surprising that 
they would show a high Rs value. The moderate correlation between SYBR Green qPCR and 
FFA is notable given that the majority of the isolates measured by these two methods could not 
be titrated by PFU but were able to be titrated by FFA, perhaps indicating a lack of plaque-
forming phenotype. Perhaps most surprising it that the lowest Rs is found in comparing MID50 
with other methods (except Choy perhaps). Possible explanations include: a) MID50 being the 
only method in which virus is grown in mosquitoes rather than a mosquito cell line b) MID50 
used an later cell passage from all except for the Choy plaque assay (and latter was in BHK cells 
rather than Vero) c) the higher potential for “operator error” inherent in MID50 technique. 
This analysis suggests that the assay methods have a modest degree of correlation but 
perhaps lend more support for settling upon a single assay method sensitive enough to measure 
all isolates and provide consistency across successive measurements.  
Discussion 
DENV pathogenesis has been a subject of serious scientific enquiry for more than 100 years. The 
progress made in the last ten years has been outstanding, exemplified by the successful trials and 
licensing of the first vaccine against DENV, Dengvaxia.60,254 Yet the most basic of questions 
regarding DENV pathogenesis still await answers. We still lack a fundamental understanding of 
the mechanisms that determine why those infected with DENV have such a variety of clinical 
outcomes and indeed, still lack reliable markers for identifying individuals at risk for severe 
disease. The research described in this dissertation has been directed towards increasing our 
understanding of DENV pathogenicity through comparisons of phenotypic differences between 
DENV that were previously documented as differing in both their clinical and/or epidemic 
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outcomes as well as genetically.  
Thus, this dissertation has described research carried out to explain the phenomena of a 
DENV-2 outbreak of dramatic attenuation on the island of Tonga as compared to outbreaks on 
other South Pacific islands surrounding it and which we were subsequently able to show 
correlated with specific amino acid substitutions. The aim with this current research was to 
identify specific phenotypic traits that correlate with virulence and epidemic potential, and using 
both in vitro and in vivo models, to explore their relationship with genetic variation in the 
DENV-2 epidemic strains. Among the variety of phenotypic differences that this research hoped 
to examine, viral productivity, i.e., the number of virus produced per unit volume, that is, titer, 
received the most attention.  
As noted previously, evidence for molecular markers for pathogenesis in DENV is 
generally lacking. Given a lack of an effective animal model for DENV studies and the current 
poor understanding of the functional aspects of DENV structure, it is difficult to attribute 
specific correlates between viral phenotypes and pathogenesis. Nevertheless, titer has the 
strongest claim to being a candidate for a viral phenotypic marker given that a number of papers 
have identified a relationship between peak viremia titer and disease severity as well as increased 
rates of Aedes vector infection.  For example, in a prospective study of dengue-infected children 
in Thailand, Vaughn et al. (2000) noted that disease severity was most strongly associated with 
DENV-2 serotype infections, secondary infections, and higher peak titers; indeed “as peak 
viremia titer increased so did the pleural effusion” with little to no pleural effusion detected until 
reaching higher peak levels of viremia.237 Other studies have also found a strong association 
between disease severity and viremia levels; some with high early viremia determined to be 
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more significant than peak viremia (although peak viremia was often missed because it occurred 
prior to enrolment).138,221 while Wang et al. (2003) found high late viremia a more accurate 
marker for severe dengue.242 In terms of the role of human viremia in mosquito transmission, a 
study in Vietnam by Nguyen et al. (2013) found that high early DENV plasma viremia was 
associated with longer human infectiousness leading to increased prevalence of infection among 
mosquitoes allowed to blood feed.167 
In spite of these many studies, the relationship between DENV titer, human viremia and 
disease severity is still unclear. Data on viremia levels in naturally occurring DENV infections is 
still sparse because, as mentioned above, clinical observation usually takes place long after the 
onset of infection, and thus the level of viremia already decreasing. In addition, it is not clear that 
studies have been done to isolate virus from infected patients and compare isolate titer with 
patient disease severity. Nonetheless, a correlation between high viral load and disease severity 
has long been suggested and indeed is assumed to be important in both antibody dependent 
enhancement and viral pathogenicity. 87,100 
In this context, the unusually low titer of the DENV-2 isolated from Tonga patients was a 
distinctive characteristic that drew attention from the beginning. As Dr. Gubler wrote his 
description of the Tonga outbreak,85  
Despite ideal timing, collection, and storage of serum specimens from the 1974 outbreak 
the virus isolation rate was considerably lower than that obtained in other dengue type 2 
outbreaks in Tahiti and New Caledonia and that of the 1975 outbreak in Tonga – where 
timing, collection, and storage were less satisfactory. It is logical to attribute the abortive 
nature of the 1974 outbreak and undetected presence on the island of dengue type 2 prior 
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to August 1973 to the relatively low viremias observed. It also is natural to wonder if 
relatively low viremia is not associated with relatively benign disease. (Emphasis added). 
In this context, what is most striking is that, regardless of the method used to measure 
titer, isolates from the attenuated outbreak on Tonga consistently demonstrated the lowest titer 
compared to those DENV-2 isolated from any of the other South Pacific outbreaks. Figure 26 
below (also shown as Figure 25 on page 140) illustrates clearly how the majority of low titer 
isolates, as measured by the MID50 assay, fall within the Tonga clade and as a group demonstrate 
generally lower titer than those isolates from the other South Pacific outbreaks. 
 
Figure 26. MID50 titers of each isolate mapped onto phylogenetic tree for purposes of comparison.  
The concentration of low titer isolates within the Tonga clade is even more pronounced 
when titers from the SYBR Green qPCR assay are mapped upon the phylogenetic tree of the 
D2/TO/Tonga/74/1974
D2/TO/UH19/1974
D2/TO/UH20/1974
D2/TO/UH39/1974
D2/TO/UH04/1974
D2/AS/UH79/1972
D2/AS/UH77/1972
D2/AS/UH85/1972
D2/AS/UH73/1972
D2/FJ/UH21/1971
1
1
1
1
1
1
0.96
0.53
0.36
0.98
0.94
1
0.65
0.22
0.89
0.22
0.85
1
1
D2/FJ/UH22/1971
D2/FJ/UH40/1971
D2/PF/UH00/1973
D2/PF/UH50/1972
D2/PF/UH57/1971
D2/NC/UH37/1971
D2/NC/UH97/1972
D2/TO/UH94/1974
D2/TO/UH16/1974
D2/TO/UH44/1974
 
46
NS4A
I > M
 
54
prM
H > R
83
NS2A
S > G
Tonga 146
Tonga 14620
Tonga 1463
Tonga 1 644
Tonga 14 6
Tonga 14694
Tonga 14704
American Samoa 5279
American Samoa 5277
American Samoa 5285
Fiji 1021
Fiji 1422
Fiji 1040
New Caledonia 9297
New Caledonia 9137
American Samoa 5373
Tahiti 12
Tahiti 10 0
Tonga 74 (vaccine strain)
Tahiti 7857
2.6 E+05
3.1 E+04
4.5 E+04
2.5 E+05
2.6 E+05
8.6 E+06
NA
NA
5.9 E+05
2.4 E+06
2.6 E+05
2.3 E+07
1.2 E+06
8.1 E+07
1.6 E+05
7.5 E+06
2.5 E+06
3.3 E+07
NA
NA
Low Titer 
< 3.4 E+05
Med. Titer 
3.4 E+05 - 
3.8 E+06
High Titer 
> 3.8 E+06
 
149 
South Pacific sweep. (Figure 27.)  
 
Figure 27. Quantitative PCR titers of each isolate mapped onto phylogenetic tree for purposes of 
comparison.  
Such agreement between these two titer assay methods is striking given the preceding 
analysis using the Spearman’s Correlation Test of titration data. That test showed the MID50 and 
qPCR assays as having a relatively poor level of correlation. This is unsurprising for the reasons 
previously given: a) DENV was replicated in C6/36 cells in the qPCR assay and adult 
mosquitoes in MID50, b) MID50 used an later cell passage from the SYBR Green qPCR, c) MID50 
only detected infectious virus while the SYBR Green qPCR measured the quantity of nucleic 
acid. Yet in spite of their differences both assays clearly demonstrate that, as a group, the Tonga 
clade is distinctively lower in titer than DENV isolated from the other outbreaks in the South 
Pacific DENV-2 epidemic sweep. 
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Also worth noting is the phylogenetic clustering of the Tonga clade with the Tonga 74 
vaccine strain; this strain shared an amino acid substitution in the NS4A gene region and also 
exhibited an attenuated phenotype both in terms of its failure to infect the midgut or head of Ae. 
aegypti and in its relatively low replication rate in SCID mice transplanted with HuH-7 human 
hepatoma cells (a mean titer of 7.9 E+05 as measured by plaque assay with Vero cells).23 Blaney 
et al. (2004) point out that as a member of the DENV-2 American genotype, the Tonga isolates 
(along with the rest of the South Pacific sweep) share point mutations that, when in other 
research were introduced into DENV-2 of the more virulent Asian genotype, were found to result 
in reduced replication within dendritic cells and monocytes.45 Blaney et al. (2004) go on to 
suggest that the introduction of further mutations might lead to a “small, incremental increase in 
attenuation,” a possible explanation for the lower viral titer exhibited by those DENV-2 isolated 
from Tonga compared with other American genotype DENV-2 isolated from the South Pacific 
sweep. 
A final observation, albeit anecdotal, refers back to remarks first made in Chapter 6 
(Time-course experiments for replication dynamics in vitro). As written there in reference to 
passaging the DENV-2 isolates from the South Pacific sweep ”we have been struck by the 
difficulty in growing the Tonga isolates, their consistently poor fluorescence using the Direct 
Fluorescent Assay to assess DENV-2 infections in C6/36 cells (data not shown) and their 
consistently low qPCR titers even after passage.” 
Thus, the results from the variety of titration assays carried out over the course of this 
dissertation research corroborate our previous phylogenetic analysis demonstrating genetic 
clustering correlating with the attenuation of the Tonga isolates. Together, their conclusions 
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appear to support the original hypothesis: evolutionary changes in the DENV genome can give 
rise to significant variations in disease severity and epidemic potential between different 
populations of DENV. 
Given the lack of an animal model with which to compare DENV variation directly, 
measurements of specific virus phenotypes, such as virus quantity, both in vitro and in vivo as 
have been carried out here, offer possible insights into the role of DENV evolution on disease 
severity. In addition, this work is strengthened by its use of low passage DENV from outbreaks 
whose epidemiology and clinical nature has been relatively well documented. 
Nonetheless, this study has its weaknesses which can be summarized as two-fold: first, as 
the Spearman’s Correlation analysis (Table 14) points out, the variety of titration methods used 
only showed a modest degree of correlation. For the purposes of this study and with time 
permitting, it would have been optimal to eventually settle upon a single assay method sensitive 
enough to measure all isolates and provide consistency across successive measurements. 
However, further investigation into the causes of such variation in titer would be interesting to 
pursue. As pointed out in the Discussion in Chapter 7, to have higher titers from MID50 than 
from qPCR for some of the South Pacific isolates was unexpected given that MID50 measures 
only infective DENV, which given the poor rates of DENV maturation, is usually a small subset 
of the larger virion population.  Such a result may only be a result of experimental error but it is 
intriguing that as a group, Tonga showed the greatest variation in high titer between methods (3 
Tonga isolates showed the highest titer using  MID50 and 2 isolates were highest using qPCR; see 
Figure 24, page 138) while also showing the least variation in log difference between titers 
(Table 6, page 137). 
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A second weakness of these research results was the lack of further experimental 
evidence in addition to the titrations. Aim 1 of this dissertation research proposed to measure and 
compare a variety of phenotypes among the samples isolated from the South Pacific DENV-2 
sweep. While viral productivity, i.e., viral titer, was examined, further assays were proposed but 
were never carried out or were unsuccessful in achieving results. They will be discussed in the 
following section “Future Directions.” 
Future Directions 
Focus-forming assay with BHK-21 
As mentioned above, establishing a single, reliable, sensitive titration method proved to be a 
particular obstacle in the research. Among other titration methods, both the plaque assay and 
focus-forming assay (FFA) were attempted but in using Vero cells neither method was capable 
of detecting samples isolated from the Tonga outbreaks. However, subsequent work by a 
colleague, Dr. Milly Choy, using BHK-21 cells proved more successful revealing that a change 
in cell type might be a more viable approach. Another recommendation for reattempting FFA 
using BHK-21 cells is that this assay measures infective infectious virions rather than the RNA 
measured by qPCR. Since viral RNA can be incompletely transcribed or not yet assembled into a 
virion within the cell, or that which is associated with immature or defective virus, FFA would 
seem to have the advantage of being a more direct measure of phenotype.  
Time-course experiments  
Successful titrations measured stock virus whose starting concentrations were never normalized. 
Time-course measurements would start with identical MOI and thus allow for a more accurate 
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comparison of rates of viral replication; that is, the number of virus produced per cell. 
Comparison of South Pacific DENV-2 among various cell types  
Preliminary work with the DENV-2 isolated from the South Pacific sweep was conducted 
primarily in the Ae. albopictus cell line C6/36 and in Vero cells (kidney epithelial cells from the 
African green monkey). However, given the marked variation in the susceptibility to infection 
among cell types by different DENV strains, particularly those strains which are of low passage 
and the tropism of DENV to different cell types, it is important to compare infectivity in a range 
of cells. Moreover, immune dysfunctions specific to cell lines, such as the lack of anti-viral RNA 
interference (RNAi) response by C6/36 cells and the defective interferon (IFN) response by Vero 
cells need to be taken into account. This is particularly significant given that two of the three 
amino acid substitutions defining the Tonga clade are in the NS2A and NS4A gene regions and 
both NS2A and NS4A have been shown to act as IFN antagonists by inhibiting IFN antiviral 
immune response both alone and in coordination with one another. Accordingly, it would still be 
useful to compare the infectivity of selected DENV-2 South Pacific isolates in Vero (and 
possibly C6/36) cells against similar cell types. 
Measuring the ratio of mature to immature virions  
An alternative explanation for poor rates of viral isolation and generally lower viremia seen 
during the Tonga outbreak compared with isolation rates and patient viremia on other islands 
might be that the DENV-2 isolated from the attenuated 1974 outbreak on Tonga produce a 
higher ratio of immature (noninfectious) to mature (infectious) virions compared with the other 
DENV-2 from the South Pacific sweep. This might be a consequence of the substitution in the 
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prM gene region shared by members of the Tonga clade (histidine to arginine substitution at 
residue 54). Most studies carry out Western blots utilizing a specific anti-M antibody capable of 
distinguishing between M and prM based on the greater molecular weight (thus lower band) of 
immature (pr + M) vs. mature (M only).  
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